0001213900-23-005085.txt : 20230125 0001213900-23-005085.hdr.sgml : 20230125 20230125151216 ACCESSION NUMBER: 0001213900-23-005085 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230125 DATE AS OF CHANGE: 20230125 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Health Sciences Acquisitions Corp 2 CENTRAL INDEX KEY: 0001814114 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39421 FILM NUMBER: 23552290 BUSINESS ADDRESS: STREET 1: 412 WEST 15TH STREET, FLOOR 9 CITY: NEW YORK STATE: NY ZIP: 10011 BUSINESS PHONE: 646-343-9298 MAIL ADDRESS: STREET 1: 412 WEST 15TH STREET, FLOOR 9 CITY: NEW YORK STATE: NY ZIP: 10011 10-K 1 f10k2022_healthsciences2.htm ANNUAL REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to ________________

Commission file number: 001-39421

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

(Exact name of registrant as specified in its charter)

Cayman Islands		n/a
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

40 10th Avenue, Floor 7
New York, NY		10014
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (646) 597-6980

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value $0.0001 per share		HSAQ		The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐

At June 30, 2022, the aggregate market value of the registrant’s ordinary shares held by non-affiliates of the registrant was approximately $159.4 million.

As of January 23, 2023, 11,212,117 ordinary shares, par value $0.0001 per share, were issued and outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

None.

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

Annual Report on Form 10-K for the Year Ended December 31, 2022

part I		1
ITEM 1.	Business	1
ITEM 1A.	Risk Factors	9
ITEM 1B.	Unresolved Staff Comments	9
ITEM 2.	Properties	9
ITEM 3.	Legal Proceedings	9
ITEM 4.	Mine Safety Disclosures	9
Part II		10
ITEM 5.	Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities	10
ITEM 6.	[Reserved]	10
ITEM 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11
ITEM 7A.	Quantitative and Qualitative Disclosures About Market Risk	19
ITEM 8.	Financial Statements and Supplementary Data	19
ITEM 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	19
ITEM 9A.	Controls and Procedures	19
ITEM 9B.	Other Information	20
ITEM 9C.	Disclosure Regarding Foreign Jurisdictions That Prevent Inspections	20
Part III		21
ITEM 10.	Directors, Executive Officers and Corporate Governance	21
ITEM 11.	Executive Compensation	29
ITEM 12.	Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters	30
ITEM 13.	Certain Relationships and Related Transactions, and Director Independence	31
ITEM 14.	Principal Accountant Fees and Services	35
Part IV		36
ITEM 15.	Exhibits and Financial Statement Schedules	36
ITEM 16.	Form 10-K Summary	37

Cautionary Note Regarding Forward-Looking Statements

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. The statements contained in this report that are not purely historical are forward-looking statements. Our forward-looking statements include, but are not limited to, statements regarding our or our management’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this report may include, for example, statements about:

	●	our ability to complete our initial business combination;

	●	our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination;

	●	our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination, as a result of which they would then receive expense reimbursements and other benefits;

	●	our potential ability to obtain additional financing to complete our initial business combination;

	●	our pool of prospective target businesses;

	●	the ability of our officers and directors to generate a number of potential investment opportunities;

	●	the delisting of our securities from Nasdaq or an inability to have our securities listed on Nasdaq following a business combination;

	●	potential change in control if we acquire one or more target businesses for stock;

	●	the potential liquidity and trading of our securities;

	●	the lack of a market for our securities;

	●	use of proceeds not held in the trust account or available to us from interest income on the trust account balance; or

	●	our financial performance.

The forward-looking statements contained in this report are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws and/or if and when management knows or has a reasonable basis on which to conclude that previously disclosed projections are no longer reasonably attainable.

part I

ITEM 1. BUSINESS

General

Health Sciences Acquisitions Corporation 2 (“we,” “us,” or “our”) is a blank check company incorporated on May 25, 2020 as a Cayman Islands exempted company. We were incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses, which we refer to throughout this annual report as our initial business combination. Although there is no restriction or limitation on what industry our target operates in, it is our intention to pursue prospective targets that are focused on healthcare innovation. We are an emerging growth company and, as such, we are subject to all of the risks associated with emerging growth companies.

Our sponsor is HSAC 2 Holdings, LLC (the “Sponsor”). The registration statement for our initial public offering (the “Initial Public Offering”) was declared effective on August 3, 2020. On August 6, 2020, we consummated an Initial Public Offering of 16,000,000 ordinary shares (the “Public Shares”), including the 2,086,956 Public Shares as a result of the underwriters’ full exercise of their over-allotment option, at an offering price of $10.00 per Public Share, generating gross proceeds of $160.0 million, and incurring offering costs of approximately $9.4 million, inclusive of $5.6 million in deferred underwriting commissions.

Simultaneously with the closing of the Initial Public Offering, we consummated a private placement (the “Private Placement”) with the Sponsor of (i) 450,000 ordinary shares (the “Private Placement Shares”) at $10.00 per Private Placement Share (for a total purchase price of $4.5 million) and (ii) 1,500,000 warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant (for a total purchase price of $1.5 million), generating gross proceeds of $6.0 million.

Upon the closing of the Initial Public Offering and the Private Placement (including the exercise of the over-allotment option), $160.0 million (or $10.00 per Public Share) of the net proceeds of the sale of the Public Shares in the Initial Public Offering and the Private Placement were placed in a trust account (“Trust Account”) located in the United States with Continental Stock Transfer & Trust Company acting as trustee, and held as cash or invested only in U.S. “government securities,” within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in money market funds meeting certain conditions under the Investment Company Act, which invest only in direct U.S. government treasury obligations, as determined by us, until the earlier of: (i) the completion of an initial business combination and (ii) the distribution of the Trust Account.

We paid a total of $3.2 million in underwriting discounts and commissions (not including the $5.6 million deferred underwriting commissions payable at the consummation of the initial business combination) and approximately $0.6 million for other costs and expenses related to our formation and the Initial Public Offering.

We will have until February 6, 2023, or such later time as our shareholders may approve in accordance with the Company’s amended and restated memorandum (the “Combination Period”), or such later time as our shareholders may approve in accordance with the Company’s amended and restated memorandum and articles of association, to complete our initial business combination. If we do not complete an initial business combination by that date, it will trigger the Company’s automatic winding up, liquidation and dissolution and, upon notice from us, the trustee of the Trust Account will distribute the amount in the Trust Account to holders of the Public Shares (the “Public Shareholders”). Concurrently, we shall pay, or reserve for payment, from funds not held in trust, our liabilities and obligations, although we cannot assure that there will be sufficient funds for such purpose. If there are insufficient funds held outside the Trust Account for such purpose, our Sponsor has agreed that it will be liable to ensure that the proceeds in the Trust Account are not reduced by the claims of target businesses or claims of vendors or other entities that are owed money by us for services rendered or contracted for or products sold to us and which have not executed a waiver agreement. However, we cannot assure that the liquidator will not determine that he or she requires additional time to evaluate creditors’ claims (particularly if there is uncertainty over the validity or extent of the claims of any creditors). We also cannot assure that a creditor or shareholder will not file a petition with the Cayman Islands Court which, if successful, may result in the Company’s liquidation being subject to the supervision of that court. Such events might delay distribution of some or all of our assets to the Public Shareholders.

Proposed Business Combination

On July 4, 2022, we entered into an agreement and plan of merger agreement (as amended on July 21, 2022, the “Merger Agreement”) with HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), and Orchestra BioMed, Inc., a Delaware corporation (“Orchestra”). Pursuant to the terms of the Merger Agreement, a business combination between the Company and Orchestra (the “Orchestra Business Combination”) will be effected in two steps. First, before the closing of the Orchestra Business Combination, we will deregister in the Cayman Islands and domesticate as a Delaware corporation. Second, at the closing of the Orchestra Business Combination, Merger Sub will merge with and into Orchestra, with Orchestra surviving such merger as the surviving entity (the “Merger”). Upon consummation of the Orchestra Business Combination, Orchestra will become a wholly owned subsidiary of the Company. The Company will then change its name to “Orchestra BioMed Holdings, Inc.”. The Company, after giving effect to the Orchestra Business Combination, will be referred to as “New Orchestra”.

The Merger Agreement contains customary representations, warranties and covenants of the parties thereto. The consummation of the proposed Merger is subject to certain conditions as further described in the Merger Agreement.

Simultaneously with the execution of the Merger Agreement, we and Orchestra entered into separate forward purchase agreements (the “Forward Purchase Agreements”) with certain funds managed by RTW Investments, LP (the “RTW Funds”) and Covidien Group S.à.r.l., an affiliate of Medtronic plc (“Medtronic” and the RTW Funds, each a “Purchasing Party”), pursuant to which each of the Purchasing Parties agreed to purchase approximately $10.0 million of the Company’s ordinary shares, for a total of approximately $20.0 million, less the dollar amount of the Company’s ordinary shares holding redemption rights that the Purchasing Party acquires and holds until immediately prior to the domestication.

Simultaneously with the execution of the Merger Agreement and the Forward Purchase Agreements, we, Orchestra, and the RTW Funds entered into a Backstop Agreement (the “Backstop Agreement”) pursuant to which the RTW Funds, jointly and severally, agreed to purchase such number of the Company’s ordinary shares at a price of $10.00 per share to the extent that the amount of Parent Closing Cash (as defined in the Merger Agreement) as of immediately prior to the closing of the Orchestra Business Combination is less than $60.0 million (inclusive of the $10.0 million commitment by the RTW Funds pursuant to the Forward Purchase Agreement described above).

On October 21, 2022, the Backstop Agreement and the Forward Purchase Agreement with the RTW Funds were amended to provide that: (1) the per share purchase price under each of the Backstop Agreement and the Forward Purchase Agreement will not exceed the redemption price available to Public Shareholders exercising redemption rights at the shareholder meeting held to approve the business combination; (2) any shares purchased pursuant to the Backstop Agreement or the Forward Purchase Agreement, or otherwise acquired by the RTW Funds outside of the existing redemption offer, will not be voted in favor of approving the business combination; and (3) the RTW Funds will waive redemption rights with respect to such purchases in the vote to approve the business combination. The amendments have been filed with the SEC on a Current Report on Form 8-K on October 21, 2022. The Forward Purchase Agreement with Medtronic was not amended.

The closing under the Forward Purchase Agreement with the RTW Funds occurred on July 22, 2022, pursuant to which the RTW Funds purchased 1,000,000 of our ordinary shares at a price of $10.01 per share from an accredited investor in a privately negotiated transaction. The closing under the Forward Purchase Agreement with Medtronic and the closing under the Backstop Agreement, if any, will occur immediately prior to the domestication. The Sponsor and the Purchasing Parties will have registration rights pursuant to the Amended and Restated Registration Rights and Lock-Up Agreement with respect to the Company’s ordinary shares, received in the domestication.

In addition, the Sponsor has agreed that 25% or 1,000,000 shares of its New Orchestra common stock received in the domestication will be forfeited to New Orchestra on the first business day following the fifth anniversary of the closing unless, as to 500,000 shares, the VWAP (as defined in the Merger Agreement) of the New Orchestra common stock is greater than or equal to $15.00 per share over any 20 Trading Days (as defined in the Merger Agreement) within any 30-Trading Day period, and as to the remaining 500,000 shares, the VWAP of the New Orchestra common stock is greater than or equal to $20.00 per share over any 20-Trading Days within any 30-Trading Day period. In addition, subject to the closing of the Orchestra Business Combination, the Sponsor has agreed to forfeit 50% of its Private Placement Warrants, comprising 750,000 Private Placement Warrants, for no consideration. Further, the Sponsor and the other shareholders of the Company as of immediately prior to our Initial Public Offering (the “Initial Stockholders”) have agreed to subject the 4,000,000 shares of New Orchestra common stock to be received in the domestication in exchange for the 4,000,000 ordinary shares held or controlled by the Initial Shareholders prior to the Initial Public Offering (the “Insider Shares”) and 450,000 shares of New Orchestra common stock to be received in the domestication in exchange for the 450,000 Private Placement Shares, to a lock-up for up to 12 months.

See the proxy statement/prospectus included in the Registration Statement on Form S-4/A filed by us with the SEC on December 13, 2022 for additional information.

Extension, Redemptions and Private Purchase

On July 26, 2022, we held an extraordinary general meeting of our shareholders, where the shareholders approved a special resolution (the “Extension Proposal”) to amend the Company’s amended and restated memorandum and articles of association to (i) extend from August 6, 2022 (the “Original Termination Date”) to November 6, 2022 (the “Extended Date”), the date by which, if we had not consummated an initial business combination, the Company must liquidate and dissolve, and (ii) allow us, without another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to three times by an additional one month each time after the Extended Date, upon five days’ advance notice prior to the applicable deadlines, until February 6, 2023 or a total of up to six months after the Original Termination Date, unless the closing of our initial business combination shall have occurred. On October 31, 2022, November 15, 2022, and December 15, 2022, our board of directors of elected to extend the deadline until December 6, 2022, January 6, 2023, and February 6, 2023, respectively.

In connection with the vote to approve the Extension Proposal, the holders of 9,237,883 Public Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.02 per share, for an aggregate redemption amount of approximately $92.6 million. As such, approximately 57.7% of the Public Shares were redeemed and approximately 42.3% of the Public Shares remain outstanding. After the satisfaction of such redemptions, the balance in our Trust Account was $67.8 million.

See the proxy statement/prospectus included in the Registration Statement on Form S-4/A filed by us with the SEC on December 13, 2022 for additional information.

Business Combination Meeting

On January 24, 2023, we held an extraordinary general meeting of shareholders (the “General Meeting”) for the purpose of considering and voting upon, among other things, the Orchestra Business Combination. Each of the proposals presented at the General Meeting, as more fully described in the proxy statement/prospectus dated December 16, 2022, was approved. The submission of the Orchestra Business Combination to the shareholders entitled holders of Public Shares to redeem their shares for their pro rata portion of the funds held in the Trust Account. In connection with the General Meeting, as of January 24, 2023, we received requests for redemption from holders with respect to 1,597,888 Public Shares. The closing date of the Orchestra Business Combination is anticipated to be in January 2023.

Shareholder Approval of Business Combination

In connection with the Orchestra Business Combination, we are seeking shareholder approval of our initial business combination at a general meeting called for such purpose at which public shareholders may seek to convert their public shares, regardless of whether they vote for or against the proposed business combination, into their pro rata share of the aggregate amount then on deposit in the trust account (net of taxes payable). See the proxy statement/prospectus included in the Registration Statement on Form S-4/A filed by us with the SEC on December 13, 2022 for additional information.

In connection with the Orchestra Business Combination, we will:

●

permit shareholders to convert their shares in conjunction with a proxy solicitation pursuant to Regulation 14A of the Exchange Act, which regulates the solicitation of proxies, and not pursuant to the tender offer rules, and

●

file proxy materials with the SEC.

Notwithstanding the foregoing, our initial shareholders have agreed, pursuant to written letter agreements with us, not to convert any public shares held by them into their pro rata share of the aggregate amount then on deposit in the trust account. We will consummate our initial business combination only if we have net tangible assets of at least $5,000,001 upon such consummation and an ordinary resolution under Cayman Islands law, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the company will be required to approve the business combination..

Our initial shareholders, including our officers and directors, have agreed (1) to vote any ordinary shares owned by them in favor of any proposed business combination, subject to applicable law, (2) not to convert any ordinary shares into the right to receive cash from the trust account in connection with a shareholder vote to approve a proposed initial business combination or a vote to amend the provisions of our memorandum and articles of association relating to shareholders’ rights or pre-business combination activity and (3) not to sell any ordinary shares in any tender in connection with a proposed initial business combination. As a result, we could need as little as 126,060 of our public shares (or approximately 1.12% of our public shares) to attend the general meeting to form a quorum, none of which needs to be voted in favor of the transaction in order to have such transaction approved.

Conversion/Tender Rights

At any general meeting called to approve an initial business combination, public shareholders may seek to convert their public shares, regardless of whether they vote for or against the proposed business combination, into their pro rata share of the aggregate amount then on deposit in the trust account, less any taxes then due but not yet paid. Notwithstanding the foregoing, our initial shareholders have agreed, pursuant to written letter agreements with us, not to convert any public shares held by them into their pro rata share of the aggregate amount then on deposit in the trust account. The conversion rights will be effected under our Amended and Restated Memorandum and Articles of Association and Cayman Islands law as redemptions. If we hold a meeting to approve an initial business combination, a holder will always have the ability to vote against a proposed business combination and not seek conversion of his shares.

Our initial shareholders, officers and directors will not have conversion rights with respect to any ordinary shares owned by them, directly or indirectly.

We may also require public shareholders, whether they are a record holder or hold their shares in “street name,” to either tender their certificates (if any) to our transfer agent or to deliver their shares to the transfer agent electronically using Depository Trust Company’s DWAC (Deposit/Withdrawal At Custodian) System, at the holder’s option, at any time at or prior to the vote on the business combination. Once the shares are converted by the holder, and effectively redeemed by us under Cayman Islands law, the transfer agent will then update our Register of Members to reflect all conversions. The proxy solicitation materials that we will furnish to shareholders in connection with the vote for any proposed business combination will indicate whether we are requiring shareholders to satisfy such delivery requirements. Accordingly, a shareholder would have from the time our proxy statement is mailed through the vote on the business combination to deliver his, her or its shares if he, she or it wishes to seek to exercise his conversion rights. Under our Amended and Restated Memorandum and Articles of Association, we are required to provide at least 10 days’ advance notice of any general meeting, which would be the minimum amount of time a shareholder would have to determine whether to exercise conversion rights. As a result, if we require public shareholders who wish to convert their ordinary shares into the right to receive a pro rata portion of the funds in the trust account to comply with the foregoing delivery requirements, holders may not have sufficient time to receive the notice and deliver their shares for conversion. Accordingly, investors may not be able to exercise their conversion rights and may be forced to retain our ordinary shares when they otherwise would not want to.

There is a nominal cost associated with this tendering process and the act of certificating the shares or delivering them through the DWAC System. The transfer agent will typically charge the tendering broker a nominal fee and it would be up to the broker whether or not to pass this cost on to the converting holder. However, this fee would be incurred regardless of whether or not we require holders seeking to exercise conversion rights. The need to deliver shares is a requirement of exercising conversion rights regardless of the timing of when such delivery must be effectuated. However, in the event we require shareholders seeking to exercise conversion rights to deliver their shares prior to the consummation of the proposed business combination and the proposed business combination is not consummated, this may result in an increased cost to shareholders.

Any request to convert or tender such shares, once made, may be withdrawn at any time up to the vote on the proposed business combination. Furthermore, if a holder of a public share delivered his, her or its certificate in connection with an election of his, her or its conversion or tender and subsequently decides prior to the vote on the business combination or the expiration of the tender offer not to elect to exercise such rights, he, she or it may simply request that the transfer agent return the certificate (physically or electronically).

If the initial business combination is not approved or completed for any reason, then our public shareholders who elected to exercise their conversion or tender rights would not be entitled to convert their shares for the applicable pro rata share of the trust account. In such case, we will promptly return any shares delivered by public holders.

Liquidation if No Business Combination

If we do not complete a business combination by February 6, 2023, or such later time as our shareholders may approve in accordance with the Company’s amended and restated memorandum, it will trigger our automatic winding up, liquidation and dissolution pursuant to the terms of our Amended and Restated Memorandum and Articles of Association. As a result, this has the same effect as if we had formally gone through a voluntary liquidation procedure under the Companies Law. Accordingly, no vote would be required from our shareholders to commence such a voluntary winding up, liquidation and dissolution. At such time, the private warrants will expire and our sponsor will receive nothing upon a liquidation with respect to such private warrants, and the private warrants will be worthless.

The amount in the trust account (less approximately $1,600 representing the aggregate nominal par value of the shares of our public shareholders) under the Companies Law will be treated as share premium which is distributable under the Companies Law, provided that immediately following the date on which the proposed distribution is proposed to be made, we are able to pay our debts as they fall due in the ordinary course of business. If we are forced to liquidate the trust account, we anticipate that we would distribute to our public shareholders the amount in the trust account calculated as of the date that is two days prior to the distribution date (including any accrued interest). Prior to such distribution, we would be required to assess all claims that may be potentially brought against us by our creditors for amounts they are actually owed and make provision for such amounts, as creditors take priority over our public shareholders with respect to amounts that are owed to them. We cannot assure you that we will properly assess all claims that may be potentially brought against us. As such, our shareholders could potentially be liable for any claims of creditors to the extent of distributions received by them as an unlawful payment in the event we enter an insolvent liquidation. Furthermore, while we will seek to have all vendors and service providers (which would include any third parties we engaged to assist us in any way in connection with our search for a target business) and prospective target businesses execute agreements with us waiving any right, title, interest or claim of any kind they may have in or to any monies held in the trust account, there is no guarantee that they will execute such agreements. Nor is there any guarantee that, even if such entities execute such agreements with us, they will not seek recourse against the trust account or that a court would conclude that such agreements are legally enforceable.

Each of our initial shareholders and our sponsor has agreed to waive its rights to participate in any liquidation of our trust account or other assets with respect to the insider shares and private shares and to vote their insider shares and private shares in favor of any dissolution and plan of distribution which we submit to a vote of shareholders. There will be no distribution from the trust account with respect to our private warrants, which will expire worthless.

If we do not complete an initial business combination and expend all of the proceeds of our initial public offering other than the proceeds deposited in the trust account, and without taking into account interest, if any, earned on the trust account, the initial per-share distribution from the trust account would be $10.00.

The proceeds deposited in the trust account could, however, become subject to the claims of our creditors, which would be prior to the claims of our public shareholders. Although we will seek to have all vendors, including lenders for money borrowed, prospective target businesses or other entities we engage execute agreements with us waiving any right, title, interest or claim of any kind in or to any monies held in the trust account for the benefit of our public shareholders, there is no guarantee that they will execute such agreements or even if they execute such agreements that they would be prevented from bringing claims against the trust account, including but not limited to, fraudulent inducement, breach of fiduciary responsibility or other similar claims, as well as claims challenging the enforceability of the waiver, in each case in order to gain an advantage with a claim against our assets, including the funds held in the trust account. If any third party refused to execute an agreement waiving such claims to the monies held in the trust account, we would perform an analysis of the alternatives available to us if we chose not to engage such third party and evaluate if such engagement would be in the best interest of our shareholders if such third party refused to waive such claims. Examples of possible instances where we may engage a third party that refused to execute a waiver include the engagement of a third-party consultant whose particular expertise or skills are believed by management to be significantly superior to those of other consultants that would agree to execute a waiver or in cases where management is unable to find a provider of required services willing to provide the waiver. In any event, our management would perform an analysis of the alternatives available to it and would only enter into an agreement with a third party that did not execute a waiver if management believed that such third party’s engagement would be significantly more beneficial to us than any alternative. In addition, there is no guarantee that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations, contracts or agreements with us and will not seek recourse against the trust account for any reason.

Our sponsor, HSAC 2 Holdings, LLC, has agreed that, if we liquidate the trust account prior to the consummation of a business combination, it will be liable to pay debts and obligations to target businesses or vendors or other entities that are owed money by us for services rendered or contracted for or products sold to us, but only to the extent necessary to ensure that such debts or obligations do not reduce the amounts in the trust account and only if such parties have not executed a waiver agreement. However, we cannot assure you that our sponsor will be able to satisfy those obligations if it is required to do so. Accordingly, the actual per-share distribution could be less than $10.00 due to claims of creditors. Additionally, if we are forced to file a bankruptcy case or an involuntary bankruptcy case is filed against us which is not dismissed, the proceeds held in the trust account could be subject to applicable bankruptcy or insolvency law, and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our shareholders. To the extent any bankruptcy claims deplete the trust account, we cannot assure you we will be able to return to our public shareholders at least $10.00 per ordinary share.

Potential Revisions to Agreements with our Initial Shareholders

Each of our initial shareholders has entered into letter agreements with us pursuant to which each of them has agreed to do certain things relating to us and our activities prior to a business combination. We could seek to amend these letter agreements without the approval of shareholders, although we have no intention to do so. In particular:

●

Restrictions relating to liquidating the trust account if we failed to consummate a business combination in the time frames specified above could be amended, but only if we allowed all shareholders to redeem their shares in connection with such amendment;

●

Restrictions relating to our initial shareholders being required to vote in favor of a business combination or against any amendments to our organizational documents could be amended to allow our initial shareholders to vote on a transaction as they wished;

●

The requirement of members of the management team to remain our officer or director until the closing of a business combination could be amended to allow persons to resign from their positions with us if, for example, the current management team was having difficulty locating a target business and another management team had a potential target business;

●

The restrictions on transfer of our ordinary shares could be amended to allow transfer to third parties who were not members of our original management team;

●

The obligation of our management team to not propose amendments to our organizational documents could be amended to allow them to propose such changes to our shareholders;

●

The obligation of our initial shareholders to not receive any compensation in connection with a business combination could be modified in order to allow them to receive such compensation; and

●

The requirement to obtain a valuation for any target business affiliated with our initial shareholders, in the event it was too expensive to do so.

Except as specified above, shareholders would not be required to be given the opportunity to redeem their shares in connection with such changes. Such changes could result in:

●

Our initial shareholders being able to vote against a business combination or in favor of changes to our organizational documents;

●

Our operations being controlled by a new management team that our shareholders did not elect to invest with;

●

Our initial shareholders receiving compensation in connection with a business combination; and

●

Our initial shareholders closing a transaction with one of their affiliates without receiving an independent valuation of such business.

We will not agree to any such changes unless we believed that such changes were in the best interests of our shareholders (for example, if we believed such a modification were necessary to complete a business combination). Each of our officers and directors has fiduciary obligations to us requiring that he or she act in our best interests and the best interests of our shareholders.

Emerging Growth Company Status and Other Information

We are an emerging growth company as defined in Section 2(a) of the Securities Act of 1933, as amended, or the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (which we refer to herein as the JOBS Act). As such, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. If some investors find our securities less attractive as a result, there may be a less active trading market for our securities and the prices of our securities may be more volatile.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised, and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the date of the IPO, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our ordinary shares that are held by non-affiliates exceeds $700 million as of the prior June 30, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three year period.

Competition

In identifying, evaluating and selecting a target business, we encountered and may continue to encounter intense competition from other entities having a business objective similar to ours. Many of these entities are well established and have extensive experience identifying and effecting business combinations directly or through affiliates. Many of these competitors possess greater technical, human and other resources than us and our financial resources will be relatively limited when contrasted with those of many of these competitors. While we believe there may be numerous potential target businesses that we could complete a business combination with utilizing the net proceeds of our initial public offering, our ability to compete in completing a business combination with certain sizable target businesses may be limited by our available financial resources.

The following also may not be viewed favorably by certain target businesses:

●

our obligation to seek shareholder approval of our initial business combination or engage in a tender offer may delay the completion of a transaction;

●

our obligation to convert ordinary shares held by our public shareholders may reduce the resources available to us for our initial business combination;

●

our outstanding private warrants and the potential future dilution they represent;

●

our obligation to pay the deferred underwriting commission to Chardan Capital Markets, LLC upon consummation of our initial business combination;

●

our obligation to either repay working capital loans that may be made to us by our initial shareholders or their affiliates;

●

our obligation to register the resale of the insider shares, as well as the private shares and private warrants (and underlying securities) and any shares issued to our initial shareholders or their affiliates upon conversion of working capital loans; and

●

the impact on the target business’ assets as a result of unknown liabilities under the securities laws or otherwise depending on developments involving us prior to the consummation of a business combination.

Any of these factors may place us at a competitive disadvantage in successfully negotiating our initial business combination. Our management believes, however, that our status as a public entity and potential access to the United States public equity markets may give us a competitive advantage over privately held entities having a similar business objective as ours in connection with an initial business combination with a target business with significant growth potential on favorable terms.

If we succeed in effecting our initial business combination, there will be, in all likelihood, intense competition from competitors of the target business. Subsequent to our initial business combination, we may not have the resources or ability to compete effectively.

Employees

We have four executive officers. These individuals are not obligated to devote any specific number of hours to our matters and intend to devote only as much time as they deem necessary to our affairs. The amount of time they will devote in any time period will vary based on whether a target business has been selected for the business combination and the stage of the business combination process the company is in. Accordingly, once a suitable target business to consummate our initial business combination with has been located, management will spend more time investigating such target business and negotiating and processing the business combination (and consequently spend more time on our affairs) than had been spent prior to locating a suitable target business. We presently expect our executive officers to devote an average of approximately 10 hours per week to our business. We do not intend to have any full-time employees prior to the consummation of our initial business combination.

ITEM 1A. RISK FACTORS

As a smaller reporting company, we are not required to make disclosures under this Item.

ITEM 1B. UNRESOLVED STAFF COMMENTS

Not applicable.

ITEM 2. PROPERTIES

We currently maintain our principal executive offices at 40 10^th Avenue, Floor 7, New York, NY 10014. The cost for this space is included in the $10,000 per-month fee (subject to deferral as described herein) payable to HSAC 2 Holdings, LLC, for office space, utilities and secretarial services. Our agreement with HSAC 2 Holdings, LLC provides that, commencing on the date that our ordinary shares were first listed on the Nasdaq Capital Market and until we consummate a business combination, such office space, as well as utilities and secretarial services, will be made available to us as may be required from time to time. We believe that the fee charged by HSAC 2 Holdings, LLC is at least as favorable as we could have obtained from an unaffiliated person. We consider our current office space, combined with the other office space otherwise available to our executive officers, adequate for our current operations.

ITEM 3. LEGAL PROCEEDINGS

We may be subject to legal proceedings, investigations and claims incidental to the conduct of our business from time to time. We are not currently a party to any material litigation or other legal proceedings brought against us. We are also not aware of any legal proceeding, investigation or claim, or other legal exposure that has a more than remote possibility of having a material adverse effect on our business, financial condition or results of operations.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

part II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Our ordinary shares began to trade on The Nasdaq Capital Market, or Nasdaq, under the symbol “HSAQ” on August 4, 2020.

Holders of Record

As of January 23, 2023, there were 11,212,117 of our ordinary shares issued and outstanding held by 7 holders of record. The number of record holders was determined from the records of our transfer agent and does not include beneficial owners of ordinary shares whose shares are held in the names of various security brokers, dealers, and registered clearing agencies.

Dividends

We have not paid any cash dividends on our ordinary shares to date and do not intend to pay cash dividends prior to the completion of an initial business combination. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition subsequent to completion of a business combination. The payment of any dividends subsequent to a business combination will be within the discretion of our board of directors at such time. It is the present intention of our board of directors to retain all earnings, if any, for use in our business operations and, accordingly, our board of directors does not anticipate declaring any dividends in the foreseeable future. In addition, our board of directors is not currently contemplating and does not anticipate declaring any share dividends in the foreseeable future. Further, if we incur any indebtedness, our ability to declare dividends may be limited by restrictive covenants we may agree to in connection therewith.

Securities Authorized for Issuance Under Equity Compensation Plans

None.

Recent Sales of Unregistered Securities

None.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

Extension Proposal

Business Combination Meeting

ITEM 6. [RESERVED]

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

References to the “Company,” “Health Sciences Acquisitions Corporation 2,” “our,” “us” or “we” refer to Health Sciences Acquisitions Corporation 2. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the annual financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Cautionary Note Regarding Forward-Looking Statements

This Annual Report on Form 10-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other U.S. Securities and Exchange Commission (“SEC”) filings

Overview

We are a blank check company incorporated as a Cayman Islands exempted company on May 25, 2020. We were formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses, which we refer to throughout this annual report as our initial business combination. Although there is no restriction or limitation on what industry our target operates in, it is our intention to pursue prospective targets that are focused on healthcare innovation. We are an emerging growth company and, as such, we are subject to all of the risks associated with emerging growth companies.

Proposed Business Combination

On July 4, 2022, we entered into an agreement and plan of merger agreement (as amended on July 21, 2022, the “Merger Agreement”) with HSAC Olympus Merger Sub, Inc., a Delaware corporation and our wholly owned subsidiary (“Merger Sub”), and Orchestra BioMed, Inc., a Delaware corporation (“Orchestra”). Pursuant to the terms of the Merger Agreement, a business combination between us and Orchestra (the “Orchestra Business Combination”) will be effected in two steps. First, before the closing of the Orchestra Business Combination, we will deregister in the Cayman Islands and domesticate as a Delaware corporation. Second, at the closing of the Orchestra Business Combination, Merger Sub will merge with and into Orchestra, with Orchestra surviving such merger as the surviving entity (the “Merger”). Upon consummation of the Orchestra Business Combination, Orchestra will become our wholly owned subsidiary. We will then change our name to “Orchestra BioMed Holdings, Inc.”. We refer to the Company, after giving effect to the Orchestra Business Combination, as “New Orchestra”.

Simultaneously with the execution of the Merger Agreement, we and Orchestra entered into separate forward purchase agreements (the “Forward Purchase Agreements”) with certain funds managed by RTW Investments, LP (the “RTW Funds”) and Covidien Group S.à.r.l., an affiliate of Medtronic plc (“Medtronic” and the RTW Funds, each a “Purchasing Party”), pursuant to which each of the Purchasing Parties agreed to purchase approximately $10.0 million of our ordinary shares, for a total of approximately $20.0 million, less the dollar amount of our ordinary shares holding redemption rights that the Purchasing Party acquires and holds until immediately prior to the domestication.

Simultaneously with the execution of the Merger Agreement and the Forward Purchase Agreements, we, Orchestra, and the RTW Funds entered into a Backstop Agreement (the “Backstop Agreement”) pursuant to which the RTW Funds, jointly and severally, agreed to purchase such number of our ordinary shares at a price of $10.00 per share to the extent that the amount of Parent Closing Cash (as defined in the Merger Agreement) as of immediately prior to the closing of the Orchestra Business Combination is less than $60.0 million (inclusive of the $10.0 million commitment by the RTW Funds pursuant to the Forward Purchase Agreement described above).

The closing under the Forward Purchase Agreement with the RTW Funds occurred on July 22, 2022, pursuant to which the RTW Funds purchased 1,000,000 of our ordinary shares at a price of $10.01 per share from an accredited investor in a privately negotiated transaction. The closing under the Forward Purchase Agreement with Medtronic and the closing under the Backstop Agreement, if any, will occur immediately prior to the domestication. The Sponsor and the Purchasing Parties will have registration rights pursuant to the Amended and Restated Registration Rights and Lock-Up Agreement with respect to our ordinary shares, received in the domestication.

In addition, the Sponsor has agreed that 25% or 1,000,000 shares of its New Orchestra common stock received in the domestication will be forfeited to New Orchestra on the first business day following the fifth anniversary of the closing unless, as to 500,000 shares, the VWAP (as defined in the Merger Agreement) of the New Orchestra common stock is greater than or equal to $15.00 per share over any 20 Trading Days (as defined in the Merger Agreement) within any 30-Trading Day period, and as to the remaining 500,000 shares, the VWAP of the New Orchestra common stock is greater than or equal to $20.00 per share over any 20-Trading Days within any 30-Trading Day period. In addition, subject to the closing of the Orchestra Business Combination, the Sponsor has agreed to forfeit 50% of its Private Placement Warrants, comprising 750,000 Private Placement Warrants, for no consideration. Further, the Sponsor and the other shareholders as of immediately prior to our Initial Public Offering (the “Initial Stockholders”) have agreed to subject the 4,000,000 shares of New Orchestra common stock to be received in the domestication in exchange for the 4,000,000 ordinary shares held or controlled by the Initial Shareholders prior to the Initial Public Offering (the “Insider Shares”) and 450,000 shares of New Orchestra common stock to be received in the domestication in exchange for the 450,000 Private Placement Shares, to a lock-up for up to 12 months.

See the proxy statement/prospectus included in the Registration Statement on Form S-4/A filed by us with the SEC on December 13, 2022 for additional information.

Extension, Redemptions and Private Purchase

See the proxy statement/prospectus included in the Registration Statement on Form S-4/A filed by us with the SEC on December 13, 2022 for additional information.

Business Combination Meeting

Liquidity and Going Concern

As of December 31, 2022, we had approximately $175,000 of cash in our operating account and a working capital deficit of approximately $1.8 million.

Prior to the completion of the Initial Public Offering, our liquidity needs had been satisfied through a payment of $28,750 from our Sponsor to exchange for the issuance of 3,593,750 ordinary shares to the Sponsor, and a loan of $300,000 pursuant to a promissory note originally issued to our Sponsor on June 11, 2020 (the “Note”), which was repaid in full on August 7, 2020. Subsequent to the consummation of the Initial Public Offering and Private Placement, our liquidity needs have been satisfied with the proceeds from the consummation of the Private Placement not held in the Trust Account. In addition, in order to finance transaction costs in connection with an initial business combination, the Sponsor may, but is not obligated to, provide us loans (the “Working Capital Loans”). As of December 31, 2022 and 2021, there were no Working Capital Loans available or outstanding.

In connection with our assessment of going concern considerations in accordance with FASB Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the working capital deficit, as well as the mandatory liquidation and subsequent dissolution raises substantial doubt about our ability to continue as a going concern. Management intends to complete a business combination prior to the mandatory liquidation date. No adjustments have been made to the carrying amounts of assets or liabilities should we be required to liquidate after February 6, 2023. The consolidated financial statements do not include any adjustment that might be necessary if we are unable to continue as a going concern.

Various social and political circumstances in the United States and around the world (including wars and other forms of conflict, including rising trade tensions between the United States and China, and other uncertainties regarding actual and potential shifts in the United States and foreign, trade, economic and other policies with other countries, terrorist acts, security operations and catastrophic events such as fires, floods, earthquakes, tornadoes, hurricanes and global health epidemics), may also contribute to increased market volatility and economic uncertainties or deterioration in the United States and worldwide. Specifically, the rising conflict between Russia and Ukraine and resulting market volatility could adversely affect our ability to complete a business combination. In response to the conflict between Russia and Ukraine, the United States and other countries have imposed sanctions or other restrictive actions against Russia. Any of the above factors, including sanctions, export controls, tariffs, trade wars and other governmental actions, could have a material adverse effect on our ability to complete a business combination and the value of our securities.

Management continues to evaluate the impact of these types of risks on the industry and has concluded that while it is reasonably possible that these types of risks could have a negative effect on our financial position, results of our operations and/or search for a target company, the specific impact is not readily determinable as of the date of these consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Results of Operations

We will not be generating any operating revenues until the closing and completion of our initial business combination, at the earliest. We generate non-operating income in the form of interest income on investments held in the Trust Account. We are incurring expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance) and expenses related to our search for an initial business combination.

For the year ended December 31, 2022, we had a net loss of approximately $2.7 million, which consisted of approximately $3.0 million in general and administrative expenses and related party administrative fees of $120,000, partially offset by approximately $345,000 of interest income from investments held in the Trust Account.

For the year ended December 31, 2021, we had a net loss of approximately $379,000 which consisted of approximately $275,000 in general and administrative expenses and related party administrative fees of $120,000, partially offset by approximately $16,000 of net income on the investments held in the Trust Account.

Related Party Transactions

Insider Shares

On June 11, 2020, we issued 3,593,750 ordinary shares to the Sponsor for an aggregate purchase price of $28,750. On August 3, 2020, we effected a share dividend of 0.113043478 ordinary shares for each outstanding share (an aggregate of 406,250 ordinary shares), resulting in an aggregate of 4,000,000 ordinary shares outstanding (the “Insider Shares”). All shares and associated amounts have been retroactively restated to reflect the share dividend. The holders of the Insider Shares had agreed to forfeit up to an aggregate of 521,739 Insider Shares, on a pro rata basis, to the extent that the option to purchase additional ordinary shares is not exercised in full by the underwriters. On August 6, 2020, the underwriters fully exercised the over-allotment option; thus, the 521,739 Insider Shares were no longer subject to forfeiture.

The Initial Shareholders have agreed not to transfer, assign or sell any of their Insider Shares (except to certain permitted transferees) until, with respect to 50% of the Insider Shares, the earlier of six months after the date of the consummation of the initial business combination and the date on which the closing price of our ordinary shares equals or exceeds $12.50 per ordinary share for any 20 trading days within a 30-trading day period following the consummation of the initial business combination, and, with respect to the remaining 50% of the Insider Shares, six months after the date of the consummation of the initial business combination, or earlier in each case if, subsequent to the initial business combination, we complete a liquidation, merger, stock exchange or other similar transaction which results in all of the shareholders having the right to exchange their ordinary shares for cash, securities or other property.

Related Party Loans

On June 11, 2020, our Sponsor agreed to loan us up to $300,000 to be used for the payment of costs related to the Initial Public Offering pursuant to the Note. The Note was non-interest bearing, unsecured and due on the date we consummate the Initial Public Offering. We borrowed $300,000 under the Note and repaid the Note in full on August 7, 2020. Subsequent to the repayment, the facility was no longer available to us.

In addition, in order to finance transaction costs in connection with an initial business combination, the Initial Shareholders or their affiliates may, but are not obligated to, loan us the Working Capital Loans, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion. Each loan would be evidenced by a promissory note. The notes would either be paid upon consummation of the business combination, without interest, or, at the lender’s discretion, up to $500,000 of such loans may be converted upon consummation of the business combination into additional private warrants at a price of $1.00 per warrant. If we do not complete a business combination within the Combination Period, the Working Capital Loans will be repaid only from amounts remaining outside the Trust Account, if any. The warrants would be identical to the Private Placement Warrants. As of December 31, 2022 and 2021, the Company had no borrowings under the Working Capital Loans.

Administrative Services Agreement

Commencing on the date of the prospectus relating to our Initial Public Offering, we agreed to pay the Sponsor a total of $10,000 per month for office space and certain office and secretarial services. Upon completion of the business combination or our liquidation, we will cease paying these monthly fees. For the years ended December 31, 2022 and 2021, we incurred $120,000 in expenses for these services. As of December 31, 2022 and 2021, $0 and $150,000 were due to the Sponsor and are included in accrued expenses - related party on the accompanying consolidated balance sheets, respectively.

Purchase Agreements and Backstop Agreement

On August 3, 2020, in connection with the consummation of the Initial Public Offering, we entered into a purchase agreement (“FPA”) with our Sponsor pursuant to which the Sponsor agreed that it will purchase an aggregate of 2,500,000 ordinary shares of our Company at a price of $10.00 per share, for an aggregate purchase price of $25.0 million prior to, currently with, or following the consummation of a business combination, either in open market transactions (to the extent permitted by law) or in a private placement with us. This FPA commitment has been satisfied by the RTW Funds through: (a) an investment of $15 million in Orchestra’s Series D Financing, and (b) the Forward Purchase Agreement described below.

Simultaneously with the execution of the Merger Agreement, our Company and Orchestra entered into separate Forward Purchase Agreements with the RTW Funds and Medtronic, pursuant to which each of the Purchasing Parties agreed to purchase approximately $10.0 million of our ordinary shares, for a total of approximately $20.0 million, less the dollar amount of the our ordinary shares holding redemption rights that the Purchasing Party acquires and holds until immediately prior to the domestication.

Simultaneously with the execution of the Merger Agreement and the Forward Purchase Agreements, our Company, Orchestra, and the RTW Funds entered into the Backstop Agreement, pursuant to which the RTW Funds, jointly and severally, agreed to purchase such number of the our ordinary shares at a price of $10.00 per share to the extent that the amount of Parent Closing Cash (as defined in the Merger Agreement) as of immediately prior to the closing of the Orchestra Business Combination is less than $60.0 million (inclusive of the $10.0 million commitment by the RTW Funds pursuant to the Forward Purchase Agreement described above).

The closing under the Forward Purchase Agreement with the RTW Funds occurred on July 22, 2022, pursuant to which the RTW Funds purchased 1,000,000 of our ordinary shares at a price of $10.01 per share from an accredited investor in a privately negotiated transaction. The closing under the Forward Purchase Agreement with Medtronic and the closing under the Backstop Agreement, if any, will occur immediately prior to the domestication. The Sponsor and the Purchasing Parties will have registration rights pursuant to the Amended and Restated Registration Rights and Lock-Up Agreement with respect to our ordinary shares, received in the domestication.

Company Shareholder Support Agreement and Forfeiture

Contemporaneously with the execution of the Merger Agreement, we and Orchestra entered into a support agreement (the “Parent Support Agreement”) with the Sponsor and certain of our other shareholders (each a “Shareholder”) pursuant to which the Shareholders identified therein have agreed (a) to appear at any shareholder meetings called to approve the Merger or any proposal to extend the period of time we are afforded under our organizational documents and our prospectus to consummate an initial business combination (an “Extension Proposal”), (b) not to redeem their shares or any other of our equity securities now or in future acquired or beneficially owned, (c) to vote such shares and equity securities, to the extent permitted by law, (i) in favor of the domestication, the Merger and related transactions, (ii) in favor of any Extension Proposal, (iii) against any change in our business, management or board contrary to the Merger Agreement and against any other proposal reasonably expected to breach, prevent or impede the Merger, and (d) to waive anti-dilution and similar rights with respect to such shares, whether under our amended and restated memorandum and articles of association, applicable law, or a contract regarding the Merger and related transactions with us. In addition, the Sponsor has agreed that 25% or 1,000,000 shares of its New Orchestra Common Stock received in the domestication will be forfeited to New Orchestra on the first business day following the fifth anniversary of the closing of the Orchestra Business Combination unless, as to 500,000 shares, the VWAP (as defined in the Merger Agreement) of the New Orchestra Common Stock is greater than or equal to $15.00 per share over any 20 Trading Days (as defined in the Merger Agreement) within any 30-Trading Day period, and as to the remaining 500,000 shares, the VWAP of the New Orchestra Common Stock is greater than or equal to $20.00 per share over any 20-Trading Days within any 30-Trading Day period. Further, subject to the closing of the Orchestra Business Combination, the Sponsor has agreed to forfeit 50% of its warrants, comprising 750,000 warrants, for no consideration, immediately prior to the Closing. Pursuant to the terms of the Merger Agreement, immediately following such forfeiture and prior to the Closing, the Company will issue 750,000 New Warrants to eleven specified employees and directors of Orchestra. These New Warrants will have substantially similar terms to the forfeited Private Warrants, except that they will become exercisable between 24 and 36 months after the Closing.

Contractual Obligations

Registration Rights

The holders of the Insider Shares, the Private Placement Shares, the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration rights agreement. The holders of a majority of these securities are entitled to make up to two demands that we register such securities. The holders of the majority of the Insider Shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these ordinary shares are to be released from escrow. The holders of a majority of the Private Placement Shares, the Private Placement Warrants or warrants that may be issued upon conversion of Working Capital Loans made to us can elect to exercise these registration rights at any time after we consummate a business combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to our consummation of the initial business combination. We will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The underwriters were entitled to an underwriting discount of $0.20 per share, or $3.2 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, the underwriters will be entitled to a deferred underwriting commission of $0.35 per share, or $5.6 million in the aggregate since the underwriters’ over-allotment option was exercised in full. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that we complete a business combination, subject to the terms of the underwriting agreement.

Critical Accounting Policies and Estimates

Cash and Investments Held in the Trust Account

Our portfolio of investments held in the Trust Account has been comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When our investments held in the Trust Account were comprised of U.S. government securities, the investments are classified as trading securities. When our investments held in the Trust Account were comprised of money market funds, the investments were recognized at fair value. Trading securities and investments in money market funds are presented on the consolidated balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in interest income from investments held in the Trust Account in the accompanying consolidated statements of operations. The estimated fair values of investments held in the Trust Account were determined using available market information. On July 25, 2022, the entire Trust Account balance was transferred into cash following redemptions in connection with the vote to approve the Extension Proposal. As of December 31, 2022, only cash is held in the Trust Account.

Ordinary Shares Subject to Possible Redemption

We account for our ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within our control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. Our Public Shares feature certain redemption rights that are considered to be outside of our control and subject to the occurrence of uncertain future events. Accordingly, as of December 31, 2022 and 2021, 6,762,117 and 16,000,000 ordinary shares subject to possible redemption, respectively, are presented as temporary equity, outside of the shareholders’ deficit section of the accompanying consolidated balance sheets.

Under ASC 480-10-S99, we have elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of the reporting period. This method would view the end of the reporting period as if it were also the redemption date of the security. Effective with the closing of the Initial Public Offering, we recognized the accretion from initial book value to redemption amount, which resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit.

Net Loss Per Ordinary Share

We comply with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net loss per ordinary share is calculated by dividing the net loss by the weighted average number of ordinary shares outstanding for the respective period.

The calculation of diluted net loss per ordinary share does not consider the effect of the Private Placement Warrants to purchase 1,500,000 ordinary shares since their exercise is contingent upon future events and their inclusion would be anti-dilutive under the treasury stock method. As a result, diluted net loss per share is the same as basic net loss per share for years ended December 31, 2022 and 2021. Accretion associated with the redeemable ordinary shares is excluded from earnings per share as the redemption value approximates fair value.

Off-Balance Sheet Arrangements

As of December 31, 2022 and 2021, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K and did not have any commitments or contractual obligations.

JOBS Act

The Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We qualify as an “emerging growth company” and under the JOBS Act are allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As a result, the financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.

Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis) and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our Initial Public Offering or until we are no longer an “emerging growth company,” whichever is earlier.

Recent Accounting Pronouncements

Our management does not believe there are any recently issued, but not yet effective, accounting pronouncements, if currently adopted, that would have a material effect on our consolidated financial statements.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, we are not required to make disclosures under this Item.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Our consolidated financial statements and the notes thereto begin on page F-1 of this Annual Report.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such as this Annual Report, is recorded, processed, summarized, and reported within the time period specified in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective as of December 31, 2022.

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Management’s Report on Internal Controls Over Financial Reporting

As required by SEC rules and regulations implementing Section 404 of the Sarbanes-Oxley Act, our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our consolidated financial statements for external reporting purposes in accordance with U.S. GAAP. Our internal control over financial reporting includes those policies and procedures that:

(1)

pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of our company,

(2)

provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors, and

(3)

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect errors or misstatements in our consolidated financial statements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate. Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2022. In making these assessments, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). Based on our assessments and those criteria, management determined that our internal controls over financial reporting were effective as of December 31, 2022.

This Annual Report on Form 10-K does not include an attestation report of internal controls from our independent registered public accounting firm due to our status as an emerging growth company under the JOBS Act.

Changes in Internal Control over Financial Reporting

During the most recently completed fiscal quarter, there has been no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION

None.

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

Not applicable.

part III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The following table sets forth information about our directors and executive officers:

Name	Age	Position
Roderick Wong	45	President, Chief Executive Officer and Chairman
Naveen Yalamanchi	46	Executive Vice President, Chief Financial Officer and Director
Alice Lee	52	Vice President of Operations, Secretary and Treasurer
Stephanie A. Sirota	48	Vice President of Corporate Strategy and Corporate Communications
Pedro Granadillo	75	Director
Carsten Boess	56	Director
Stuart Peltz	63	Director
Michael Brophy	43	Director

Roderick Wong, MD, has served as our President and Chief Executive Officer since June 2020 and as a member of our board of directors since our inception. Dr. Wong has more than 16 years of healthcare investing experience. Since 2009, he has served as Managing Partner and Chief Investment Officer of RTW. Prior to forming RTW, Dr. Wong was a Managing Director and sole Portfolio Manager for the Davidson Kempner Healthcare Funds. Prior to joining Davidson Kempner, Dr. Wong held various healthcare investment and research roles at Sigma Capital Partners and Cowen & Company. Dr. Wong served as Chairman of the board of directors of Health Sciences Acquisitions Corporation (“HSAC”) and its Chief Executive Officer from January 2019 until December 2019. Other current and previous directorships include: Rocket Pharmaceuticals, Inc., where he serves as Chairman, a position he has held since Rocket’s inception in July 2015; Attune Pharmaceuticals, a portfolio company of RTW, where he has served as a director since June 2018; Landos Biopharma, where he served as a director from 2019 to June 2022; Ji Xing Pharmaceuticals, a portfolio company of RTW, where he has served as director since 2019; and NiKang Therapeutics, a portfolio company of RTW, where he has served as a director since September 2020. Dr. Wong previously served on the board of directors of Penwest Pharmaceuticals in 2010 and Avidity Biosciences from 2019 until August 2021. He simultaneously received an MD from the University of Pennsylvania Medical School and an MBA from Harvard Business School, and graduated Phi Beta Kappa with a BS in Economics from Duke University.

Naveen Yalamanchi, MD, has served as our Executive Vice President and Chief Financial Officer and as a member of our board of directors since June 2020. Dr. Yalamanchi has more than 15 years of healthcare investment and research experience. Since 2015, Dr. Yalamanchi has been a Partner and Portfolio Manager at RTW. Prior to joining RTW, Dr. Yalamanchi was Vice President and Co-Portfolio Manager at Calamos Arista Partners, a subsidiary of Calamos Investments, a position he held from 2011 to 2015. Prior to joining Calamos Arista Partners, Dr. Yalamanchi held various healthcare investment roles at Millennium Management and Davidson Kempner Capital Management, where he worked with Dr. Wong. Dr. Yalamanchi graduated Phi Beta Kappa with a BS in Biology from the Massachusetts Institute of Technology and received an MD from the Stanford University School of Medicine. He completed his surgical internship at UCLA Medical Center. Dr. Yalamanchi served as Vice President and Chief Financial Officer of HSAC from January 2019 until December 2019 and as a director of HSAC from December 2018 until December 2019. Other prior and current directorships include: Rocket Pharmaceuticals, Inc., where he has served as a director since Rocket’s inception in July 2015, and Ancora Heart and Magnolia Medical Technologies, portfolio companies of RTW, where Dr. Yalamanchi serves as an observer to the board of directors.

Alice Lee, JD, has served as our Vice President of Operations and as our Secretary and Treasurer since June 2020. Ms. Lee has served as RTW’s Senior Counsel since October 2017 and Chief Compliance Officer from February 2019 to February 2021 and has more than a decade of experience advising life sciences companies in corporate and transactional matters. Prior to joining RTW, she most recently served as a senior associate in the Life Sciences practice at Ropes & Gray LLP from 2015 to 2017. Prior to that, she worked in the Intellectual Property Transactions and Technology practice at Sullivan & Cromwell LLP from 2010 to 2015, and she began her legal career in the Mergers & Acquisitions practice at Cravath, Swaine & Moore LLP. Ms. Lee served as Vice President of Operations of HSAC from January 2019 until December 2019. Ms. Lee received her law degree from Columbia Law School, where she served as a Senior Editor of Columbia Law Review and was a Harlan Fiske Stone Scholar. She earned an MS from Stanford University in Computer Science (with an emphasis in Bioinformatics), completed two years of pre-clinical coursework at the Stanford University School of Medicine, where she was an MD candidate, and graduated Phi Beta Kappa and summa cum laude with a BA in Philosophy from Columbia University. Prior to law school, Ms. Lee worked as a computational biologist at the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida and co-authored “The promise of gene signatures in cancer diagnosis and prognosis” included in the Encyclopedia of Genetics, Genomics, Proteomics and Bioinformatics and “Fundamentals of Cancer Genomics and Proteomics” included in Surgery: Basic Science and Clinical Evidence. She also worked as a software development engineer intern at Amazon.com.

Stephanie A. Sirota has served as our Vice President of Corporate Strategy and Corporate Communications since June 2020. Ms. Sirota has served as RTW’s Chief Business Officer since 2012 and as a Partner since 2014. Ms. Sirota is responsible for strategy and oversight of RTW’s business development and strategic partnerships with counterparties including limited partners, banks and academic institutions. She is also responsible for shaping the firm’s governance policies underscoring impact and sustainability. Ms. Sirota has more than a decade of deal experience in financial services. Prior to joining RTW, from 2006 to 2010, she served as a director at Valhalla Capital Advisors, a macro and commodity investment manager. From 2000 to 2003, Ms. Sirota worked in the New York and London offices of Lehman Brothers, where she advised on various mergers & acquisitions, IPOs, and capital market financing transactions with a focus on cross-border transactions for the firm’s global corporate clients. She began her career on the Fixed Income trading desk at Lehman Brothers, structuring derivatives for municipal issuers from 1997 to 1999. Ms. Sirota served as Vice President of Corporate Strategy of HSAC from January 2019 until December 2019. Other current directorships include RTW Venture Fund Limited (LSE: “RTW”), where Ms. Sirota has served as a director since October 2019. Ms. Sirota graduated with honors from Columbia University and also received an MS from the Columbia Graduate School of Journalism. She has contributed to Fortune Magazine and ABCNews.com. Ms. Sirota is a supporter of the arts, science, and children’s initiatives. She serves as Co-Chairman of the Council of the Phil at the New York Philharmonic. She also serves as President of RTW Charitable Foundation.

Pedro Granadillo has served as our director since August 2020. Mr. Granadillo has nearly 50 years of biopharmaceutical industry experience with expertise in human resources, manufacturing, quality control, and corporate governance. From 1970 until his retirement in 2004, Mr. Granadillo held multiple leadership roles at Eli Lilly and Company, including Senior Vice President of Global Manufacturing and Human Resources and a member of the Executive Committee. Mr. Granadillo currently serves on the board of directors of Rocket Pharmaceuticals, Inc., a position he has held since January 2018. Mr. Granadillo has previously served on the boards of directors at Haemonetics Corporation from 2004 to 2019, Dendreon Corporation, Nile Therapeutics and Noven Pharmaceuticals, as well as NPS Pharmaceuticals, which was sold to Shire for $5.2 billion in 2015. Mr. Granadillo is also a co-founder and board member of Neumentum Pharmaceuticals, a private non opioid pain company. Mr. Granadillo graduated from Purdue University with a Bachelor of Science in Industrial Engineering.

Carsten Boess has served as our director since August 2020. Mr. Boess has served as a director for Rocket Pharmaceuticals, Inc. since January 2016, Avidity Biosciences since April 2020, and Achilles Therapeutics since April 2020. Previously, Mr. Boess was the Executive Vice President of Corporate Affairs at Kiniksa Pharmaceuticals, Ltd. from August 2015 until February 2020. Before Kiniksa, Mr. Boess was the Chief Financial Officer at Alexion Pharmaceuticals from 2004 to 2005 and the Senior Vice President and Chief Financial Officer at Synageva BioPharma Corp. from 2011 until the company’s acquisition by Alexion Pharmaceuticals in 2015. Previously, Mr. Boess served in multiple roles with increasing responsibility at Insulet Corporation, including Chief Financial Officer from 2006 to 2009 and Vice President of International Operations from 2009 to 2011. Prior to that, Mr. Boess served as Executive Vice President of Finance at Serono Inc. from 2005 to 2006. In addition, he was a member of the Geneva-based World Wide Executive Finance Management Team while at Serono. Mr. Boess also held several financial executive roles at Novozymes of North America and Novo Nordisk in France, Switzerland and China. During his tenure at Novo Nordisk, he served on Novo Nordisk’s Global Finance Board. Mr. Boess received a Bachelor’s degree and Master’s degree in Economics and Finance, specializing in Accounting and Finance from the University of Odense, Denmark.

Stuart Peltz, PhD, has served as our director since August 2020. Dr. Peltz founded PTC Therapeutics in 1998 and has served as Chief Executive Officer and a member of the board of directors since its inception. Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz currently serves as a director of the Biotechnology Industry Organization (BIO) and serves on BIO’s Emerging Companies Section Governing Board. Dr. Peltz received a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.

Michael Brophy has served as our director since August 2020. Mr. Brophy has served as the Chief Financial Officer of Natera since February 2017. Previously, Mr. Brophy served as Natera’s Senior Vice President, Finance and Investor Relations since September 2016, and prior to that, as Vice President, Corporate Development and Investor Relations since September 2015. Prior to joining Natera, Mr. Brophy served in the investment banking division at Morgan Stanley and Deutsche Bank where he focused on advising corporate clients in the life science tools and diagnostics sector. Mr. Brophy holds an MBA from the University of California, Los Angeles and a Bachelor of Science in Economics from the United States Air Force Academy.

Number and Terms of Office of Officers and Directors

Our board of directors has six members, four of whom are “independent” under SEC and Nasdaq rules. Our board of directors is divided into three classes with only one class of directors being elected in each year and each class serving a three-year term. We may not hold an annual general meeting until after we consummate our initial business combination.

Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our Amended and Restated Memorandum and Articles of Association as it deems appropriate. Our Amended and Restated Memorandum and Articles of Association provide that our directors may consist of a chairman of the board, and that our officers may consist of chief executive officer, president, chief financial officer, executive vice president(s), vice president(s), secretary, treasurer and such other officers as may be determined by the board of directors.

Director Independence

Nasdaq listing standards require that within one year of the listing of our ordinary shares on the Nasdaq Capital Market we have at least three independent directors and that a majority of our board of directors be independent. An “independent director” is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the opinion of the company’s board of directors, would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director. Our Board of Directors had determined that Pedro Granadillo, Carsten Boess, Stuart Peltz, and Michael Brophy are “independent directors” as defined in the Nasdaq listing standards and applicable SEC rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present.

We will only enter into a business combination if it is approved by a majority of our independent directors. Additionally, we will only enter into transactions with our officers and directors and their respective affiliates that are on terms no less favorable to us than could be obtained from independent parties. Any related-party transactions must be approved by our audit committee and a majority of disinterested directors.

Audit Committee

We have established an audit committee of the board of directors, which consists of Carsten Boess, Pedro Granadillo, and Michael Brophy, each of whom is an independent director. Carsten Boess serves as chairman of the audit committee. The audit committee’s duties, which are specified in our Audit Committee Charter, include, but are not limited to:

●

reviewing and discussing with management and the independent registered public accounting firm the annual audited financial statements, and recommending to the board whether the audited financial statements should be included in our Form 10-K;

●

discussing with management and the independent registered public accounting firm significant financial reporting issues and judgments made in connection with the preparation of our financial statements;

●

discussing with management major risk assessment and risk management policies;

●

monitoring the independence of the independent registered public accounting firm;

●

verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law;

●

reviewing and approving all related-party transactions;

●

inquiring and discussing with management our compliance with applicable laws and regulations;

●

pre-approving all audit services and permitted non-audit services to be performed by our independent registered public accounting firm, including the fees and terms of the services to be performed;

●

appointing or replacing the independent registered public accounting firm;

●

determining the compensation and oversight of the work of the independent registered public accounting firm (including resolution of disagreements between management and the independent registered public accounting firm regarding financial reporting) for the purpose of preparing or issuing an audit report or related work;

●

establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or reports which raise material issues regarding our financial statements or accounting policies; and

●

approving reimbursement of expenses incurred by our management team in identifying potential target businesses.

Financial Experts on Audit Committee

The audit committee will at all times be composed exclusively of “independent directors” who are “financially literate” as defined under the Nasdaq listing standards. The Nasdaq listing standards define “financially literate” as being able to read and understand fundamental financial statements, including a company’s balance sheet, income statement and cash flow statement.

In addition, we must certify to Nasdaq that the committee has, and will continue to have, at least one member who has past employment experience in finance or accounting, requisite professional certification in accounting, or other comparable experience or background that results in the individual’s financial sophistication. The board of directors has determined that Carsten Boess qualifies as an “audit committee financial expert,” as defined under rules and regulations of the SEC.

Compensation Committee

We have established a compensation committee of the board of directors consisting of Pedro Granadillo and Carsten Boess, each of whom is an independent director. Pedro Granadillo serves as chairman of the compensation committee. We adopted a Compensation Committee Charter, will detail the principal functions of the compensation committee, including:

●

reviewing and approving on an annual basis the corporate goals and objectives relevant to our President and Chief Executive Officer’s compensation, evaluating our President and Chief Executive Officer’s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our President and Chief Executive Officer based on such evaluation;

●

reviewing and approving the compensation of all of our other executive officers;

●

reviewing our executive compensation policies and plans;

●

implementing and administering our incentive compensation equity-based remuneration plans;

●

assisting management in complying with our proxy statement and annual report disclosure requirements;

●

approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers and employees;

●

producing a report on executive compensation to be included in our annual proxy statement; and

●

reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.

The charter will also provide that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC.

Director Nominations

We do not have a standing nominating committee, though we intend to form a corporate governance and nominating committee as and when required to do so by law or Nasdaq rules. In accordance with Rule 5605(e)(2) of the Nasdaq rules, a majority of the independent directors may recommend a director nominee for selection by the board of directors.

Our board of directors believes that the independent directors can satisfactorily carry out the responsibility of properly selecting or approving director nominees without the formation of a standing nominating committee. Michael Brophy, Stuart Peltz, Carsten Boess, and Pedro Granadillo will participate in the consideration and recommendation of director nominees. In accordance with Rule 5605(e)(1)(A) of the Nasdaq rules, all such directors are independent. As there is no standing nominating committee, we do not have a nominating committee charter in place.

Our board of directors will also consider director candidates recommended for nomination by our shareholders during such times as they are seeking proposed nominees to stand for election at the next annual general meeting (or, if applicable, extraordinary general meeting). Our shareholders that wish to nominate a director for election to the Board should follow the procedures set forth in our Amended and Restated Memorandum and Articles of Association.

We have not formally established any specific, minimum qualifications that must be met or skills that are necessary for directors to possess. In general, in identifying and evaluating nominees for director, our board of directors considers educational background, diversity of professional experience, knowledge of our business, integrity, professional reputation, independence, wisdom, and the ability to represent the best interests of our shareholders.

Code of Ethics

We adopted a Code of Ethics that applies to all of our executive officers, directors and employees. The Code of Ethics codifies the business and ethical principles that govern all aspects of our business.

Conflicts of Interest

Potential investors should be aware of the following potential conflicts of interest:

●

None of our officers and directors is required to commit their full time to our affairs and, accordingly, they may have conflicts of interest in allocating their time among various business activities.

●

In the course of their other business activities, our officers and directors may become aware of investment and business opportunities which may be appropriate for presentation to our company as well as the other entities with which they are affiliated. Our management has pre-existing fiduciary duties and contractual obligations and may have conflicts of interest in determining to which entity a particular business opportunity should be presented.

●

Our officers and directors may in the future become affiliated with entities, including other blank check companies, engaged in business activities similar to those intended to be conducted by our company.

●

The insider shares owned by our officers and directors will be released from escrow only if a business combination is successfully completed and subject to certain other limitations. Additionally, our officers and directors will not receive distributions from the trust account with respect to any of their insider shares if we do not complete a business combination. Furthermore, our sponsor has agreed that the private shares and private warrants will not be sold or transferred by it until after we have completed our initial business combination. In addition, our officers and directors may loan funds to us and may be owed reimbursement for expenses incurred in connection with certain activities on our behalf which would only be repaid if we complete an initial business combination. For the foregoing reasons, the personal and financial interests of our directors and executive officers may influence their motivation in identifying and selecting a target business, completing a business combination in a timely manner and securing the release of their shares.

Under Cayman Islands law, directors and officers owe the following fiduciary duties:

(i)

duty to act in good faith in what the director believes to be in the best interests of the company as a whole;

(ii)

duty to exercise powers for the purposes for which those powers were conferred and not for a collateral purpose;

(iii)

directors should not improperly fetter the exercise of future discretion;

(iv)

duty not to put themselves in a position in which there is a conflict between their duty to the company and their personal interests; and

(v)

duty to exercise independent judgment.

In addition to the above, directors also owe a duty of care which is not fiduciary in nature. This duty has been defined as a requirement to act as a reasonably diligent person having both the general knowledge, skill and experience that may reasonably be expected of a person carrying out the same functions as are carried out by that director in relation to the company and the general knowledge skill and experience which that director has.

As set out above, directors have a duty not to put themselves in a position of conflict and this includes a duty not to engage in self-dealing, or to otherwise benefit as a result of their position. However, in some instances what would otherwise be a breach of this duty can be forgiven and/or authorized in advance by the shareholders, provided that there is full disclosure by the directors. This can be done by way of permission granted in the Amended and Restated Memorandum and Articles of Association or alternatively by shareholder approval at general meetings.

Accordingly, as a result of multiple business affiliations, our officers and directors may have similar legal obligations relating to presenting business opportunities meeting the above-listed criteria to multiple entities. In addition, conflicts of interest may arise when our board evaluates a particular business opportunity with respect to the above-listed criteria. We cannot assure you that any of the above-mentioned conflicts will be resolved in our favor. Furthermore, most of our officers and directors have pre-existing fiduciary obligations to other businesses of which they are officers or directors. To the extent they identify business opportunities which may be suitable for the entities to which they owe pre-existing fiduciary obligations, our officers and directors will honor those fiduciary obligations. Accordingly, it is possible they may not present opportunities to us that otherwise may be attractive to us unless the entities to which they owe pre-existing fiduciary obligations and any successors to such entities have declined to accept such opportunities.

In order to minimize potential conflicts of interest which may arise from multiple corporate affiliations, each of our officers and directors has contractually agreed, pursuant to a written agreement with us, until the earliest of a business combination, our liquidation or such time as he or she ceases to be an officer or director, to present to our company for our consideration, prior to presentation to any other entity, any suitable business opportunity which may reasonably be required to be presented to us, subject to any pre-existing fiduciary or contractual obligations he might have.

In connection with the vote required for any business combination, all of our existing shareholders, including all of our officers and directors, have agreed to vote their respective insider shares and private shares in favor of any proposed business combination. However, any ordinary shares of our Company acquired outside of the redemption offer period, including the 1,000,000 Forward Purchase Shares purchased by the RTW Funds and any Backstop Purchases, will not be voted in favor of approving the Business Combination and, further, will not carry redemption rights. Therefore, while the Insider Shares, the Private Shares and the 30,000 Public Shares held by our officers will be voted in favor of the Business Combination, the 1,000,000 Forward Purchase Shares purchased by the RTW Funds and any Backstop Purchases will not. In addition, the Initial Stockholders have agreed to waive their respective rights to participate in any liquidation distribution with respect to those ordinary shares acquired by them prior to our initial public offering. For any other shares, however, they would be entitled to participate in any liquidation distribution in respect of such shares but have agreed not to convert such shares (or sell their shares in any tender offer) in connection with the consummation of our initial business combination or an amendment to our Amended and Restated Memorandum and Articles of Association relating to pre-business combination activity.

All ongoing and future transactions between us and any of our officers and directors or their respective affiliates will be on terms believed by us to be no less favorable to us than are available from unaffiliated third parties. Such transactions will require prior approval by our audit committee and a majority of our uninterested “independent” directors, or the members of our board who do not have an interest in the transaction, in either case who had access, at our expense, to our attorneys or independent legal counsel. We will not enter into any such transaction unless our audit committee and a majority of our disinterested “independent” directors determine that the terms of such transaction are no less favorable to us than those that would be available to us with respect to such a transaction from unaffiliated third parties.

To further minimize conflicts of interest, we have agreed not to consummate our initial business combination with an entity that is affiliated with any of our officers, directors or other initial shareholders, unless we have obtained (i) an opinion from an independent investment banking firm that the business combination is fair to our unaffiliated shareholders from a financial point of view and (ii) the approval of a majority of our disinterested and independent directors (if we have any at that time). In no event will our initial shareholders or any of the members of our management team be paid any finder’s fee, consulting fee or other similar compensation prior to, or for any services they render in order to effectuate, the consummation of our initial business combination (regardless of the type of transaction that it is).

Limitation on Liability and Indemnification of Directors and Officers

Our memorandum and articles of association provide that, subject to certain limitations, the company shall indemnify its directors and officers against all expenses, including legal fees, and against all judgments, fines and amounts paid in settlement and reasonably incurred in connection with legal, administrative or investigative proceedings. Such indemnity only applies if the person acted honestly and in good faith with a view to what the person believes is in the best interests of the company and, in the case of criminal proceedings, the person had no reasonable cause to believe that their conduct was unlawful. The decision of the directors as to whether the person acted honestly and in good faith and with a view to the best interests of the company and as to whether the person had no reasonable cause to believe that his conduct was unlawful and is, in the absence of fraud, sufficient for the purposes of the memorandum and articles of association, unless a question of law is involved. The termination of any proceedings by any judgment, order, settlement, conviction or the entering of a nolle prosequi does not, by itself, create a presumption that the person did not act honestly and in good faith and with a view to the best interests of the company or that the person had reasonable cause to believe that his conduct was unlawful.

We have entered into agreements with our officers and directors to provide contractual indemnification in addition to the indemnification provided for in our memorandum and articles of association. Our memorandum and articles of association also permit us to purchase and maintain insurance on behalf of any officer or director who at the request of the company is or was serving as a director or officer of, or in any other capacity is or was acting for, another company or a partnership, joint venture, trust or other enterprise, against any liability asserted against the person and incurred by the person in that capacity, whether or not the company has or would have had the power to indemnify the person against the liability as provided in the memorandum and articles of association. We have purchased a policy of directors’ and officers’ liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors.

These provisions may discourage shareholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against officers and directors, even though such an action, if successful, might otherwise benefit us and our shareholders. Furthermore, a shareholder’s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against officers and directors pursuant to these indemnification provisions.

We believe that these provisions, the insurance and the indemnity agreements are necessary to attract and retain talented and experienced officers and directors.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is theretofore unenforceable.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, requires our executive officers, directors and persons who beneficially own more than 10% of a registered class of our equity securities to file with the Securities and Exchange Commission initial reports of ownership and reports of changes in ownership of our ordinary shares and other equity securities. These executive officers, directors, and greater than 10% beneficial owners are required by SEC regulation to furnish us with copies of all Section 16(a) forms filed by such reporting persons.

Based solely on our review of such forms furnished to us and written representations from certain reporting persons, we believe that all filing requirements applicable to our executive officers, directors and greater than 10% beneficial owners were filed in a timely manner.

ITEM 11. EXECUTIVE COMPENSATION

Employment Agreements

We have not entered into any employment agreements with our executive officers and have not made any agreements to provide benefits upon termination of employment.

Executive Officers and Director Compensation

No executive officer has received any cash compensation for services rendered to us. We pay to HSAC 2 Holdings, LLC, our sponsor, a fee of $10,000 per month for providing us with office space and certain office and secretarial services. However, pursuant to the terms of such agreement, we may delay payment of such monthly fee upon a determination by our audit committee that we lack sufficient funds held outside the trust to pay actual or anticipated expenses in connection with our initial business combination. Any such unpaid amount will accrue without interest and be due and payable no later than the date of the consummation of our initial business combination. Other than the $10,000 per month administrative fee, no compensation or fees of any kind, including finder’s fees, consulting fees and other similar fees, will be paid to our initial shareholders or any of the members of our management team, for services rendered prior to or in connection with the consummation of our initial business combination (regardless of the type of transaction that it is). However, such individuals will receive reimbursement for any out-of-pocket expenses incurred by them in connection with activities on our behalf, such as identifying potential target businesses, performing business due diligence on suitable target businesses and business combinations as well as traveling to and from the offices, plants or similar locations of prospective target businesses to examine their operations. There is no limit on the amount of out-of-pocket expenses reimbursable by us; provided, however, that to the extent such expenses exceed the available proceeds not deposited in the trust account and the interest income earned on the amounts held in the trust account, such expenses would not be reimbursed by us unless we consummate an initial business combination.

After our initial business combination, members of our management team who remain with us may be paid consulting, management or other fees from the combined company with any and all amounts being fully disclosed to shareholders, to the extent then known, in the proxy solicitation materials furnished to our shareholders. It is unlikely the amount of such compensation will be known at the time of a general meeting held to consider our initial business combination, as it will be up to the directors of the post-combination business to determine executive and director compensation. In this event, such compensation will be publicly disclosed at the time of its determination in a Current Report on Form 8-K, as required by the SEC.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS

The following table sets forth as of January 23, 2023, the number of ordinary shares beneficially owned by (i) each person who is known by us to be the beneficial owner of more than five percent of our issued and outstanding ordinary shares; (ii) each of our officers and directors; and (iii) all of our officers and directors as a group. As of January 23, 2023, we had 11,212,117 ordinary shares issued and outstanding.

Unless otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all ordinary shares owned by them. The following table does not reflect record of beneficial ownership of any ordinary shares issuable upon exercise of derivative securities that are not exercisable within 60 days of January 23, 2023.

Name and Address of Beneficial Owner⁽¹⁾	Number of Shares Beneficially Owned		Approximate Percentage of Outstanding Ordinary Shares
HSAC 2 Holdings, LLC (Sponsor)⁽²⁾		4,360,956		38.9	%
Roderick Wong⁽³⁾		1,000,000		8.9	%
Naveen Yalamanchi		—		—
Alice Lee		10,000			*
Stephanie A. Sirota⁽⁴⁾		20,000			*
Pedro Granadillo		22,261			*
Carsten Boess		22,261			*
Stuart Peltz		22,261			*
Michael Brophy		22,261			*

All directors, executive officers and our sponsor as a group (eight individuals)		5,480,000		48.9	%

*	Less than 1 %.

(1)	Unless otherwise indicated, the business address of each of the individuals is 40 10^th Ave., Floor 7, New York, New York 10014.

(2)

Our sponsor is governed by a board of directors consisting of three directors: Roderick Wong, Naveen Yalamanchi, and Alice Lee. Each director has one vote, and the approval of a majority of the directors is required to approve an action of our sponsor. Under the so-called “rule of three,” if voting and dispositive decisions regarding an entity’s securities are made by three or more individuals, and a voting or dispositive decision requires the approval of a majority of those individuals, then none of the individuals is deemed a beneficial owner of the entity’s securities. Based upon the foregoing analysis, no director of our sponsor exercises voting or dispositive control over any of the securities held by our sponsor, even those in which he or she directly holds a pecuniary interest. Accordingly, none of them will be deemed to have or share beneficial ownership of such shares.

(3)

Consists of shares held by RTW Master Fund, Ltd., RTW Venture Fund Limited and RTW Innovation Master Fund, Ltd., which are investment funds managed by RTW Investments, LP. Our Chief Executive Officer serves as the Managing Partner and Chief Investment Officer of RTW Investments, LP. Both he and RTW Investments, LP may be deemed the beneficial owner of such shares and each disclaims beneficial ownership except to the extent of their pecuniary interest in the holders.

(4)	Held by the Stephanie Anne Sirota Revocable Trust, of which Ms. Sirota is the trustee.

Restrictions on Transfers of Insider Shares and Private Warrants

All of the insider shares outstanding prior to our initial public offering were placed in escrow with Continental Stock Transfer & Trust Company, as escrow agent. Subject to certain limited exceptions, 50% of these shares will not be transferred, assigned, sold or released from escrow until the earlier of six months after the date of the consummation of our initial business combination and the date the closing price of our ordinary shares equals or exceeds $12.50 per ordinary share (as adjusted for share sub-divisions, share dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after our initial business combination and the remaining 50% of the insider shares will not be transferred, assigned, sold or released from escrow until six months after the date of the consummation of our initial business combination or earlier in either case if, subsequent to our initial business combination, we complete a liquidation, merger, stock exchange or other similar transaction which results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property.

During the escrow period, the holders of these shares will not be able to sell or transfer their securities except (1) transfers among the initial shareholders, to our officers, directors, advisors and employees, (2) transfers to an insider’s affiliates or its members upon its liquidation, (3) transfers to relatives and trusts for estate planning purposes, (4) transfers by virtue of the laws of descent and distribution upon death, (5) transfers pursuant to a qualified domestic relations order, (6) private sales made at prices no greater than the price at which the securities were originally purchased or (7) transfers to us for cancellation in connection with the consummation of an initial business combination, in each case (except for clause 7) where the transferee agrees to the terms of the escrow agreement, as well as the other applicable restrictions and agreements of the holders of the insider shares. If dividends are declared and payable in ordinary shares, such dividends will also be placed in escrow. If we are unable to effect a business combination and liquidate, there will be no liquidation distribution with respect to the insider shares.

Registration Rights

The holders of our Insider Shares, as well as the holders of the private shares and private warrants (and underlying securities) and any shares our Initial Shareholders or their affiliates may be issued in payment of Working Capital Loans made to us, will be entitled to registration rights pursuant to a Registration Rights Agreement entered into as of August 3, 2020. The holders of a majority of these securities are entitled to make up to two demands that we register such securities. The holders of the majority of the Insider Shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these ordinary shares are to be released from escrow. The holders of a majority of the private shares, private warrants or shares issued in payment of Working Capital Loans made to us can elect to exercise these registration rights at any time after we consummate a business combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the consummation of our initial business combination. We will bear the expenses incurred in connection with the filing of any such registration statements. The foregoing Registration Rights Agreement will be amended and restated by the Amended and Restated Registration Rights and Lock-Up Agreement.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

Insider Shares

On June 11, 2020, we issued the 3,593,750 Insider Shares to the Sponsor for an aggregate purchase price of $28,750. On August 3, 2020, we effected a share dividend of 0.113043478 ordinary shares for each outstanding share (an aggregate of 406,250 ordinary shares), resulting in an aggregate of 4,000,000 Insider Shares outstanding. All shares and associated amounts have been retroactively restated to reflect the share dividend. The holders of the Insider Shares had agreed to forfeit an aggregate of up to 521,739 Insider Shares, on a pro rata basis, to the extent that the option to purchase additional ordinary shares is not exercised in full by the underwriters. On August 6, 2020, the underwriters fully exercised the over-allotment option; thus, the 521,739 Insider Shares were no longer subject to forfeiture.

Related Party Loans

On June 11, 2020, our Sponsor agreed to loan us up to $300,000 to be used for the payment of costs related to the IPO pursuant to the Note. The Note was non-interest bearing, unsecured and due on the date we consummate the IPO. We borrowed $300,000 under the Note and repaid the Note in full on August 7, 2020. Subsequent to the repayment, the facility was no longer available to us.

Private Placement Shares

HSAC 2 Holdings, LLC purchased, pursuant to a written purchase agreement with us, an aggregate of (i) 450,000 ordinary shares, or “private shares,” at $10.00 per ordinary share (for a total purchase price of $4,500,000) and (ii) 1,500,000 warrants, or “private warrants,” at $1.00 per warrant (for a total purchase price of $1,500,000). These purchases took place on a private placement basis simultaneously with the consummation of our initial public offering on August 6, 2020.

The private shares are identical to the ordinary shares sold in our initial public offering. However, our initial shareholders have agreed (A) to vote their founder shares, private shares and any public shares in favor of any proposed business combination, (B) not to propose, or vote in favor of, prior to and unrelated to an initial business combination, an amendment to our memorandum and articles of association that would affect the substance or timing of the ability of public shareholders to exercise redemption rights as described herein or of our redemption obligation to redeem all public shares if we cannot complete an initial business combination by February 6, 2023, unless we provide public shareholders an opportunity to redeem their public shares in conjunction with any such amendment, (C) not to redeem any shares, including founder shares, private shares and any public shares into the right to receive cash from the trust account in connection with a shareholder vote to approve our proposed initial business combination or sell any shares to us in any tender offer in connection with our proposed initial business combination, and (D) that the founder shares and private shares shall not participate in any liquidating distribution upon winding up if a business combination is not consummated.

Each private warrant entitles the holder thereof to purchase one ordinary share at a price of $11.50 per ordinary share, subject to adjustment as provided therein. The private warrants will become exercisable 30 days after the completion of our initial business combination and will expire five years after the completion of our initial business combination. Each private warrant will be non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to be held by our sponsor or its permitted transferees.

Additionally, HSAC 2 Holdings, LLC has agreed not to transfer, assign or sell any of the private shares, private warrants or underlying securities (except to the same permitted transferees as the insider shares and provided the transferees agree to the same terms and restrictions as the permitted transferees of the insider shares must agree to, each as described above) until the completion of our initial business combination.

Purchase Agreements and Backstop Agreement

On August 3, 2020, in connection with the consummation of the IPO, we entered into a purchase agreement (“FPA”) with our Sponsor pursuant to which the Sponsor agreed that it will purchase an aggregate of 2,500,000 of our ordinary shares at a price of $10.00 per share, for an aggregate purchase price of $25.0 million prior to, currently with, or following the consummation of a business combination, either in open market transactions (to the extent permitted by law) or in a private placement with us. This FPA commitment has been satisfied by the RTW Funds through: (a) an investment of $15 million in Orchestra’s Series D Financing, and (b) the Forward Purchase Agreements described below.

Simultaneously with the execution of the Merger Agreement, we and Orchestra entered into separate Forward Purchase Agreements with the RTW Funds and Medtronic (the “Purchasing Parties”), pursuant to which each of the Purchasing Parties agreed to purchase approximately $10.0 million of our ordinary shares, for a total of approximately $20.0 million, less the dollar amount of our ordinary shares holding redemption rights that the Purchasing Party acquires and holds until immediately prior to the domestication.

Simultaneously with the execution of the Merger Agreement and the Forward Purchase Agreements, we, Orchestra, and the RTW Funds entered into the Backstop Agreement, pursuant to which the RTW Funds, jointly and severally, agreed to purchase such number of our ordinary shares at a price of $10.00 per share to the extent that the amount of Parent Closing Cash (as defined in the Merger Agreement) as of immediately prior to the closing of the Orchestra Business Combination is less than $60.0 million (inclusive of the $10.0 million commitment by the RTW Funds pursuant to the Forward Purchase Agreement described above).

Company Shareholder Support Agreement and Forfeiture

Contemporaneously with the execution of the Merger Agreement, the Company and Orchestra entered into the Parent Support Agreement, which was subsequently amended and restated on November 21, 2022, with the Sponsor and certain of our other shareholders (each a “Shareholder”) pursuant to which the Shareholders identified therein have agreed (a) to appear at any shareholder meetings called to approve the Merger or any proposal to extend the period of time we are afforded under our organizational documents and our prospectus to consummate an initial business combination, (b) not to redeem their shares or any other of our equity securities now or in future acquired or beneficially owned, (c) to vote such shares and equity securities, to the extent permitted by law, (i) in favor of the domestication, the Merger and related transactions (except that any such additional equity securities acquired in the future, including the 1,000,000 Forward Purchase Shares and any Backstop Purchases, will not be voted in favor of approving the business combination), (ii) in favor of any such extension proposal, and (iii) against any change in our business, management or board contrary to the Merger Agreement and against any other proposal reasonably expected to breach, prevent or impede the Merger, and (d) to waive anti-dilution and similar rights with respect to such shares, whether under our amended and restated memorandum and articles of association, applicable law, or a contract regarding the Merger and related transactions with us. In addition, the Sponsor has agreed that 25% or 1,000,000 shares of its New Orchestra Common Stock received in the domestication will be forfeited to New Orchestra on the first business day following the fifth anniversary of the closing of the business combination unless, as to 500,000 shares, the VWAP of the New Orchestra Common Stock is greater than or equal to $15.00 per share over any 20 Trading Days within any 30-Trading Day period, and as to the remaining 500,000 shares, the VWAP of the New Orchestra Common Stock is greater than or equal to $20.00 per share over any 20-Trading Days within any 30-Trading Day period. Further, the Sponsor has agreed to forfeit 50% of its warrants, comprising 750,000 warrants, for no consideration, immediately prior to the Closing. Pursuant to the terms of the Merger Agreement, immediately following such forfeiture and prior to the Closing, the Company will issue 750,000 New Warrants to eleven specified employees and directors of Orchestra. These New Warrants will have substantially similar terms to the forfeited Private Warrants, except that they will become exercisable between 24 and 36 months after the Closing.

Registration Rights

The holders of our insider shares issued and outstanding prior to our initial public offering, as well as the holders of the private shares and private warrants (and underlying securities) and any shares our initial shareholders or their affiliates may be issued in payment of working capital loans made to us, will be entitled to registration rights. The holders of a majority of these securities are entitled to make up to two demands that we register such securities. The holders of the majority of the insider shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these ordinary shares are to be released from escrow. The holders of a majority of the private shares, private warrants or warrants that may be issued upon conversion of working capital loans made to us can elect to exercise these registration rights at any time after we consummate a business combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to our consummation of our initial business combination. We will bear the expenses incurred in connection with the filing of any such registration statements.

Administrative Services Agreement

HSAC 2 Holdings, LLC, our sponsor, has agreed that, until the earlier of our consummation of our initial business combination or our liquidation, it will make available to us certain general and administrative services, including office space, utilities and administrative support, as we may require from time to time. We have agreed to pay HSAC 2 Holdings, LLC $10,000 per month for these services. However, pursuant to the terms of such agreement, we may delay payment of such monthly fee upon a determination by our audit committee that we lack sufficient funds held outside the trust to pay actual or anticipated expenses in connection with our initial business combination. Any such unpaid amount will accrue without interest and be due and payable no later than the date of the consummation of our initial business combination. We believe that the fee charged by our sponsor is at least as favorable as we could have obtained from an unaffiliated person.

Other than the fees described above, no compensation or fees of any kind, including finder’s fees, consulting fees or other similar compensation, will be paid to our initial shareholders or any of the members of our management team, for services rendered to us prior to, or in connection with the consummation of our initial business combination (regardless of the type of transaction that it is). However, such individuals will receive reimbursement for any out-of-pocket expenses incurred by them in connection with activities on our behalf, such as identifying potential target businesses, performing business due diligence on suitable target businesses and business combinations as well as traveling to and from the offices, plants or similar locations of prospective target businesses to examine their operations. There is no limit on the amount of out-of-pocket expenses reimbursable by us; provided, however, that to the extent such expenses exceed the available proceeds not deposited in the trust account and the interest income earned on the amounts held in the trust account, such expenses would not be reimbursed by us unless we consummate an initial business combination.

After our initial business combination, members of our management team who remain with us may be paid consulting, board, management or other fees from the combined company with any and all amounts being fully disclosed to shareholders, to the extent then known, in the proxy solicitation materials furnished to our shareholders. It is unlikely the amount of such compensation will be known at the time of a general meeting held to consider our initial business combination, as it will be up to the directors of the post-combination business to determine executive and director compensation. In this event, such compensation will be publicly disclosed at the time of its determination in a Current Report on Form 8-K, as required by the SEC.

All ongoing and future transactions between us and any of our officers and directors or their respective affiliates will be on terms believed by us to be no less favorable to us than are available from unaffiliated third parties. Such transactions will require prior approval by our audit committee and a majority of our uninterested independent directors, in either case who had access, at our expense, to our attorneys or independent legal counsel. We will not enter into any such transaction unless our audit committee and a majority of our disinterested independent directors determine that the terms of such transaction are no less favorable to us than those that would be available to us with respect to such a transaction from unaffiliated third parties.

Related Party Policy

Our Code of Ethics requires us to avoid, wherever possible, all related party transactions that could result in actual or potential conflicts of interests, except under guidelines approved by the board of directors (or the audit committee). Related party transactions are defined as transactions in which (1) the aggregate amount involved will or may be expected to exceed $120,000 in any calendar year, (2) we or any of our subsidiaries is a participant, and (3) any (a) executive officer, director or nominee for election as a director, (b) greater than 5% beneficial owner of our ordinary shares, or (c) immediate family member, of the persons referred to in clauses (a) and (b), has or will have a direct or indirect material interest (other than solely as a result of being a director or a less than 10% beneficial owner of another entity). A conflict of interest situation can arise when a person takes actions or has interests that may make it difficult to perform his or her work objectively and effectively. Conflicts of interest may also arise if a person, or a member of his or her family, receives improper personal benefits as a result of his or her position.

We also require each of our directors and executive officers to annually complete a directors’ and officers’ questionnaire that elicits information about related party transactions.

These procedures are intended to determine whether any such related party transaction impairs the independence of a director or presents a conflict of interest on the part of a director, employee or officer.

To further minimize conflicts of interest, we have agreed not to consummate our initial business combination with an entity that is affiliated with any of our initial shareholders, officers or directors unless we have obtained an opinion from an independent investment banking firm and the approval of a majority of our disinterested and independent directors (if we have any at that time) that the business combination is fair to our unaffiliated shareholders from a financial point of view. In no event will our initial shareholders, or any of the members of our management team be paid any finder’s fee, consulting fee or other similar compensation prior to, or for any services they render in order to effectuate, the consummation of our initial business combination (regardless of the type of transaction that it is).

Director Independence

Nasdaq listing standards require that a majority of our board of directors be independent. For a description of the director independence, see above Part III, Item 10 - Directors, Executive Officers and Corporate Governance.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The firm of WithumSmith+Brown, PC, or Withum, acts as our independent registered public accounting firm. The following is a summary of fees paid to Withum for services rendered.

Audit Fees. Audit fees consist of fees billed for professional services rendered for the audit of our year-end financial statements and services that are normally provided by Withum in connection with regulatory filings. The aggregate fees billed by Withum for audit fees, inclusive of required filings with the SEC for years ended December 31, 2022 and 2021, totaled $130,640 and $65,920, respectively.

Audit-Related Fees. Audit-related fees consist of fees billed for assurance and related services that are reasonably related to performance of the audit or review of our year-end financial statements and are not reported under “Audit Fees.” These services include attest services that are not required by statute or regulation and consultation concerning financial accounting and reporting standards. During the years ended December 31, 2022 and 2021, we did not pay Withum any audit-related fees.

Tax Fees. Tax fees consist of fees billed for professional services relating to tax compliance, tax planning and tax advice. During years ended December 31, 2022 and 2021, we paid Withum $4,160 and $4,120 tax fees, respectively.

All Other Fees. All other fees consist of fees billed for all other services. During the years ended December 31, 2022 and 2021, we did not pay Withum any other fees.

part IV

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a)

The following are filed with this report:

(1)

Financial Statements - The financial statements listed on the Index to Financial Statements

(2)

Financial Statement Schedules - Not applicable

(3)

Exhibits - The exhibits listed in the Exhibit Index

(b)

Exhibits

The following exhibits are filed with this report. Exhibits which are incorporated herein by reference can be obtained from the SEC’s website at sec.gov.

Exhibit No.		Description
1.1		Underwriting Agreement, dated August 3, 2020, by and between Registrant and Chardan Capital Markets LLC (incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 7, 2020)
2.1		Agreement and Plan of Merger dated as of July 4, 2022 by and among Health Sciences Acquisitions Corporation 2, HSAC Olympus Merger Sub, Inc., and Orchestra BioMed, Inc. (included as Annex A-1 to the proxy statement/prospectus which forms part of the Registration Statement on Form S-4/A filed with the Securities and Exchange Commission on December 13, 2022)
2.2		Amendment No. 1 to Agreement and Plan of Merger dated as of July 21, 2022 by and among Health Sciences Acquisitions Corporation 2, HSAC Olympus Merger Sub, Inc., and Orchestra BioMed, Inc. (included as Annex A-2 to the proxy statement/prospectus which forms part of the Registration Statement on Form S-4/A filed with the Securities and Exchange Commission on December 13, 2022)
2.3		Amendment No. 2 to Agreement and Plan of Merger dated as of November 21, 2022 by and among Health Sciences Acquisitions Corporation 2, HSAC Olympus Merger Sub, Inc., and Orchestra BioMed, Inc. (included as Annex A-3 to the proxy statement/prospectus which forms part of the Registration Statement on Form S-4/A filed with the Securities and Exchange Commission on December 13, 2022)
3.1		Amended & Restated Memorandum and Articles of Association (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 7, 2020)
3.2		First Amendment to Amended and Restated Memorandum and Articles of Association of Health Sciences Acquisitions Corporation 2 filed July 27, 2022 (incorporated by reference to Exhibit 3.2 to the Registration Statement on Form S-4 filed with the Securities and Exchange Commission on August 8, 2022)
4.1		Specimen Ordinary Share Certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on July 24, 2020)
4.2		Form of Warrant (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on July 24, 2020)
4.3		Warrant to Purchase Ordinary Shares of Health Sciences Acquisitions Corporation 2 issued to HSAC 2 Holdings, LLC, dated August 6, 2020 (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-4 filed with the Securities and Exchange Commission on August 8, 2022)
4.4*		Description of Securities
10.1		Letter Agreements, dated August 3, 2020, among the Registrant and each of the initial shareholders, officers and directors of Registrant (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 7, 2020)
10.2		Investment Management Trust Agreement, dated August 3, 2020, between Continental Stock Transfer & Trust Company and the Registrant (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 7, 2020)
10.3		Share Escrow Agreement, dated August 3, 2020, among the Registrant, the initial shareholders of Registrant and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 7, 2020)
10.4		Registration Rights Agreement, dated August 3, 2020, among the Registrant and the initial shareholders of Registrant (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 7, 2020)
10.5		Indemnity Agreements, dated August 3, 2020, among the Registrant and each of the officers and directors of Registrant (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 7, 2020)
10.6		Subscription Agreement, dated August 3, 2020, between the Registrant and HSAC 2 Holdings, LLC (incorporated by reference to Exhibit 10.6 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 7, 2020)
10.7		Administrative Services Agreement, dated August 3, 2020, between the Registrant and HSAC 2 Holdings, LLC (incorporated by reference to Exhibit 10.7 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 7, 2020)

10.8		Purchase Agreement, dated August 3, 2020, between the Registrant and HSAC 2 Holdings, LLC (incorporated by reference to Exhibit 10.8 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on August 7, 2020)
10.9		Forward Purchase Agreement dated as of July 4, 2022, by and among Health Sciences Acquisitions Corporation 2, Orchestra BioMed, Inc., and Covidien Group S.à.r.l. (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 5, 2022)
10.10		Forward Purchase Agreement dated as of July 4, 2022, by and among Health Sciences Acquisitions Corporation 2, Orchestra BioMed, Inc., and RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW Venture Fund Limited (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 5, 2022)
10.11		Amendment No. 1 to Forward Purchase Agreement dated as of October 21, 2022, by and among Health Sciences Acquisitions Corporation 2, Orchestra BioMed, Inc., and RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW Venture Fund Limited (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 21, 2022)
10.12		Backstop Agreement dated as of July 4, 2022, by and among Health Sciences Acquisitions Corporation 2, Orchestra BioMed, Inc., RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW Venture Fund Limited (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 5, 2022)
10.13		Amendment No. 1 to Backstop Agreement dated as of October 21, 2022, by and among Health Sciences Acquisitions Corporation 2, Orchestra BioMed, Inc., RTW Master Fund, Ltd., RTW Innovation Master Fund, Ltd., and RTW Venture Fund Limited (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 21, 2022)
10.14		Amended and Restated Parent Support Agreement dated as of November 21, 2022 by and among Health Sciences Acquisitions Corporation 2, Orchestra BioMed, Inc., HSAC 2 Holdings, LLC, Alice Lee, Stephanie A. Sirota, Pedro Granadillo, Stuart Peltz, Michael Brophy, and Carsten Boess (incorporated by reference to Exhibit 10.16 to the Registration Statement on Form S-4/A filed with the Securities and Exchange Commission on November 22, 2022)
10.15		Orchestra Support Agreement dated as of July 4, 2022 by and among Health Sciences Acquisitions Corporation 2, Orchestra BioMed, Inc., and Covidien Group S.À.R.L. (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed with the SEC on July 5, 2022)
14		Form of Code of Ethics (incorporated by reference to Exhibit 14 to the Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on July 24, 2020)
21*		List of Subsidiaries
31.1*		Certification of Chief Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended
31.2*		Certification of Chief Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended
32**		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
99.1		Form of Audit Committee Charter (incorporated by reference to Exhibit 99.1 to the Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on July 24, 2020)
99.2		Form of Compensation Committee Charter (incorporated by reference to Exhibit 99.2 to the Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on July 24, 2020)
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

Filed herewith.

Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filings of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

ITEM 16. FORM 10-K SUMMARY

Not applicable.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	HEALTH SCIENCES ACQUISITIONS CORPORATION 2

Dated: January 25, 2023	By:	/s/ Roderick Wong
	Name:	Roderick Wong
	Title:	President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Name	Position	Date

/s/ Roderick Wong	President, Chief Executive Officer	January 25, 2023
Roderick Wong	and Chairman of the Board
	(Principal Executive Officer)

/s/ Naveen Yalamanchi	Executive Vice President, Chief	January 25, 2023
Naveen Yalamanchi	Financial Officer and Director
	(Principal Accounting and Financial Officer)

/s/ Pedro Granadillo	Director	January 25, 2023
Pedro Granadillo

/s/ Michael Brophy	Director	January 25, 2023
Michael Brophy

/s/ Stuart Peltz	Director	January 25, 2023
Stuart Peltz

/s/ Carsten Boess	Director	January 25, 2023
Carsten Boess

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

INDEX TO FINANCIAL STATEMENTS

	Page
Report of Independent Registered Public Accounting Firm	F-2
Financial Statements:
Consolidated Balance Sheets as of December 31, 2022 and 2021	F-3
Consolidated Statements of Operations for the Years Ended December 31, 2022 and 2021	F-4
Consolidated Statements of Changes in Shareholders’ Deficit for the Years Ended December 31, 2022 and 2021	F-5
Consolidated Statements of Cash Flows for the Years Ended December 31, 2022 and 2021	F-6
Notes to Consolidated Financial Statements	F-7

F-1

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of

Health Sciences Acquisitions Corporation 2

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Health Sciences Acquisitions Corporation 2 (the “Company”) as of December 31, 2022 and 2021, the related consolidated statements of operations, changes in shareholders’ deficit and cash flows for the years then ended and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, if the Company is unable to raise additional funds to alleviate liquidity needs and complete a business combination by February 6, 2023 then the Company will cease all operations except for the purpose of liquidating. The liquidity condition and date for mandatory liquidation and subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ WithumSmith+Brown, PC

We have served as the Company's auditor since 2020.

New York, New York

January 25, 2023

PCAOB Number 100

F-2

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

CONSOLIDATED BALANCE SHEETS

	December 31, 2022			December 31, 2021

Assets:
Current assets:
Cash	$	175,161		$	1,754,460
Prepaid expenses		123,918			46,667
Total current assets		299,079			1,801,127
Cash and investments held in Trust Account		67,776,498			160,022,447
Total Assets	$	68,075,577		$	161,823,574

Liabilities, Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit
Current liabilities:
Accounts payable	$	376,930		$	1,388
Accrued expenses		1,366,825			14,151
Accrued expenses - related party		-			150,000
Total current liabilities		1,743,755			165,539
Deferred underwriting commissions		5,600,000			5,600,000
Total liabilities		7,343,755			5,765,539

Commitments and Contingencies

Ordinary shares subject to possible redemption, $0.0001 par value; 6,762,117 and 16,000,000 shares issued and outstanding at approximately $10.01 and $10.00 per share redemption value as of December 31, 2022 and 2021, respectively		67,676,498			160,000,000

Shareholders’ Deficit:
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding as of December 31, 2022 and 2021		-			-
Ordinary shares, $0.0001 par value; 100,000,000 shares authorized; 4,450,000 non-redeemable shares issued and outstanding as of December 31, 2022 and 2021		445			445
Additional paid-in capital		-			-
Accumulated deficit		(6,945,121	)		(3,942,410	)
Total shareholders’ deficit		(6,944,676	)		(3,941,965	)
Total Liabilities, Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit	$	68,075,577		$	161,823,574

The accompanying notes are an integral part of these consolidated financial statements.

F-3

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

CONSOLIDATED STATEMENTS OF OPERATIONS

	For the Years Ended
	December 31, 2022			December 31, 2021
Operating expenses
General and administrative expenses	$	2,960,264		$	274,756
Administrative fee - related party		120,000			120,000
Loss from operations		(3,080,264	)		(394,756	)
Interest income from investments held in Trust Account		345,141			16,003
Net loss	$	(2,735,123	)	$	(378,753	)

Weighted average shares outstanding of ordinary shares, basic and diluted		16,425,826			20,450,000

Basic and diluted net loss per ordinary share	$	(0.17	)	$	(0.02	)

The accompanying notes are an integral part of these consolidated financial statements.

F-4

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ DEFICIT

For the Years Ended December 31, 2022 and 2021

	Ordinary Shares				Additional Paid-In		Accumulated			Total Shareholders’
	Shares		Amount		Capital		Deficit			Deficit
Balance - December 31, 2020		4,450,000	$	445	$	-	$	(3,563,657	)	$	(3,563,212	)
Net loss		-		-		-		(378,753	)		(378,753	)
Balance - December 31, 2021		4,450,000		445		-		(3,942,410	)		(3,941,965	)
Increase in redemption value of ordinary shares subject to possible redemption		-		-		-		(267,588	)		(267,588	)
Net loss		-		-		-		(2,735,123	)		(2,735,123	)
Balance - December 31, 2022		4,450,000	$	445	$	-	$	(6,945,121	)	$	(6,944,676	)

The accompanying notes are an integral part of these consolidated financial statements.

F-5

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the Years Ended
	December 31, 2022			December 31, 2021
Cash Flows from Operating Activities:
Net loss	$	(2,735,123	)	$	(378,753	)
Adjustments to reconcile to net loss to net cash used in operating activities
Interest income from investments held in Trust Account		(345,141	)		(16,003	)
Changes in operating assets and liabilities:
Prepaid expenses		(77,251	)		75,811
Accounts payable		375,542			(12,422	)
Accrued expenses		1,352,674			(60,995	)
Accrued expenses - related party		(150,000	)		120,000
Net cash used in operating activities		(1,579,299	)		(272,362	)

Cash Flows from Investing Activities:
Cash withdrawn from Trust Account to redeem Public Shares		92,591,090			-
Cash provided by investing activities		92,591,090			-

Cash Flows from Financing Activities:
Redemption of Public Shares		(92,591,090	)		-
Cash used in financing activities		(92,591,090	)		-

Net change in cash		(1,579,299	)		(272,362	)
Cash - beginning of the year		1,754,460			2,026,822
Cash - end of the year	$	175,161		$	1,754,460

The accompanying notes are an integral part of these consolidated financial statements.

F-6

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2022

Note 1-Description of Organization, Business Operations and Going Concern

Organization and General

Health Sciences Acquisitions Corporation 2 (the “Company”) was incorporated on May 25, 2020 as a Cayman Islands exempted company for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities (“Business Combination”). Although the Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination, the Company intends to pursue prospective targets that are focused on healthcare innovation. The Company has neither engaged in any operations nor generated any operating revenue to date. The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).

As of December 31, 2022, the Company had not commenced any operations. All activity for the period from May 25, 2020 (inception) through December 31, 2022 was related to the Company’s formation and its Initial Public Offering (as defined below), and, since the Initial Public Offering, the search for a prospective initial Business Combination. The Company will not generate any operating revenue until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income from its investments held in the Trust Account (as defined below).

Sponsor and Financing

The Company’s sponsor is HSAC 2 Holdings, LLC (the “Sponsor”). The registration statement for the Company’s initial public offering (the “Initial Public Offering”) was declared effective on August 3, 2020. On August 6, 2020, the Company consummated its Initial Public Offering of 16,000,000 ordinary shares (the “Public Shares”), including the issuance of 2,086,956 Public Shares as a result of the underwriters’ full exercise of their over-allotment option, at an offering price of $10.00 per Public Share, generating gross proceeds of $160.0 million, and incurring offering costs of approximately $9.4 million, inclusive of $5.6 million in deferred underwriting commissions (see Note 6).

Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (the “Private Placement”) with the Sponsor of (i) 450,000 ordinary shares (the “Private Placement Shares”), at a price of $10.00 per Private Placement Share (for a total purchase price of $4.5 million), and (ii) 1,500,000 warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant (for a total purchase price of $1.5 million), generating gross proceeds to the Company of $6.0 million (see Note 4).

Trust Account

Upon the closing of the Initial Public Offering and the Private Placement (including the exercise of the over-allotment option), $160.0 million (or $10.00 per Public Share) of the net proceeds of the Initial Public Offering and the Private Placement was placed in a U.S. based trust account (the “Trust Account”), maintained by Continental Stock Transfer & Trust Company, acting as trustee, and invested in U.S. “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act, which invest only in direct U.S. government treasury obligations, until the earlier of (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below. On July 25, 2022, the entire Trust Account balance was transferred into cash in connection with the redemptions as described below.

Initial Business Combination

The Company’s management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering and the Private Placement, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. Furthermore, there is no assurance that the Company will be able to successfully complete a Business Combination.

F-7

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2022

Pursuant to stock exchange listing rules, the Company’s initial Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding the amount of any deferred underwriting discount held in trust and taxes payable on the income earned on the Trust Account) at the time the Company signs a definitive agreement in connection with the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.

The Company will provide holders of the Public Shares (“Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to Public Shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). As a result, such ordinary shares have been recorded at redemption amount and classified as temporary equity, in accordance with the Financial Accounting Standard Board (“FASB”), Accounting Standard Codification (“ASC”) 480, “Distinguishing Liabilities from Equity.” The amount in the Trust Account is initially anticipated to be $10.00 per Public Share. In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the ordinary shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, a shareholder approval of the transactions is required by law, or the Company decides to obtain shareholder approval for business or legal reasons, the Company will offer to redeem ordinary shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks shareholder approval in connection with a Business Combination, the holders of the Insider Shares (as defined in Note 5) prior to the Initial Public Offering (the “Initial Shareholders”) have agreed to vote their Insider Shares and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination, to the extent permitted by law. In addition, the Initial Shareholders have agreed to waive their redemption rights with respect to their Insider Shares, Private Placement Shares, and Public Shares in connection with the completion of a Business Combination.

Notwithstanding the foregoing, the Company’s Amended and Restated Memorandum and Articles of Association provides that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its ordinary shares with respect to more than 20% the ordinary shares sold in the Initial Public Offering, without the prior consent of the Company.

The Company’s Sponsor, executive officers, directors and director nominees have agreed not to propose an amendment to the Company’s Amended and Restated Memorandum and Articles of Association that would affect the substance or timing of the Company’s obligation to provide for the redemption of its Public Shares in connection with a Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the Public Shareholders with the opportunity to redeem their ordinary shares in conjunction with any such amendment.

F-8

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2022

If a Business Combination has not been consummated by February 6, 2023 (taking into account the extension as described under “Extension, Redemptions and Private Purchase” section below, the “Combination Period”), or such later time as the Company’s shareholders may approve in accordance with the Amended and Restated Memorandum and Articles of Association, it will trigger the Company’s automatic winding up, liquidation and dissolution. If the Company does not consummate a Business Combination within the Combination Period, upon notice from the Company, the trustee of the Trust Account will distribute the amount in the Trust Account to the Public Shareholders. Concurrently, the Company shall pay, or reserve for payment, from funds not held in the Trust Account, its liabilities and obligations, although the Company cannot assure that there will be sufficient funds for such purpose. If there are insufficient funds held outside the Trust Account for such purpose, the Sponsor has agreed that it will be liable to ensure that the proceeds in the Trust Account are not reduced by the claims of target businesses or claims of vendors or other entities that are owed money by the Company for services rendered or contracted for or products sold to the Company and which have not executed a waiver agreement. However, the Company cannot assure that the liquidator will not determine that he or she requires additional time to evaluate creditors’ claims (particularly if there is uncertainty over the validity or extent of the claims of any creditors). The Company also cannot assure that a creditor or shareholder will not file a petition with the Cayman Islands Court which, if successful, may result in the Company’s liquidation being subject to the supervision of that court. Such events might delay distribution of some or all of the Company’s assets to the Public Shareholders.

The Initial Shareholders have agreed to waive their liquidation rights with respect to the Insider Shares and the Private Placement Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Shareholders should acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commissions held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Company’s Public Shares. In the event of such distribution, it is possible that the per ordinary share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00 per ordinary share initially held in the Trust Account.

Liquidity and Going Concern

As of December 31, 2022, the Company had approximately $175,000 of cash in its operating account and a working capital deficit of approximately $1.8 million.

Prior to the completion of the Initial Public Offering, the Company’s liquidity needs had been satisfied through the capital contribution of $28,750 from the Sponsor to purchase the Insider Shares, and a loan of $300,000 pursuant to the Note (as defined in Note 5) issued to the Sponsor, which was repaid in full on August 7, 2020. Subsequent to the consummation of the Initial Public Offering and the Private Placement, the Company’s liquidity needs have been satisfied with the net proceeds from the Private Placement not held in the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Initial Shareholders or their affiliates may, but are not obligated to, provide the Company with Working Capital Loans (see Note 5). As of December 31, 2022 and 2021, there were no Working Capital Loans available or outstanding.

In connection with the Company’s assessment of going concern considerations in accordance with FASB Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the working capital deficit, as well as the mandatory liquidation and subsequent dissolution, raises substantial doubt about the Company’s ability to continue as a going concern. Management intends to complete a business combination prior to the mandatory liquidation date. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after February 6, 2023. The consolidated financial statements do not include any adjustment that might be necessary if the Company’s is unable to continue as a going concern.

F-9

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2022

Proposed Business Combination

On July 4, 2022, the Company entered into an agreement and plan of merger agreement (as amended on July 21, 2022, the “Merger Agreement”) with HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), and Orchestra BioMed, Inc., a Delaware corporation (“Orchestra”). Pursuant to the terms of the Merger Agreement, a business combination between the Company and Orchestra (the “Orchestra Business Combination”) will be effected in two steps. First, before the closing of the Orchestra Business Combination, the Company will deregister in the Cayman Islands and domesticate as a Delaware corporation. Second, at the closing of the Orchestra Business Combination, Merger Sub will merge with and into Orchestra, with Orchestra surviving such merger as the surviving entity (the “Merger”). Upon consummation of the Orchestra Business Combination, Orchestra will become a wholly owned subsidiary of the Company. The Company will then change its name to “Orchestra BioMed Holdings, Inc.”. The Company, after giving effect to the Orchestra Business Combination, will be referred to as “New Orchestra”.

Simultaneously with the execution of the Merger Agreement, the Company and Orchestra entered into separate forward purchase agreements (the “Forward Purchase Agreements”) with certain funds managed by RTW Investments, LP (the “RTW Funds”) and Covidien Group S.à.r.l., an affiliate of Medtronic plc (“Medtronic” and the RTW Funds, each a “Purchasing Party”), pursuant to which each of the Purchasing Parties agreed to purchase approximately $10.0 million of the Company’s ordinary shares, for a total of approximately $20.0 million, less the dollar amount of the Company’s ordinary shares holding redemption rights that the Purchasing Party acquires and holds until immediately prior to the domestication.

Simultaneously with the execution of the Merger Agreement and the Forward Purchase Agreements, the Company, Orchestra, and the RTW Funds entered into a Backstop Agreement (the “Backstop Agreement”) pursuant to which the RTW Funds, jointly and severally, agreed to purchase such number of the Company’s ordinary shares at a price of $10.00 per share to the extent that the amount of Parent Closing Cash (as defined in the Merger Agreement) as of immediately prior to the closing of the Orchestra Business Combination is less than $60.0 million (inclusive of the $10.0 million commitment by the RTW Funds pursuant to the Forward Purchase Agreement described above).

On October 21, 2022, the Backstop Agreement and the Forward Purchase Agreement with the RTW Funds were amended to provide that (1) the per share purchase price under each of the Backstop Agreement and the Forward Purchase Agreement will not exceed the redemption price available to Public Shareholders exercising redemption rights at the shareholder meeting held to approve the Business Combination; (2) any shares purchased pursuant to the Backstop Agreement or the Forward Purchase Agreement, or otherwise acquired by the RTW Funds outside of the existing redemption offer, will not be voted in favor of approving the Business Combination; and (3) the RTW Funds will waive redemption rights with respect to such purchases in the vote to approve the Business Combination. The amendments have been filed with the SEC on a Current Report on Form 8-K on October 21, 2022. The Forward Purchase Agreement with Medtronic was not amended.

The closing under the Forward Purchase Agreement with the RTW Funds occurred on July 22, 2022, pursuant to which the RTW Funds purchased 1,000,000 of the Company’s ordinary shares at a price of $10.01 per share from an accredited investor in a privately negotiated transaction (see Note 5). The closing under the Forward Purchase Agreement with Medtronic and the closing under the Backstop Agreement, if any, will occur immediately prior to the domestication. The Company’s Sponsor, and the Purchasing Parties will have registration rights pursuant to the Amended and Restated Registration Rights and Lock-Up Agreement with respect to the Company’s ordinary shares, received in the domestication.

F-10

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2022

In addition, the Sponsor has agreed that 25% or 1,000,000 shares of its New Orchestra common stock received in the domestication will be forfeited to New Orchestra on the first business day following the fifth anniversary of the closing unless, as to 500,000 shares, the VWAP (as defined in the Merger Agreement) of the New Orchestra common stock is greater than or equal to $15.00 per share over any 20 Trading Days (as defined in the Merger Agreement) within any 30-Trading Day period, and as to the remaining 500,000 shares, the VWAP of the New Orchestra common stock is greater than or equal to $20.00 per share over any 20-Trading Days within any 30-Trading Day period. In addition, subject to the closing of the Orchestra Business Combination, the Sponsor has agreed to forfeit 50% of its Private Placement Warrants, comprising 750,000 Private Placement Warrants, for no consideration. Further, the Sponsor and the other Initial Shareholders prior to the Company’s initial public offering have agreed to subject the 4,000,000 shares of New Orchestra common stock to be received in the domestication in exchange for the 4,000,000 Insider Shares and 450,000 shares of New Orchestra common stock to be received in the domestication in exchange for the 450,000 Private Placement Shares, to a lock-up for up to 12 months.

See the proxy statement/prospectus included in the Registration Statement on Form S-4/A filed by the Company with the SEC on December 13, 2022 for additional information.

Extension, Redemptions and Private Purchase

On July 26, 2022, the Company held an extraordinary general meeting of its shareholders, where the shareholders approved a special resolution (the “Extension Proposal”) to amend the Company’s amended and restated memorandum and articles of association to (i) extend from August 6, 2022 (the “Original Termination Date”) to November 6, 2022 (the “Extended Date”), the date by which, if the Company has not consummated a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination involving one or more businesses or entities, the Company must liquidate and dissolve, and (ii) allow the Company, without another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to three times by an additional one month each time after the Extended Date, upon five days’ advance notice prior to the applicable deadlines, until February 6, 2023 or a total of up to six months after the Original Termination Date, unless the closing of the Company’s initial business combination shall have occurred. On October 31, 2022, November 15, 2022, and December 15, 2022, the directors of the Company elected to extend the deadline until December 6, 2022, January 6, 2023, and February 6, 2023, respectively.

On July 22, 2022, the RTW Funds purchased 1,000,000 of the Company’s ordinary shares at a price of $10.01 per share from an accredited investor in a privately negotiated transaction, in order to fulfill their obligations under the Forward Purchase Agreements and to ensure that such shares purchased were not redeemed and the amounts that would have been paid by the Company if such shares were redeemed remain in the Company’s trust account at the closing of the Orchestra Business Combination.

See the preliminary proxy statement/prospectus included in the Registration Statement on Form S-4 filed by the Company with the SEC on August 8, 2022, and any amendments thereto and the final proxy statement/prospectus that the Company may subsequently file with the SEC, for additional information.

Business Combination Meeting

On January 24, 2023, the Company held an extraordinary general meeting of shareholders (the “General Meeting”) for the purpose of considering and voting upon, among other things, the Orchestra Business Combination. Each of the proposals presented at the General Meeting, as more fully described in the proxy statement/prospectus filed by the Company with the SEC on December 16, 2022, was approved. The submission of the Orchestra Business Combination to the shareholders entitled holders of Public Shares to redeem their shares for their pro rata portion of the funds held in the Trust Account. In connection with the General Meeting, as of January 24, 2023, we received requests for redemption from holders with respect to 1,597,888 Public Shares.

F-11

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2022

Note 2-Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC.

Principles of Consolidation

The consolidated financial statements of the Company include its wholly owned subsidiary in connection with the planned merger. All inter-company accounts and transactions are eliminated in consolidation.

Emerging Growth Company

As an emerging growth company, the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

Further, section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s consolidated financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period, difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents as of December 31, 2022 and 2021.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times, may exceed the federal depository insurance coverage of $250,000, and investments held in Trust Account. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

F-12

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2022

Cash and Investments Held in the Trust Account

The Company’s portfolio of investments held in the Trust Account has been comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments were classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments were recognized at fair value. Trading securities and investments in money market funds are presented on the consolidated balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in interest income from investments held in Trust Account in the accompanying consolidated statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. On July 25, 2022, the entire Trust Account balance was transferred into cash following redemptions in connection with the vote to approve the Extension Proposal. As of December 31, 2022, only cash is held in the Trust Account.

Fair Value of Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC Topic 820, “Fair Value Measurements,” equals or approximates the carrying amounts represented in the consolidated balance sheets, primarily due to their short-term nature.

Fair Value Measurements

Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers consist of:

●

Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;

●

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

●

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

Derivative Assets and Liabilities

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.

F-13

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2022

Offering Costs Associated with Initial Public Offering

The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin Topic 5A - “Expenses of Offering.” Offering costs consist of costs incurred in connection with the formation and preparation for the Initial Public Offering. These costs, together with the underwriting discount, were charged to the carrying value of the Public Shares upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.

Ordinary Shares Subject to Possible Redemption

The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480, “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Public Shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, as of December 31, 2022 and 2021, 6,762,117 and 16,000,000 ordinary shares subject to possible redemption at the redemption amount, respectively, were presented at redemption value as temporary equity, outside of the shareholders’ deficit section of the Company’s consolidated balance sheets.

Under ASC 480-10-S99, the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Effective with the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit.

Net Loss Per Ordinary Share

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net loss per ordinary share is calculated by dividing the net loss by the weighted average number of ordinary shares outstanding for the respective period.

Income Taxes

ASC Topic 740, “Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman Islands federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s consolidated financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

F-14

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2022

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have an effect on the Company’s consolidated financial statements.

Note 3-Initial Public Offering

On August 6, 2020, the Company consummated its Initial Public Offering of 16,000,000 Public Shares, including the 2,086,956 Public Shares as a result of the underwriters’ full exercise of their over-allotment option, at an offering price of $10.00 per Public Share, generating gross proceeds of $160.0 million, and incurring offering costs of approximately $9.4 million, inclusive of $5.6 million in deferred underwriting commissions.

Note 4-Private Placement

Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement with the Sponsor of (i) 450,000 Private Placement Shares at $10.00 per Private Placement Share (for a total purchase price of $4.5 million) and (ii) 1,500,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant (for a total purchase price of $1.5 million), generating gross proceeds to the Company of $6.0 million.

Each Private Placement Warrant entitles the holder thereof to purchase one ordinary share at an exercise price of $11.50 per ordinary share. A portion of the proceeds from the Private Placement was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees.

Note 5-Related Party Transactions

Insider Shares

On June 11, 2020, the Company issued 3,593,750 ordinary shares to the Sponsor (the “Insider Shares”) for an aggregate purchase price of $28,750. On August 3, 2020, the Company effected a share dividend of 0.113043478 ordinary shares for each outstanding ordinary share (an aggregate of 406,250 ordinary shares), resulting in an aggregate of 4,000,000 ordinary shares outstanding. All shares and associated amounts have been retroactively restated to reflect the share dividend. The holders of the Insider Shares had agreed to forfeit up to an aggregate of 521,739 Insider Shares, on a pro rata basis, to the extent that the option to purchase additional ordinary shares is not exercised in full by the underwriters. On August 6, 2020, the underwriters fully exercised the over-allotment option; thus, the 521,739 Insider Shares were no longer subject to forfeiture.

F-15

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2022

The Initial Shareholders agreed not to transfer, assign or sell any of their Insider Shares (except to certain permitted transferees) until, with respect to 50% of the Insider Shares, the earlier of six months after the date of the consummation of the initial Business Combination and the date on which the closing price of the Company’s ordinary shares equals or exceeds $12.50 per ordinary share for any 20 trading days within a 30-trading day period following the consummation of the initial Business Combination, and, with respect to the remaining 50% of the Insider Shares, six months after the date of the consummation of the initial Business Combination, or earlier in each case if, subsequent to the initial Business Combination, the Company completes a liquidation, merger, stock exchange or other similar transaction which results in all of the shareholders having the right to exchange their ordinary shares for cash, securities or other property.

Related Party Loans

On June 11, 2020, the Sponsor agreed to loan the Company up to $300,000 to be used for the payment of costs related to the Initial Public Offering pursuant to a promissory note (the “Note”). The Note was non-interest bearing, unsecured and due on the date the Company consummates the Initial Public Offering or the date on which the Company determines not to conduct the Initial Public Offering. The Company borrowed $300,000 under the Note and repaid the Note in full on August 7, 2020. Subsequent to the repayment, the facility was no longer available to the Company.

In addition, in order to finance transaction costs in connection with a Business Combination, the Initial Shareholders or their affiliates may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion (the “Working Capital Loans”). Each loan would be evidenced by a promissory note. The notes would either be paid upon consummation of the initial Business Combination, without interest, or, at the lender’s discretion, up to $500,000 of such loans may be converted upon consummation of the Business Combination into additional private warrants at a price of $1.00 per warrant. If the Company does not complete a Business Combination within the Combination Period, the Working Capital Loans will be repaid only from amounts remaining outside the Trust Account, if any. The warrants would be identical to the Private Placement Warrants. As of December 31, 2022 and 2021, the Company had no outstanding Working Capital Loans.

Administrative Services Agreement

Commencing on the date of the Company’s prospectus, the Company agreed to pay the Sponsor a total of $10,000 per month for office space and certain office and secretarial services. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. For the years ended December 31, 2022 and 2021, the Company incurred $120,000 in expenses for these services. As of December 31, 2022 and 2021, $0 and $150,000 were due to the Sponsor and are included in accrued expenses - related party on the accompanying consolidated balance sheets, respectively.

Purchase Agreements and Backstop Agreement

On August 3, 2020, in connection with the consummation of the Initial Public Offering, the Company entered into a purchase agreement (“FPA”) with its Sponsor pursuant to which the Sponsor agreed that it will purchase an aggregate of 2,500,000 ordinary shares of the Company at a price of $10.00 per share, for an aggregate purchase price of $25.0 million prior to, currently with, or following the consummation of a Business Combination, either in open market transactions (to the extent permitted by law) or in a private placement with the Company. This FPA commitment has been satisfied by the RTW Funds through: (a) an investment of $15 million in Orchestra’s Series D Financing, and (b) the Forward Purchase Agreements described below.

Simultaneously with the execution of the Merger Agreement, the Company and Orchestra entered into separate Forward Purchase Agreements with the RTW Funds and Medtronic, pursuant to which each of the Purchasing Parties agreed to purchase approximately $10.0 million of the Company’s ordinary shares, for a total of approximately $20.0 million, less the dollar amount of the Company’s ordinary shares holding redemption rights that the Purchasing Party acquires and holds until immediately prior to the domestication.

F-16

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2022

Simultaneously with the execution of the Merger Agreement and the Forward Purchase Agreements, the Company, Orchestra, and the RTW Funds entered into the Backstop Agreement, pursuant to which the RTW Funds, jointly and severally, agreed to purchase such number of the Company’s ordinary shares at a price of $10.00 per share to the extent that the amount of Parent Closing Cash (as defined in the Merger Agreement) as of immediately prior to the closing of the Orchestra Business Combination is less than $60.0 million (inclusive of the $10.0 million commitment by the RTW Funds pursuant to the Forward Purchase Agreement described above).

On October 21, 2022, the Backstop Agreement and the Forward Purchase Agreement with the RTW Funds were amended to provide that: (1) the per share purchase price under each of the Backstop Agreement and the Forward Purchase Agreement will not exceed the redemption price available to Public Shareholders exercising redemption rights at the shareholder meeting held to approve the Business Combination; (2) any shares purchased pursuant to the Backstop Agreement or the Forward Purchase Agreement, or otherwise acquired by the RTW Funds outside of the existing redemption offer, will not be voted in favor of approving the Business Combination; and (3) the RTW Funds will waive redemption rights with respect to such purchases in the vote to approve the Business Combination. The amendments have been filed with the SEC on a Current Report on Form 8-K on October 21, 2022. The Forward Purchase Agreement with Medtronic was not amended.

The closing under the Forward Purchase Agreement with Medtronic and the closing under the Backstop Agreement, if any, will occur immediately prior to the domestication. The Company’s Sponsor, and the Purchasing Parties will have registration rights pursuant to the Amended and Restated Registration Rights and Lock-Up Agreement with respect to the Company’s ordinary shares, received in the domestication.

Company Shareholder Support Agreement and Forfeiture

Contemporaneously with the execution of the Merger Agreement, the Company and Orchestra entered into a support agreement (the “Parent Support Agreement”) with the Sponsor and certain of the Company’s other shareholders (each a “Shareholder”) pursuant to which the Shareholders identified therein have agreed (a) to appear at any shareholder meetings called to approve the Merger or any proposal to extend the period of time the Company is afforded under its organizational documents and its prospectus to consummate an initial business combination (an “Extension Proposal”), (b) not to redeem their shares or any other of the Company’s equity securities now or in future acquired or beneficially owned, (c) to vote such shares and equity securities, to the extent permitted by law, (i) in favor of the domestication, the Merger and related transactions, (ii) in favor of any Extension Proposal, (iii) against any change in the Company’s business, management or board contrary to the Merger Agreement and against any other proposal reasonably expected to breach, prevent or impede the Merger, and (d) to waive anti-dilution and similar rights with respect to such shares, whether under the Company’s amended and restated memorandum and articles of association, applicable law, or a contract regarding the Merger and related transactions with the Company. In addition, the Sponsor has agreed that 25% or 1,000,000 shares of its New Orchestra common stock received in the domestication will be forfeited to New Orchestra on the first business day following the fifth anniversary of the closing of the Orchestra Business Combination unless, as to 500,000 shares, the VWAP (as defined in the Merger Agreement) of the New Orchestra common stock is greater than or equal to $15.00 per share over any 20 Trading Days (as defined in the Merger Agreement) within any 30-Trading Day period, and as to the remaining 500,000 shares, the VWAP of the New Orchestra common stock is greater than or equal to $20.00 per share over any 20-Trading Days within any 30-Trading Day period. Further, subject to the closing of the Orchestra Business Combination, the Sponsor has agreed to forfeit 50% of its warrants, comprising 750,000 warrants for no consideration.

Note 6-Commitments and Contingencies

Registration Rights

The holders of the Insider Shares, the Private Placement Shares, the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration rights agreement. The holders of a majority of these securities are entitled to make up to two demands that the Company registers such securities. The holders of the majority of the Insider Shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these ordinary shares are to be released from escrow. The holders of a majority of the Private Placement Shares, the Private Placement Warrants or warrants that may be issued upon conversion of Working Capital Loans made to the Company can elect to exercise these registration rights at any time after the Company consummates a Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s consummation of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

F-17

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2022

Underwriting Agreement

The Company granted the underwriters a 45-day option from the effective date of the registration statement relating to the Initial Public Offering to purchase up to 2,086,956 additional ordinary shares at the Initial Public Offering price less the underwriting discounts and commissions. On August 6, 2020, the underwriters fully exercised the over-allotment option.

The underwriters were entitled to an underwriting discount of $0.20 per Public Share, or $3.2 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, the underwriters were entitled to a deferred underwriting commission of $0.35 per Public Share, or $5.6 million in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

Risks and Uncertainties

Various social and political circumstances in the United States and around the world (including wars and other forms of conflict, including rising trade tensions between the United States and China, and other uncertainties regarding actual and potential shifts in the United States and foreign, trade, economic and other policies with other countries, terrorist acts, security operations and catastrophic events such as fires, floods, earthquakes, tornadoes, hurricanes and global health epidemics) may contribute to increased market volatility and economic uncertainties or deterioration in the United States and worldwide. Specifically, the rising conflict between Russia and Ukraine, and resulting market volatility could adversely affect the Company’s ability to complete a business combination. In response to the conflict between Russia and Ukraine, the United States and other countries have imposed sanctions or other restrictive actions against Russia. Any of the above factors, including sanctions, export controls, tariffs, trade wars and other governmental actions, could have a material adverse effect on the Company’s ability to complete a business combination and the value of the Company’s securities.

Management continues to evaluate the impact of these types of risks on the industry and has concluded that while it is reasonably possible that these types of risks could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Note 7-Ordinary Shares Subject to Possible Redemption

The Company’s Public Shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of future events. The Company is authorized to issue 100,000,000 ordinary shares with a par value of $0.0001 per share. Holders of the Company’s ordinary shares are entitled to one vote for each share. As of December 31, 2022 and 2021, there were 11,212,117 and 20,450,000 ordinary shares outstanding, respectively, 6,762,117 and 16,000,000 of which were subject to possible redemption, respectively, and are classified outside of permanent equity in the consolidated balance sheets.

F-18

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2022

The ordinary shares subject to possible redemption reflected on the consolidated balance sheets is reconciled on the following table:

Gross proceeds received from Initial Public Offering	$	160,000,000
Less:
Offering costs allocated to Public Shares		(9,418,420	)
Plus:
Accretion on ordinary shares to redemption value		9,418,420
Ordinary shares subject to possible redemption as of December 31, 2021		160,000,000
Redemption of Public Shares		(92,591,090	)
Increase in redemption value of ordinary shares subject to possible redemption		267,588
Ordinary shares subject to possible redemption as of December 31, 2022	$	67,676,498

Note 8-Shareholders’ Deficit

Preference Shares - The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share. As of December 31, 2022 and 2021, there are no preference shares issued or outstanding.

Ordinary Shares - The Company is authorized to issue 100,000,000 ordinary shares, par value $0.0001. Holders of the Company’s ordinary shares are entitled to one vote for each share. As of December 31, 2022 and 2021, there were 11,212,117 and 20,450,000 ordinary shares issued or outstanding, respectively, including 6,762,117 and 16,000,000 ordinary shares subject to possible redemption, respectively, and classified as temporary equity.

Private Warrants - Private Placement Warrants may only be exercised for a whole number of ordinary shares. The Private Placement Warrants will become exercisable 30 days after the completion of a Business Combination; provided in each case that the Company has an effective registration statement under the Securities Act covering the ordinary shares issuable upon exercise of the Private Placement Warrants and a current prospectus relating to them is available and such ordinary shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or the Company permit holders to exercise their warrants on a cashless basis under certain circumstances).

Each warrant is exercisable to purchase one of ordinary shares at an exercise price of $11.50 per full share and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.

The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share capitalization, or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants shares. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

F-19

HEALTH SCIENCES ACQUISITIONS CORPORATION 2

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2022

Note 9-Fair Value Measurements

The following table presents information about the Company’s financial assets that are measured at fair value on a recurring basis as of December 31, 2021 by level within the fair value hierarchy:

	Fair Value Measured as of December 31, 2021
	Level 1		Level 2		Level 3		Total
Investments held in Trust Account - U.S. Treasury Securities	$	160,022,447	$	-	$	-	$	160,022,447

Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for years ended December 31, 2022 and 2021.

Level 1 instruments include investments in money market funds that invest in U.S. Treasury securities with an original maturity of 185 days or less. The Company uses inputs such as actual trade data, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments.

As of December 31, 2022, only cash is held in the Trust Account.

Note 10-Subsequent Events

The Company evaluated subsequent events and transactions that occurred after the consolidated balance sheet date up to the date that the consolidated financial statements were issued. Based upon this review, other than as described above, the Company did not identify any other subsequent events that have occurred that would require adjustments to the disclosures in the consolidated financial statements.

F-20

EX-4.4 2 f10k2022ex4-4_healthscien2.htm DESCRIPTION OF SECURITIES

Exhibit 4.4

DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

As of December 31, 2022, the end of the period covered by this Annual Report on Form 10-K, Health Sciences Acquisitions Corporation 2 (the “Company,” “we,” “us,” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): the Company’s ordinary shares.

The following description of the Company’s capital stock and provisions of the Company’s amended and restated memorandum and articles of association (as amended, the “Existing Charter”) and the Companies Act (2022 Revision) (As Revised) of the Cayman Islands (the “Companies Act”) are summaries and are qualified in their entirety by reference to the Existing Charter and the text of the Companies Act. The Existing Charter has been filed with the SEC as exhibit to the Annual Report on Form 10-K to which this description has been filed as an exhibit.

General

We are a company incorporated in the Cayman Islands as an exempted company and our affairs are governed by the Existing Charter, the Companies Act and the common law of the Cayman Islands. We are currently authorized to issue 100,000,000 ordinary shares, par value $0.0001, and 1,000,000 preference shares, par value $0.0001. As of January 23, 2023, 11,212,117 ordinary shares were issued and outstanding.

Ordinary Shares

Our registered shareholders are entitled to one vote for each share held on all matters to be voted on by shareholders. In connection with any vote held to approve our initial business combination, all of our shareholders as of immediately prior to our initial public offering (the “initial shareholders”), as well as all of our officers and directors, have agreed to vote their respective ordinary shares owned by them in favor of any proposed business combination. However, any ordinary shares acquired outside of the redemption offer will not be voted in favor of approving the business combination and, further, will not carry redemption rights.

We will proceed with the business combination only if we have net tangible assets of at least $5,000,001 upon consummation of such business combination and an ordinary resolution under Cayman Islands law, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company will be required to approve the business combination. At least five days’ notice must be given for each general meeting (although we will provide whatever minimum number of days are required under federal securities laws). Shareholders may vote at meetings in person or by proxy.

The members of our board of directors serve until the next annual general meeting. There is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50% of the shares eligible to vote for the election of directors can elect all of the directors.

Pursuant to our Existing Charter, if we do not consummate a business combination by February 6, 2023, or such later time as our shareholders may approve in accordance with the Existing Charter, it will trigger our automatic winding up, liquidation and dissolution. Our initial shareholders have agreed to waive their rights to share in any distribution from the trust account with respect to their insider shares and private shares upon our winding up, liquidation and dissolution.

Our shareholders have no conversion, preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to the ordinary shares, except that public shareholders have the right to have their public shares converted to cash equal to their pro rata share of the trust account if the business combination is completed.

Register of Members

Under Cayman Islands law, we must keep a register of members (which contains details of the registered holders of the shares) and there will be entered therein:

●

the names and addresses of the members, a statement of the shares held by each member, and of the amount paid or agreed to be considered as paid, on the shares of each member and the voting rights of the shares of each member;

●

the date on which the name of any person was entered on the register as a member; and

●

the date on which any person ceased to be a member.

Under Cayman Islands law, the register of members of our Company is prima facie evidence of the matters set out therein (i.e., the register of members will raise a presumption of fact on the matters referred to above unless rebutted) and a member registered in the register of members will be deemed as a matter of Cayman Islands law to have legal title to the shares as set against its name in the register of members. Upon the closing of our initial public offering, the register of members will be immediately updated to reflect the issue of shares by us. Once our register of members has been updated, the shareholders recorded in the register of members will be deemed to have legal title to the shares set against their name. However, there are certain limited circumstances where an application may be made to a Cayman Islands court for a determination on whether the register of members reflects the correct legal position. Further, the Cayman Islands court has the power to order that the register of members maintained by a company should be rectified where it considers that the register of members does not reflect the correct legal position. If an application for an order for rectification of the register of members were made in respect of the ordinary shares, then the validity of such shares may be subject to re-examination by a Cayman Islands court.

Private Warrants

Each of the warrants sold in a private placement simultaneously with our initial public offering (each, a “private warrant”) entitles the registered holder to purchase one ordinary share at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing 30 days after the completion of our initial business combination. The private warrants have a net exercise provision under which its holder may, in lieu of payment of the exercise price in cash, surrender the warrant and receive a net amount of shares based on the fair market value of the ordinary shares at the time of exercise of the private warrants after deduction of the aggregate exercise price. The private warrants will expire five years after the date on which they first became exercisable, at 5:00 p.m., New York City time.

None of the private warrants will be redeemable by us.

We will not be obligated to deliver any ordinary shares pursuant to the exercise of a private warrant and will have no obligation to settle such private warrant exercise unless a registration statement under the Securities Act with respect to the ordinary shares underlying the private warrants is then effective and a prospectus relating thereto is current, subject to our satisfying our obligations described below with respect to registration. No private warrant will be exercisable and we will not be obligated to issue ordinary shares upon exercise of a private warrant unless the ordinary shares issuable upon such private warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the private warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a private warrant, the holder of such private warrant will not be entitled to exercise such private warrant and such private warrant may have no value and expire worthless. In no event will we be required to net cash settle any private warrant. In the event that a registration statement is not effective for the exercised private warrants, the purchaser of the private warrant will have paid the full purchase price for the private warrant solely for the ordinary share underlying such private warrant.

If the number of outstanding ordinary shares is increased by a share dividend payable in ordinary shares, then, on the effective date of such share dividend, or split-up or similar event, the number of shares issuable on exercise of each private warrant will be increased in proportion to such increase in the outstanding shares.

In addition, if we, at any time while the private warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to the holders of ordinary shares on account of their holdings (or other securities into which the private warrants are convertible), other than (a) as described above, (b) certain ordinary cash dividends which are deemed to be dividends of up to $0.50 per ordinary share per year), (c) to satisfy the redemption rights of the holders of ordinary shares in connection with a proposed initial business combination or (d) in connection with the redemption of our public shares upon our failure to complete our initial business combination, then the private warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each share in respect of such event.

If the number of outstanding shares is decreased by a consolidation, combination, reverse share split or reclassification of ordinary shares or other similar event, then, on the effective date of such consolidation, combination, reverse share split, reclassification or similar event, the number of shares issuable on exercise of each warrant will be decreased in proportion to such decrease in outstanding ordinary shares.

Whenever the number of ordinary shares issuable upon the exercise of the private warrants is adjusted, as described above, the private warrant exercise price will be adjusted by multiplying the private warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of shares purchasable upon the exercise of the warrants immediately prior to such adjustment and (y) the denominator of which will be the number of shares so purchasable immediately thereafter.

If, at any time while a private warrant is outstanding, (i) we effect any merger or consolidation with or into another person, (ii) we effect any sale of all or substantially all of our assets or a majority of the ordinary shares is acquired by a third party, in each case, in one or a series of related transactions, (iii) any tender offer or exchange offer is completed pursuant to which all or substantially all of the holders of ordinary shares are permitted to tender or exchange their shares for other securities, cash or property, or (iv) we effect any reorganization or reclassification of ordinary shares or any compulsory share exchange pursuant to which the ordinary shares is effectively converted into or exchanged for other securities, cash or property (in any such case, a “Fundamental Transaction”), then the holder of a private warrant shall have the right thereafter to receive, upon exercise of the private warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of shares then issuable upon exercise in full of such private warrant.

As a holder of the private warrants, our sponsor does not have the right or privileges of holders of ordinary shares and any voting rights until they exercise their private warrants and receive ordinary shares. After the issuance of ordinary shares upon exercise of the private warrants, our sponsor will be entitled to one vote for each share registered in the name of the sponsor in the register of members of the Company on all matters to be voted on by shareholders.

Dividends

We have not paid any cash dividends on the ordinary shares to date and do not intend to pay cash dividends prior to the completion of a business combination. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition subsequent to completion of a business combination. The payment of any dividends subsequent to a business combination will be within the discretion of our then board of directors. It is the present intention of our board of directors to retain all earnings, if any, for use in our business operations and, accordingly, our board does not anticipate declaring any dividends in the foreseeable future.

Our Transfer Agent

The transfer agent for our ordinary shares is Continental Stock Transfer & Trust Company, 1 State Street, 30th Floor, New York, New York 10004.

Listing of our Ordinary Shares

Our ordinary shares are listed on The Nasdaq Capital Market under the symbol “HSAQ”. We cannot assure you that our ordinary shares will continue to be listed on Nasdaq as we might not meet certain continued listing standards.

Certain Differences in Corporate Law

Cayman Islands companies are governed by the Companies Act. The Companies Act is modeled on English law but does not follow recent English law statutory enactments and differs from laws applicable to United States corporations and their shareholders. Set forth below is a summary of the material differences between the provisions of the Companies Act applicable to us and the laws applicable to companies incorporated in the United States and their shareholders.

Mergers and Similar Arrangements. In certain circumstances, the Companies Act allows for mergers or consolidations between two Cayman Islands companies, or between a Cayman Islands exempted company and a company incorporated in another jurisdiction (provided that is facilitated by the laws of that other jurisdiction).

Where the merger or consolidation is between two Cayman Islands companies, the directors of each company must approve a written plan of merger or consolidation containing certain prescribed information. That plan or merger or consolidation must then be authorized by either (a) a special resolution (usually a majority of 66.6%) of the shareholders of each company; or (b) such other authorization, if any, as may be specified in such constituent company’s articles of association. No shareholder resolution is required for a merger between a parent company (i.e., a company that hold issued shares carrying at least 90% of the votes exercisable in a shareholder meeting of the subsidiary company) and its subsidiary company. The consent of each holder of a fixed or floating security interest of a constituent company must be obtained, unless the court waives such requirement. If the Cayman Islands Registrar of Companies is satisfied that the requirements of the Companies Act (which includes certain other formalities) have been complied with, the Registrar of Companies will register the plan of merger or consolidation.

Where the above procedures are adopted, subject to certain exceptions, the Companies Act provides for a right of dissenting shareholders to be paid the fair value of his shares upon their dissenting to the merger or consolidation if they follow a prescribed procedure. In essence, that procedure is as follows: (a) the shareholder must give his, her or its written objection to the merger or consolidation to the constituent company before the vote on the merger or consolidation, including a statement that the shareholder proposes to demand payment for his shares if the merger or consolidation is authorized by the vote; (b) within 20 days following the date on which the merger or consolidation is approved by the shareholders, the constituent company must give written notice to each shareholder who made a written objection; (c) a shareholder must, within 20 days following receipt of such notice from the constituent company, give the constituent company a written notice of his intention to dissent including, among other details, a demand for payment of the fair value of his shares; (d) within seven days following the date of the expiration of the period set out in paragraph (b) above or seven days following the date on which the plan of merger or consolidation is filed, whichever is later, the constituent company, the surviving company or the consolidated company must make a written offer to each dissenting shareholder to purchase his, her or its shares at a price that the company determines is the fair value and if the company and the shareholder agree the price within 30 days following the date on which the offer was made, the company must pay the shareholder such amount; (e) if the company and the shareholder fail to agree to a price within such 30-day period, within 20 days following the date on which such 30-day period expires, the company must (and any dissenting shareholder may) file a petition with the Cayman Islands Grand Court to determine the fair value and such petition must be accompanied by a list of the names and addresses of the dissenting shareholders with whom agreements as to the fair value of their shares have not been reached by the company. At the hearing of that petition, the court has the power to determine the fair value of the shares together with a fair rate of interest, if any, to be paid by the company upon the amount determined to be the fair value. Any dissenting shareholder whose name appears on the list filed by the company may participate fully in all proceedings until the determination of fair value is reached. These rights of a dissenting shareholder are not available in certain circumstances, for example, to dissenters holding shares of any class in respect of which an open market exists on a recognized stock exchange or recognized interdealer quotation system at the relevant date or where the consideration for such shares to be contributed are shares of any company listed on a national securities exchange or shares of the surviving or consolidated company.

Moreover, Cayman Islands law also has separate statutory provisions (including to facilitate the reconstruction or amalgamation of companies in certain circumstances) commonly referred to in the Cayman Islands as “schemes of arrangement,” which may be tantamount to a merger. A scheme of arrangement must currently be approved by a majority in number of each class of shareholders or creditors with whom the arrangement is to be made and who must in addition represent three-fourths in value of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or by proxy at a meeting, or meetings summoned for that purpose. The convening of the meetings and subsequently the terms of the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder would have the right to express to the court the view that the scheme of arrangement should not be approved, the court can be expected to approve the arrangement if it satisfies itself that:

●

we are not proposing to act illegally or beyond the scope of our corporate authority and the statutory provisions as to the required vote have been complied with and there is no coercion of the minority shareholders or “fraud on the minority”;

●

the shareholders have been fairly represented at the shareholder meeting in question;

●

the arrangement is such that an honest and intelligent person, being a member of the class of shareholders affected by the arrangement and acting in respect of his interests, might reasonably approve; and

●

the arrangement is not one that would more properly be sanctioned under some other provision of the Companies Act.

If a scheme of arrangement or takeover offer (as described below) is approved, any dissenting shareholder would have no rights comparable to appraisal rights, which would otherwise ordinarily be available to dissenting shareholders of United States corporations, providing rights to receive payment in cash for the judicially determined value of the shares.

Squeeze-out Provisions. When a takeover offer is made and accepted by the holders of at least 90% of the shares affected within four months of the offer being made, the offeror may, within a two-month period following the expiration of such four-month period, require the holders of the remaining shares to transfer their shares on the terms of the offer. An objection can be made to the Grand Court of the Cayman Islands within one month of the requisite compulsory acquisition notice being given but this is unlikely to succeed unless there is a breach of the Companies Act or fraud or dishonesty.

Further, transactions similar to a merger, reconstruction and/or an amalgamation may in some circumstances be achieved through other means to these statutory provisions, such as a share capital exchange, asset acquisition or control, through contractual arrangements, of an operating business.

Shareholders’ Suits. Our Cayman Islands legal counsel is not aware of any reported class action having been brought in a Cayman Islands court. Derivative actions have been brought in the Cayman Islands courts, and the Cayman Islands courts have confirmed the availability for such actions. In most cases, we will be the proper plaintiff in any claim based on a breach of duty owed to us, and a claim against (for example) our officers or directors usually may not be brought by a shareholder (other than on behalf of the Company). However, based both on Cayman Islands authorities and on English authorities, which would in all likelihood be of persuasive authority and be applied by a court in the Cayman Islands, exceptions to the foregoing principle apply in circumstances in which:

●

a company is acting, or proposing to act, illegally or beyond the scope of its authority;

●

the act complained of, although not beyond the scope of the authority, could be effected if duly authorized by more than the number of votes which have actually been obtained; or

●

those who control the company are perpetrating a “fraud on the minority.”

A shareholder may have a direct right of action against us where the individual rights of that shareholder have been infringed or are about to be infringed.

Enforcement of civil liabilities. The Cayman Islands has a different body of securities laws as compared to the United States and may provide less protection to investors. Additionally, Cayman Islands companies may not have standing to sue before the federal courts of the United States.

We have been advised by our Cayman Islands legal counsel that the courts of the Cayman Islands are unlikely (i) to recognize or enforce against us judgments of courts of the United States predicated upon the civil liability provisions of the federal securities laws of the United States or any state and (ii) in original actions brought in the Cayman Islands, to impose liabilities against us predicated upon the civil liability provisions of the federal securities laws of the United States or any state, so far as the liabilities imposed by those provisions are penal in nature. In those circumstances, although there is no statutory enforcement in the Cayman Islands of judgments obtained in the United States, the courts of the Cayman Islands will recognize and enforce a foreign money judgment of a foreign court of competent jurisdiction without retrial on the merits based on the principle that a judgment of a competent foreign court imposes upon the judgment debtor an obligation to pay the sum for which judgment has been given, provided certain conditions are met. For a foreign judgment to be enforced in the Cayman Islands, such judgment must be final and conclusive and for a liquidated sum and must not be in respect of taxes or a fine or penalty, inconsistent with a Cayman Islands judgment in respect of the same matter, impeachable on the grounds of fraud or obtained in a manner, or be of a kind the enforcement of which is contrary to natural justice or the public policy of the Cayman Islands (awards of punitive or multiple damages may well be held to be contrary to public policy). A Cayman Islands court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere.

Special Considerations for Exempted Companies. We are an exempted company with limited liability under the Companies Act. The Companies Act distinguishes between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an exempted company are essentially the same as for an ordinary company except for the exemptions and privileges listed below:

●

annual reporting requirements are minimal and consist mainly of a statement that the company has conducted its operations mainly outside of the Cayman Islands and has complied with the provisions of the Companies Act;

●

an exempted company’s register of members is not open to inspection;

●

an exempted company does not have to hold an annual general meeting;

●

an exempted company may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 20 years in the first instance);

●

an exempted company may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;

●

an exempted company may register as a limited duration company; and

●

an exempted company may register as a segregated portfolio company.

Amended and Restated Memorandum and Articles of Association

Our Existing Charter filed under the laws of the Cayman Islands contain provisions designed to provide certain rights and protections to our shareholders prior to the consummation of a business combination. The following are the material rights and protections contained in our Existing Charter:

●

the right of public shareholders to have their public shares redeemed in lieu of participating in a proposed business combination;

●

a prohibition against completing a business combination unless we have net tangible assets of at least $5,000,001 upon consummation of such business combination;

●

a requirement that if we seek shareholder approval of any business combination, an ordinary resolution under Cayman Islands law, which requires the affirmative vote of a majority of the shareholders who attend and vote at a shareholder meeting of the company, will be required to approve the business combination;

●

the ability of the directors to call general meetings on their own accord;

●

a prohibition, prior to a business combination, against our issuing (i) any ordinary shares or any securities convertible into ordinary shares or (ii) any other securities (including preference shares) which participate in or are otherwise entitled in any manner to any of the proceeds in the trust account or which vote as a class with the ordinary shares on a business combination;

●

a requirement that our management take all actions necessary to liquidate our trust account in the event we do not consummate a business combination by February 6, 2023, or such later time as our shareholders may approve in accordance with the Existing Charter;

●

the limitation on shareholders’ rights to receive a portion of the trust account.

The Companies Act permits a company incorporated in the Cayman Islands to amend its memorandum and articles of association with the approval of the holders of a majority of at least two-thirds of such company’s shares present and voting at a shareholders’ meeting and this is the approval specified in our articles of association. Accordingly, although we could amend any of the provisions relating to our proposed offering, structure and business plan which are contained in our Existing Charter, we view all of these provisions as binding obligations to our shareholders and neither we, nor our officers or directors, will take any action to amend or waive any of these provisions unless we provide dissenting public shareholders with the opportunity to convert their public shares in connection with any such vote.

Anti-Money Laundering — Cayman Islands

If any person in the Cayman Islands knows or suspects or has reasonable grounds for knowing or suspecting that another person is engaged in criminal conduct or money laundering or is involved with terrorism or terrorist financing and property and the information for that knowledge or suspicion came to their attention in the course of business in the regulated sector, or other trade, profession, business or employment, the person will be required to report such knowledge or suspicion to (i) the Financial Reporting Authority of the Cayman Islands, pursuant to the Proceeds of Crime Act (As Revised) of the Cayman Islands if the disclosure relates to criminal conduct or money laundering, or (ii) a police officer of the rank of constable or higher, or the Financial Reporting Authority, pursuant to the Terrorism Act (As Revised) of the Cayman Islands, if the disclosure relates to involvement with terrorism or terrorist financing and property. Such a report shall not be treated as a breach of confidence or of any restriction upon the disclosure of information imposed by any enactment or otherwise.

Data Protection – Cayman Islands

We have certain duties under the Data Protection Act (2021 Revision) (As Revised) of the Cayman Islands (the “DPA”) based on internationally accepted principles of data privacy.

Privacy Notice

Introduction

This privacy notice puts our shareholders on notice that through your investment in the company you will provide us with certain personal information which constitutes personal data within the meaning of the DPA (“personal data”).

In the following discussion, the “company” refers to us and our affiliates and/or delegates, except where the context requires otherwise.

Investor Data

We will collect, use, disclose, retain and secure personal data to the extent reasonably required only and within the parameters that could be reasonably expected during the normal course of business. We will only process, disclose, transfer or retain personal data to the extent legitimately required to conduct our activities of on an ongoing basis or to comply with legal and regulatory obligations to which we are subject. We will only transfer personal data in accordance with the requirements of the DPA and will apply appropriate technical and organizational information security measures designed to protect against unauthorized or unlawful processing of the personal data and against the accidental loss, destruction or damage to the personal data.

In our use of this personal data, we will be characterized as a “data controller” for the purposes of the DPA, while our affiliates and service providers who may receive this personal data from us in the conduct of our activities may either act as our “data processors” for the purposes of the DPA or may process personal information for their own lawful purposes in connection with services provided to us.

We may also obtain personal data from other public sources. Personal data includes, without limitation, the following information relating to a shareholder and/or any individuals connected with a shareholder as an investor: name, residential address, email address, contact details, corporate contact information, signature, nationality, place of birth, date of birth, tax identification, credit history, correspondence records, passport number, bank account details, source of funds details and details relating to the shareholder’s investment activity.

Who this Affects

If you are a natural person, this will affect you directly. If you are a corporate investor (including, for these purposes, legal arrangements such as trusts or exempted limited partnerships) that provides us with personal data on individuals connected to you for any reason in relation your investment in the company, this will be relevant for those individuals and you should transmit the content of this privacy notice to such individuals or otherwise advise them of its content.

How the Company May Use Your Personal Data

The company, as the data controller, may collect, store and use personal data for lawful purposes, including, in particular:

(i)

where this is necessary for the performance of our rights and obligations under any purchase agreements;

(ii)

where this is necessary for compliance with a legal and regulatory obligation to which we are subject (such as compliance with anti-money laundering and FATCA/CRS requirements); and/or

(iii)

where this is necessary for the purposes of our legitimate interests and such interests are not overridden by your interests, fundamental rights or freedoms.

Should we wish to use personal data for other specific purposes (including, if applicable, any purpose that requires your consent), we will contact you.

Why We May Transfer Your Personal Data

In certain circumstances, we may be legally obliged to share personal data and other information with respect to your shareholding with the relevant regulatory authorities such as the Cayman Islands Monetary Authority or the Tax Information Authority. They, in turn, may exchange this information with foreign authorities, including tax authorities.

We anticipate disclosing personal data to persons who provide services to us and their respective affiliates (which may include certain entities located outside the U.S., the Cayman Islands or the European Economic Area), who will process your personal data on our behalf.

The Data Protection Measures We Take

Any transfer of personal data by us or our duly authorized affiliates and/or delegates outside of the Cayman Islands shall be in accordance with the requirements of the DPA.

We and our duly authorized affiliates and/or delegates shall apply appropriate technical and organizational information security measures designed to protect against unauthorized or unlawful processing of personal data, and against accidental loss or destruction of, or damage to, personal data.

We shall notify you of any personal data breach that is reasonably likely to result in a risk to your interests, fundamental rights or freedoms or those data subjects to whom the relevant personal data relates.

Staggered Board of Directors

Our Existing Charter provides that our board of directors will be classified into three classes of directors. As a result, in most circumstances, a person can gain control of our board only by successfully engaging in a proxy contest at two or more annual meetings.

Extraordinary General Meeting

Our Existing Charter provides that extraordinary general meetings of shareholders may be called only by a majority vote of our board of directors, by our chief executive officer or by our chairman.

Advance Notice Requirements for Shareholder Proposals and Director Nominations

Our Existing Charter provides that shareholders seeking to bring business before our annual general meeting, or to nominate candidates for election as directors at our annual general meeting must provide timely notice of their intent in writing. To be timely, a shareholder’s notice will need to be delivered to our principal executive offices not less than 120 calendar days before the date of the Company’s proxy statement released to shareholders in connection with the previous year’s annual general meeting or, if the Company did not hold an annual general meeting the previous year, or if the date of the current year’s annual general meeting has been changed by more than 30 days from the date of the previous year’s annual general meeting, then the deadline will be set by our board of directors with such deadline being a reasonable time before the Company begins to print and send its related proxy materials. Our Existing Charter also specifies certain requirements as to the form and content of a shareholders’ meeting. These provisions may preclude our shareholders from bringing matters before our annual general meeting or from making nominations for directors at our annual general meeting.

Authorized but Unissued Shares

Our authorized but unissued ordinary shares and preference shares are available for future issuances without shareholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved ordinary shares and preference shares could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.

EX-21 3 f10k2022ex21_healthscien2.htm LIST OF SUBSIDIARIES

Exhibit 21

List of Subsidiaries of Health Sciences Acquisitions Corporation 2

Subsidiary		Jurisdiction of Organization
HSAC Olympus Merger Sub, Inc.		Delaware

EX-31.1 4 f10k2022ex31-1_healthscien2.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Roderick Wong, certify that:

I have reviewed this Annual Report on Form 10-K of Health Sciences Acquisitions Corporation 2;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: January 25, 2023	/s/ Roderick Wong
	Roderick Wong
	President and Chief Executive Officer
	(Principal executive officer)

EX-31.2 5 f10k2022ex31-2_healthscien2.htm CERTIFICATION

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Naveen Yalamanchi, certify that:

I have reviewed this Annual Report on Form 10-K of Health Sciences Acquisitions Corporation 2;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: January 25, 2023	/s/ Naveen Yalamanchi
	Naveen Yalamanchi
	Executive Vice President and Chief Financial Officer
	(Principal financial and accounting officer)

EX-32 6 f10k2022ex32_healthscien2.htm CERTIFICATION

Exhibit 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Health Sciences Acquisitions Corporation 2 (the “Company”) on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission (the “Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date:

January 25, 2023

	/s/ Roderick Wong
	Roderick Wong
	President and Chief Executive Officer
	(Principal executive officer)

Date:

January 25, 2023

	/s/ Naveen Yalamanchi
	Naveen Yalamanchi
	Executive Vice President and Chief Financial Officer
	(Principal financial and accounting officer)

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

EX-101.SCH 7 hsaq-20221231.xsd XBRL SCHEMA FILE 001 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statements of Operations (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Consolidated Statements of Changes in Shareholders’ Deficit link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Description of Organization, Business Operations and Going Concern link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Initial Public Offering link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Private Placement link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Ordinary Shares Subject to Possible Redemption link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Shareholders’ Deficit link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Ordinary Shares Subject to Possible Redemption (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Description of Organization, Business Operations and Going Concern (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Initial Public Offering (Details) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Private Placement (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Ordinary Shares Subject to Possible Redemption (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Ordinary Shares Subject to Possible Redemption (Details) - Schedule of condensed consolidated balance sheets link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Shareholders’ Deficit (Details) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Fair Value Measurements (Details) - Schedule of financial assets that are measured at fair value on a recurring basis link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 hsaq-20221231_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 hsaq-20221231_def.xml XBRL DEFINITION FILE EX-101.LAB 10 hsaq-20221231_lab.xml XBRL LABEL FILE Total current assets Total Assets Total current liabilities Total liabilities Total shareholders’ deficit Balance Balance Total Liabilities, Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit Loss from operations Net loss Net loss Balance (in Shares) Balance (in Shares) Equity Components [Axis] Net cash used in operating activities Cash provided by investing activities Cash used in financing activities Net change in cash Cash - beginning of the year Cash - end of the year Organization, Consolidation and Presentation of Financial Statements [Abstract] Initial Public Offering [Abstract] Fair Value Hierarchy and NAV [Axis] Document Type Document Annual Report Current Fiscal Year End Date Document Period End Date Document Fiscal Year Focus Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period ICFR Auditor Attestation Flag Entity Shell Company Entity Public Float Entity Common Stock, Shares Outstanding Auditor Name Auditor Location Auditor Firm ID Amendment Flag Document Fiscal Period Focus Entity Central Index Key Assets: Current assets: Cash Prepaid expenses Cash and investments held in Trust Account Liabilities, Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit Current liabilities: Accounts payable Accrued expenses Accrued expenses - related party Deferred underwriting commissions Commitments and Contingencies Ordinary shares subject to possible redemption, $0.0001 par value; 6,762,117 and 16,000,000 shares issued and outstanding at approximately $10.01 and $10.00 per share redemption value as of December 31, 2022 and 2021, respectively Ordinary shares subject to possible redemption, par value (in Dollars per share) Ordinary shares subject to possible redemption, shares issued Ordinary shares subject to possible redemption, shares outstanding Ordinary shares subject to possible redemption, per share redemption value (in Dollars per share) Shareholders’ Deficit: Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding as of December 31, 2022 and 2021 Preference shares, par value (in Dollars per share) Preference shares, shares authorized Preference shares, shares outsatanding Preference shares, shares issued Preference shares, shares outstanding PreferredStockSharesOutstanding Ordinary shares, $0.0001 par value; 100,000,000 shares authorized; 4,450,000 non-redeemable shares issued and outstanding as of December 31, 2022 and 2021 Ordinary shares, par value (in Dollars per share) Ordinary shares, shares authorized Non-redeemable, shares issued Non-redeemable, shares outstanding Additional paid-in capital Accumulated deficit Operating expenses General and administrative expenses Administrative fee - related party Interest income from investments held in Trust Account Weighted average shares outstanding of ordinary shares, basic and diluted (in Shares) Weighted average shares outstanding of ordinary shares, basic and diluted Basic and diluted net loss per ordinary share (in Dollars per share) Basic and diluted net loss per ordinary share Cash Flows from Operating Activities: Adjustments to reconcile to net loss to net cash used in operating activities Changes in operating assets and liabilities: Accounts payable Accrued expenses Accrued expenses - related party Cash Flows from Investing Activities: Cash withdrawn from Trust Account to redeem Public Shares Cash Flows from Financing Activities: Increase in redemption value of ordinary shares subject to possible redemption Interest income from investments held in Trust Account Prepaid expenses Redemption of Public Shares Ordinary Shares Ordinary Shares [Member] Ordinary share [Member] Additional Paid-In Capital Accumulated Deficit Description of Organization, Business Operations and Going Concern Summary of Significant Accounting Policies Initial Public Offering Private Placement Related Party Transactions Commitments and Contingencies Ordinary Shares Subject to Possible Redemption Schedule of condensed consolidated balance sheets Gross proceeds received from Initial Public Offering Less: Plus: Accretion on ordinary shares to redemption value Ordinary shares subject to possible redemption Redemption of Public Shares Increase in redemption value of ordinary shares subject to possible redemption Shareholders’ Deficit Fair Value Measurements Schedule of financial assets that are measured at fair value on a recurring basis Investments held in Trust Account - money market funds Subsequent Events Offering costs allocated to Public Shares Level 1 [Member] Level 2 [Member] Level 3 [Member] Sale of Stock [Axis] Business Acquisition [Axis] Ownership [Axis] Related Party [Axis] Subsequent Event Type [Axis] Class of Stock [Axis] Accounting Policies [Abstract] Issuance of initial public offering units (in Shares) Shares issued (in Shares) Issuance of public shares under over-allotment (in Shares) Price per share (in Dollars per share) Gross proceeds Offering cost Deferred underwriting commission Description of private placement warrant Private placement amount Assets held in the trust account, percentage Outstanding voting security percentage Price per unit (in Dollars per share) Public per share (in Dollars per share) Net tangible assets Aggregate shares, percentage Redeem shares, percentage Cash Working capital deficit Capital contribution Loan amount Purchase amount Ordinary shares total amount Shares per share (in Dollars per share) Ordinary shares price per share (in Dollars per share) Minimum of closing business combination amount Funds amount Public shares purchased (in Shares) Share price share (in Dollars per share) Proposed business combination Extension, redemptions and private purchase description. Public shares for redemption (in Shares) Public shares for redemption Federal depository insurance coverage (in Dollars) Shares subject to possible redemption Warrants to purchase ordinary shares Price per share (in Dollars per share) Redemption price Gross proceeds Offering costs Deferred underwriting commissions Purchase of warrants EX-101.PRE 11 hsaq-20221231_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
Document And Entity Information - USD ($) $ in Millions	Dec. 31, 2022	Jan. 23, 2023	Jun. 30, 2022
Document Information Line Items
Entity Registrant Name	HEALTH SCIENCES ACQUISITIONS CORPORATION 2
Trading Symbol	HSAQ
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		11,212,117
Entity Public Float			$ 159.4
Amendment Flag	false
Entity Central Index Key	0001814114
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-39421
Entity Incorporation, State or Country Code	E9
Entity Tax Identification Number	00-0000000
Entity Address, Address Line One	40 10th Avenue
Entity Address, Address Line Two	Floor 7
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10014
City Area Code	(646)
Local Phone Number	597-6980
Title of 12(b) Security	Ordinary Shares, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Auditor Name	WithumSmith+Brown, PC
Auditor Location	New York
Auditor Firm ID	100

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash	$ 175,161	$ 1,754,460
Prepaid expenses	123,918	46,667
Total current assets	299,079	1,801,127
Cash and investments held in Trust Account	67,776,498	160,022,447
Total Assets	68,075,577	161,823,574
Current liabilities:
Accounts payable	376,930	1,388
Accrued expenses	1,366,825	14,151
Accrued expenses - related party		150,000
Total current liabilities	1,743,755	165,539
Deferred underwriting commissions	5,600,000	5,600,000
Total liabilities	7,343,755	5,765,539
Commitments and Contingencies
Ordinary shares subject to possible redemption, $0.0001 par value; 6,762,117 and 16,000,000 shares issued and outstanding at approximately $10.01 and $10.00 per share redemption value as of December 31, 2022 and 2021, respectively	67,676,498	160,000,000
Shareholders’ Deficit:
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding as of December 31, 2022 and 2021
Ordinary shares, $0.0001 par value; 100,000,000 shares authorized; 4,450,000 non-redeemable shares issued and outstanding as of December 31, 2022 and 2021	445	445
Additional paid-in capital
Accumulated deficit	(6,945,121)	(3,942,410)
Total shareholders’ deficit	(6,944,676)	(3,941,965)
Total Liabilities, Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit	$ 68,075,577	$ 161,823,574

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Ordinary shares subject to possible redemption, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Ordinary shares subject to possible redemption, shares issued	6,762,117	16,000,000
Ordinary shares subject to possible redemption, shares outstanding	6,762,117	16,000,000
Ordinary shares subject to possible redemption, per share redemption value (in Dollars per share)	$ 10.01	$ 10
Preference shares, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preference shares, shares authorized	1,000,000	1,000,000
Preference shares, shares issued
Preference shares, shares outstanding
Ordinary shares, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized	100,000,000	100,000,000
Non-redeemable, shares issued	4,450,000	4,450,000
Non-redeemable, shares outstanding	4,450,000	4,450,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Operating expenses
General and administrative expenses	$ 2,960,264	$ 274,756
Administrative fee - related party	120,000	120,000
Loss from operations	(3,080,264)	(394,756)
Interest income from investments held in Trust Account	345,141	16,003
Net loss	$ (2,735,123)	$ (378,753)
Weighted average shares outstanding of ordinary shares, basic and diluted (in Shares)	16,425,826	20,450,000
Basic and diluted net loss per ordinary share (in Dollars per share)	$ (0.17)	$ (0.02)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Weighted average shares outstanding of ordinary shares, basic and diluted	16,425,826	20,450,000
Basic and diluted net loss per ordinary share	$ (0.17)	$ (0.02)

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Changes in Shareholders’ Deficit - USD ($)	Ordinary Shares	Accumulated Deficit	Total
Balance at Dec. 31, 2020	$ 445	$ (3,563,657)	$ (3,563,212)
Balance (in Shares) at Dec. 31, 2020	4,450,000
Net loss		(378,753)	(378,753)
Balance at Dec. 31, 2021	$ 445	(3,942,410)	(3,941,965)
Balance (in Shares) at Dec. 31, 2021	4,450,000
Increase in redemption value of ordinary shares subject to possible redemption		(267,588)	(267,588)
Net loss		(2,735,123)	(2,735,123)
Balance at Dec. 31, 2022	$ 445	$ (6,945,121)	$ (6,944,676)
Balance (in Shares) at Dec. 31, 2022	4,450,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 18 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Cash Flows from Operating Activities:
Net loss	$ (2,735,123)	$ (378,753)
Adjustments to reconcile to net loss to net cash used in operating activities
Interest income from investments held in Trust Account	(345,141)	(16,003)
Changes in operating assets and liabilities:
Prepaid expenses	(77,251)	75,811
Accounts payable	375,542	(12,422)
Accrued expenses	1,352,674	(60,995)
Accrued expenses - related party	(150,000)	120,000
Net cash used in operating activities	(1,579,299)	(272,362)
Cash Flows from Investing Activities:
Cash withdrawn from Trust Account to redeem Public Shares	92,591,090
Cash provided by investing activities	92,591,090
Cash Flows from Financing Activities:
Redemption of Public Shares	(92,591,090)
Cash used in financing activities	(92,591,090)
Net change in cash	(1,579,299)	(272,362)
Cash - beginning of the year	1,754,460	2,026,822
Cash - end of the year	$ 175,161	$ 1,754,460

XML 19 R8.htm IDEA: XBRL DOCUMENT

Description of Organization, Business Operations and Going Concern

12 Months Ended

Dec. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of Organization, Business Operations and Going Concern

Note 1-Description of Organization, Business Operations and Going Concern

Organization and General

Sponsor and Financing

Trust Account

Upon the closing of the Initial Public Offering and the Private Placement (including the exercise of the over-allotment option), $160.0 million (or $10.00 per Public Share) of the net proceeds of the Initial Public Offering and the Private Placement was placed in a U.S. based trust account (the “Trust Account”), maintained by Continental Stock Transfer & Trust Company, acting as trustee, and invested in U.S. “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act, which invest only in direct U.S. government treasury obligations, until the earlier of (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below. On July 25, 2022, the entire Trust Account balance was transferred into cash in connection with the redemptions as described below.

Initial Business Combination

Liquidity and Going Concern

As of December 31, 2022, the Company had approximately $175,000 of cash in its operating account and a working capital deficit of approximately $1.8 million.

Proposed Business Combination

In addition, the Sponsor has agreed that 25% or 1,000,000 shares of its New Orchestra common stock received in the domestication will be forfeited to New Orchestra on the first business day following the fifth anniversary of the closing unless, as to 500,000 shares, the VWAP (as defined in the Merger Agreement) of the New Orchestra common stock is greater than or equal to $15.00 per share over any 20 Trading Days (as defined in the Merger Agreement) within any 30-Trading Day period, and as to the remaining 500,000 shares, the VWAP of the New Orchestra common stock is greater than or equal to $20.00 per share over any 20-Trading Days within any 30-Trading Day period. In addition, subject to the closing of the Orchestra Business Combination, the Sponsor has agreed to forfeit 50% of its Private Placement Warrants, comprising 750,000 Private Placement Warrants, for no consideration. Further, the Sponsor and the other Initial Shareholders prior to the Company’s initial public offering have agreed to subject the 4,000,000 shares of New Orchestra common stock to be received in the domestication in exchange for the 4,000,000 Insider Shares and 450,000 shares of New Orchestra common stock to be received in the domestication in exchange for the 450,000 Private Placement Shares, to a lock-up for up to 12 months.

See the proxy statement/prospectus included in the Registration Statement on Form S-4/A filed by the Company with the SEC on December 13, 2022 for additional information.

Extension, Redemptions and Private Purchase

Business Combination Meeting

XML 20 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2-Summary of Significant Accounting Policies

Basis of Presentation

Principles of Consolidation

Emerging Growth Company

Use of Estimates

Cash and Cash Equivalents

Concentration of Credit Risk

Cash and Investments Held in the Trust Account

Fair Value of Financial Instruments

Fair Value Measurements

●

Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;

●

Derivative Assets and Liabilities

Offering Costs Associated with Initial Public Offering

Ordinary Shares Subject to Possible Redemption

Net Loss Per Ordinary Share

Income Taxes

Recent Accounting Pronouncements

XML 21 R10.htm IDEA: XBRL DOCUMENT

Initial Public Offering

12 Months Ended

Dec. 31, 2022

Initial Public Offering [Abstract]

Initial Public Offering

Note 3-Initial Public Offering

XML 22 R11.htm IDEA: XBRL DOCUMENT

Private Placement

12 Months Ended

Dec. 31, 2022

Private Placement [Abstract]

Private Placement

Note 4-Private Placement

XML 23 R12.htm IDEA: XBRL DOCUMENT

Related Party Transactions

12 Months Ended

Dec. 31, 2022

Related Party Transactions

Note 5-Related Party Transactions

Insider Shares

Related Party Loans

Administrative Services Agreement

Purchase Agreements and Backstop Agreement

On October 21, 2022, the Backstop Agreement and the Forward Purchase Agreement with the RTW Funds were amended to provide that: (1) the per share purchase price under each of the Backstop Agreement and the Forward Purchase Agreement will not exceed the redemption price available to Public Shareholders exercising redemption rights at the shareholder meeting held to approve the Business Combination; (2) any shares purchased pursuant to the Backstop Agreement or the Forward Purchase Agreement, or otherwise acquired by the RTW Funds outside of the existing redemption offer, will not be voted in favor of approving the Business Combination; and (3) the RTW Funds will waive redemption rights with respect to such purchases in the vote to approve the Business Combination. The amendments have been filed with the SEC on a Current Report on Form 8-K on October 21, 2022. The Forward Purchase Agreement with Medtronic was not amended.

Company Shareholder Support Agreement and Forfeiture

XML 24 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

12 Months Ended

Dec. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 6-Commitments and Contingencies

Registration Rights

The holders of the Insider Shares, the Private Placement Shares, the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration rights agreement. The holders of a majority of these securities are entitled to make up to two demands that the Company registers such securities. The holders of the majority of the Insider Shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these ordinary shares are to be released from escrow. The holders of a majority of the Private Placement Shares, the Private Placement Warrants or warrants that may be issued upon conversion of Working Capital Loans made to the Company can elect to exercise these registration rights at any time after the Company consummates a Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s consummation of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

Risks and Uncertainties

Various social and political circumstances in the United States and around the world (including wars and other forms of conflict, including rising trade tensions between the United States and China, and other uncertainties regarding actual and potential shifts in the United States and foreign, trade, economic and other policies with other countries, terrorist acts, security operations and catastrophic events such as fires, floods, earthquakes, tornadoes, hurricanes and global health epidemics) may contribute to increased market volatility and economic uncertainties or deterioration in the United States and worldwide. Specifically, the rising conflict between Russia and Ukraine, and resulting market volatility could adversely affect the Company’s ability to complete a business combination. In response to the conflict between Russia and Ukraine, the United States and other countries have imposed sanctions or other restrictive actions against Russia. Any of the above factors, including sanctions, export controls, tariffs, trade wars and other governmental actions, could have a material adverse effect on the Company’s ability to complete a business combination and the value of the Company’s securities.

Management continues to evaluate the impact of these types of risks on the industry and has concluded that while it is reasonably possible that these types of risks could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Ordinary Shares Subject to Possible Redemption

12 Months Ended

Dec. 31, 2022

Ordinary Shares Subject to Possible Redemption [Abstract]

Ordinary Shares Subject to Possible Redemption

Note 7-Ordinary Shares Subject to Possible Redemption

The ordinary shares subject to possible redemption reflected on the consolidated balance sheets is reconciled on the following table:

Gross proceeds received from Initial Public Offering	$	160,000,000
Less:
Offering costs allocated to Public Shares		(9,418,420	)
Plus:
Accretion on ordinary shares to redemption value		9,418,420
Ordinary shares subject to possible redemption as of December 31, 2021		160,000,000
Redemption of Public Shares		(92,591,090	)
Increase in redemption value of ordinary shares subject to possible redemption		267,588
Ordinary shares subject to possible redemption as of December 31, 2022	$	67,676,498

XML 26 R15.htm IDEA: XBRL DOCUMENT

Shareholders’ Deficit

12 Months Ended

Dec. 31, 2022

Stockholders' Equity Note [Abstract]

Shareholders’ Deficit

Note 8-Shareholders’ Deficit

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 27 R16.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 9-Fair Value Measurements

The following table presents information about the Company’s financial assets that are measured at fair value on a recurring basis as of December 31, 2021 by level within the fair value hierarchy:

	Fair Value Measured as of December 31, 2021
	Level 1		Level 2		Level 3		Total
Investments held in Trust Account - U.S. Treasury Securities	$	160,022,447	$	-	$	-	$	160,022,447

Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for years ended December 31, 2022 and 2021.

As of December 31, 2022, only cash is held in the Trust Account.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 28 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events

12 Months Ended

Dec. 31, 2022

Subsequent Events [Abstract]

Subsequent Events

Note 10-Subsequent Events

XML 29 R18.htm IDEA: XBRL DOCUMENT

Accounting Policies, by Policy (Policies)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Principles of Consolidation

Principles of Consolidation

Emerging Growth Company

Emerging Growth Company

Use of Estimates

Use of Estimates

Cash and Cash Equivalents

Cash and Cash Equivalents

Concentration of Credit Risk

Concentration of Credit Risk

Cash and Investments Held in the Trust Account

Cash and Investments Held in the Trust Account

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Fair Value Measurements

Fair Value Measurements

●

Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;

●

Derivative Assets and Liabilities

Derivative Assets and Liabilities

Offering Costs Associated with Initial Public Offering

Offering Costs Associated with Initial Public Offering

Ordinary Shares Subject to Possible Redemption

Ordinary Shares Subject to Possible Redemption

Net Loss Per Ordinary Share

Net Loss Per Ordinary Share

Income Taxes

Income Taxes

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 30 R19.htm IDEA: XBRL DOCUMENT

Ordinary Shares Subject to Possible Redemption (Tables)

12 Months Ended

Dec. 31, 2022

Ordinary Shares Subject to Possible Redemption Table [Abstract]

Schedule of condensed consolidated balance sheets

Gross proceeds received from Initial Public Offering	$	160,000,000
Less:
Offering costs allocated to Public Shares		(9,418,420	)
Plus:
Accretion on ordinary shares to redemption value		9,418,420
Ordinary shares subject to possible redemption as of December 31, 2021		160,000,000
Redemption of Public Shares		(92,591,090	)
Increase in redemption value of ordinary shares subject to possible redemption		267,588
Ordinary shares subject to possible redemption as of December 31, 2022	$	67,676,498

XML 31 R20.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Schedule of financial assets that are measured at fair value on a recurring basis

	Fair Value Measured as of December 31, 2021
	Level 1		Level 2		Level 3		Total
Investments held in Trust Account - U.S. Treasury Securities	$	160,022,447	$	-	$	-	$	160,022,447

XML 32 R21.htm IDEA: XBRL DOCUMENT

Description of Organization, Business Operations and Going Concern (Details) - USD ($)			12 Months Ended
	Jul. 22, 2022	Aug. 06, 2020	Dec. 31, 2022	Jan. 24, 2023
Description of Organization, Business Operations and Going Concern (Details) [Line Items]
Price per share (in Dollars per share)			$ 10
Description of private placement warrant			Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (the “Private Placement”) with the Sponsor of (i) 450,000 ordinary shares (the “Private Placement Shares”), at a price of $10.00 per Private Placement Share (for a total purchase price of $4.5 million), and (ii) 1,500,000 warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant (for a total purchase price of $1.5 million), generating gross proceeds to the Company of $6.0 million (see Note 4).
Assets held in the trust account, percentage			80.00%
Public per share (in Dollars per share)			$ 10
Net tangible assets			$ 5,000,001
Aggregate shares, percentage			20.00%
Redeem shares, percentage			100.00%
Cash			$ 175,000
Working capital deficit			1,800,000
Purchase amount			$ 10,000,000
Shares per share (in Dollars per share)	$ 10.01		$ 10
Funds amount			$ 10,000,000
Proposed business combination			In addition, the Sponsor has agreed that 25% or 1,000,000 shares of its New Orchestra common stock received in the domestication will be forfeited to New Orchestra on the first business day following the fifth anniversary of the closing unless, as to 500,000 shares, the VWAP (as defined in the Merger Agreement) of the New Orchestra common stock is greater than or equal to $15.00 per share over any 20 Trading Days (as defined in the Merger Agreement) within any 30-Trading Day period, and as to the remaining 500,000 shares, the VWAP of the New Orchestra common stock is greater than or equal to $20.00 per share over any 20-Trading Days within any 30-Trading Day period. In addition, subject to the closing of the Orchestra Business Combination, the Sponsor has agreed to forfeit 50% of its Private Placement Warrants, comprising 750,000 Private Placement Warrants, for no consideration. Further, the Sponsor and the other Initial Shareholders prior to the Company’s initial public offering have agreed to subject the 4,000,000 shares of New Orchestra common stock to be received in the domestication in exchange for the 4,000,000 Insider Shares and 450,000 shares of New Orchestra common stock to be received in the domestication in exchange for the 450,000 Private Placement Shares, to a lock-up for up to 12 months.
Extension, redemptions and private purchase description.			In connection with the vote to approve the Extension Proposal, the holders of 9,237,883 Public Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.02 per share, for an aggregate redemption amount of approximately $92.6 million. As such, approximately 57.7% of the Public Shares were redeemed and approximately 42.3% of the Public Shares remain outstanding. After the satisfaction of such redemptions, the balance in the Company’s Trust Account was $67.8 million.
Ordinary Shares [Member]
Description of Organization, Business Operations and Going Concern (Details) [Line Items]
Ordinary shares total amount			$ 20,000,000
Shares per share (in Dollars per share)			$ 10
Sponsor [Member]
Description of Organization, Business Operations and Going Concern (Details) [Line Items]
Capital contribution			$ 28,750
Loan amount			$ 300,000
Initial Public Offering [Member]
Description of Organization, Business Operations and Going Concern (Details) [Line Items]
Issuance of initial public offering units (in Shares)		16,000,000
Issuance of public shares under over-allotment (in Shares)		2,086,956
Gross proceeds		$ 160,000,000
Offering cost		9,400,000
Deferred underwriting commission		$ 5,600,000
Private Placement [Member]
Description of Organization, Business Operations and Going Concern (Details) [Line Items]
Price per share (in Dollars per share)		$ 10	$ 10
Private placement amount			$ 160,000,000
Public Shareholders [Member]
Description of Organization, Business Operations and Going Concern (Details) [Line Items]
Price per unit (in Dollars per share)			$ 10
Subsequent Event [Member]
Description of Organization, Business Operations and Going Concern (Details) [Line Items]
Public shares for redemption (in Shares)				1,597,888
Subsequent Event [Member] \| Trust Account [Member]
Description of Organization, Business Operations and Going Concern (Details) [Line Items]
Public shares for redemption (in Shares)				1,597,888
RTW Funds [Member]
Description of Organization, Business Operations and Going Concern (Details) [Line Items]
Public shares purchased (in Shares)	1,000,000
Business Acquisitions [Member]
Description of Organization, Business Operations and Going Concern (Details) [Line Items]
Outstanding voting security percentage			50.00%
Minimum of closing business combination amount			$ 60,000,000
Business Acquisitions [Member] \| RTW Funds [Member]
Description of Organization, Business Operations and Going Concern (Details) [Line Items]
Share price share (in Dollars per share)	$ 10.01

XML 33 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Federal depository insurance coverage (in Dollars)	$ 250,000
Shares subject to possible redemption	6,762,117	16,000,000
Warrants to purchase ordinary shares	1,500,000

XML 34 R23.htm IDEA: XBRL DOCUMENT

Initial Public Offering (Details) $ / shares in Units, $ in Millions	Aug. 06, 2020 USD ($) $ / shares shares
Initial Public Offering (Details) [Line Items]
Gross proceeds	$ 160.0
Offering costs	9.4
Deferred underwriting commissions	$ 5.6
Initial Public Offering [Member]
Initial Public Offering (Details) [Line Items]
Shares issued (in Shares) \| shares	16,000,000
Price per share (in Dollars per share) \| $ / shares	$ 10
Over-Allotment Option [Member]
Initial Public Offering (Details) [Line Items]
Shares issued (in Shares) \| shares	2,086,956

XML 35 R24.htm IDEA: XBRL DOCUMENT

Private Placement (Details) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Private Placement (Details) [Line Items]
Generating gross proceeds \| $	$ 6.0
Private Placement [Member]
Private Placement (Details) [Line Items]
Purchase of warrants \| shares	450,000
Price per share \| $ / shares	$ 10
Total purchase price \| $	$ 4.5
Private Placement [Member] \| Warrant [Member]
Private Placement (Details) [Line Items]
Purchase of warrants \| shares	1,500,000
Price per share \| $ / shares	$ 1
Total purchase price \| $	$ 1.5
Exercise price per share \| $ / shares	$ 11.5

XML 36 R25.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) - USD ($)					12 Months Ended
Related Party Transactions (Details) - USD ($)	Aug. 07, 2020	Aug. 06, 2020	Aug. 03, 2020	Jun. 11, 2020	Dec. 31, 2022	Dec. 31, 2021	Jul. 22, 2022
Related Party Transactions (Details) [Line Items]
Related party, description					The Initial Shareholders agreed not to transfer, assign or sell any of their Insider Shares (except to certain permitted transferees) until, with respect to 50% of the Insider Shares, the earlier of six months after the date of the consummation of the initial Business Combination and the date on which the closing price of the Company’s ordinary shares equals or exceeds $12.50 per ordinary share for any 20 trading days within a 30-trading day period following the consummation of the initial Business Combination, and, with respect to the remaining 50% of the Insider Shares, six months after the date of the consummation of the initial Business Combination, or earlier in each case if, subsequent to the initial Business Combination, the Company completes a liquidation, merger, stock exchange or other similar transaction which results in all of the shareholders having the right to exchange their ordinary shares for cash, securities or other property.
Payments of loan costs				$ 300,000
Borrowed amount	$ 300,000
Warrants conversion, description					The notes would either be paid upon consummation of the initial Business Combination, without interest, or, at the lender’s discretion, up to $500,000 of such loans may be converted upon consummation of the Business Combination into additional private warrants at a price of $1.00 per warrant.
Incurred expenses					$ 120,000	$ 120,000
Accrued expenses related party outstanding					0	$ 150,000
Aggregate purchase to ordinary shares (in Shares)			2,500,000
Price per share (in Dollars per share)			$ 10
Aggregate to purchase price			$ 25,000,000
Investment amount			$ 15,000,000
Purchasing Parties agreed					10,000,000
Ordinary shares purchased					$ 20,000,000
Ordinary shares price per share (in Dollars per share)					$ 10		$ 10.01
Business combination amount					$ 60,000,000
Purchase agreement amount					$ 10,000,000
Funds purchased							$ 1,000,000
Shareholder support agreement and forfeiture, description					In addition, the Sponsor has agreed that 25% or 1,000,000 shares of its New Orchestra common stock received in the domestication will be forfeited to New Orchestra on the first business day following the fifth anniversary of the closing of the Orchestra Business Combination unless, as to 500,000 shares, the VWAP (as defined in the Merger Agreement) of the New Orchestra common stock is greater than or equal to $15.00 per share over any 20 Trading Days (as defined in the Merger Agreement) within any 30-Trading Day period, and as to the remaining 500,000 shares, the VWAP of the New Orchestra common stock is greater than or equal to $20.00 per share over any 20-Trading Days within any 30-Trading Day period. Further, subject to the closing of the Orchestra Business Combination, the Sponsor has agreed to forfeit 50% of its warrants, comprising 750,000 warrants for no consideration.
Ordinary share [Member]
Related Party Transactions (Details) [Line Items]
Dividend per share value (in Dollars per share)			$ 0.113043478
Shares outstanding (in Shares)			406,250
Ordinary shares, shares outstanding (in Shares)			4,000,000
Ordinary shares price per share (in Dollars per share)					$ 10
Sponsor [Member]
Related Party Transactions (Details) [Line Items]
Ordinary shares, shares issued (in Shares)				3,593,750
Aggregate price				$ 28,750
Sponsor forfeit shares (in Shares)					521,739
Administrative expenses					$ 10,000
Insider Shares [Member]
Related Party Transactions (Details) [Line Items]
Subject to forfeiture, shares (in Shares)		521,739

XML 37 R26.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares
Commitments and Contingencies (Details) [Line Items]
Underwriting agreement, description	The Company granted the underwriters a 45-day option from the effective date of the registration statement relating to the Initial Public Offering to purchase up to 2,086,956 additional ordinary shares at the Initial Public Offering price less the underwriting discounts and commissions.
Underwriting discount per share \| $ / shares	$ 0.2
Deferred underwriting commission per public share \| $ / shares	$ 0.35
Initial Public Offering [Member]
Commitments and Contingencies (Details) [Line Items]
Underwriting commission \| $	$ 3.2
Deferred underwriting commission \| $	$ 5.6

XML 38 R27.htm IDEA: XBRL DOCUMENT

Ordinary Shares Subject to Possible Redemption (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Ordinary Shares Subject To Possible Redemption Disclosure Abstract
Ordinary shares, shares authorized	100,000,000	100,000,000
Ordinary shares, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Voting rights	Holders of the Company’s ordinary shares are entitled to one vote for each share.
Ordinary shares outstanding	11,212,117	20,450,000
Shares subject to possible redemption	6,762,117	16,000,000

XML 39 R28.htm IDEA: XBRL DOCUMENT

Ordinary Shares Subject to Possible Redemption (Details) - Schedule of condensed consolidated balance sheets - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Condensed Consolidated Balance Sheets Abstract
Gross proceeds received from Initial Public Offering		$ 160,000,000
Less:
Offering costs allocated to Public Shares		(9,418,420)
Plus:
Accretion on ordinary shares to redemption value		9,418,420
Ordinary shares subject to possible redemption	$ 67,676,498	$ 160,000,000
Redemption of Public Shares	(92,591,090)
Increase in redemption value of ordinary shares subject to possible redemption	$ 267,588

XML 40 R29.htm IDEA: XBRL DOCUMENT

Shareholders’ Deficit (Details) - $ / shares	12 Months Ended
Shareholders’ Deficit (Details) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Shareholders’ Deficit (Details) [Line Items]
Preference shares, shares outsatanding	1,000,000	1,000,000
PreferredStockSharesOutstanding
Ordinary shares vote, description	Holders of the Company’s ordinary shares are entitled to one vote for each share.
Ordinary shares, shares outstanding	11,212,117	20,450,000
Purchase of ordinary shares	1
Warrant exercisable (in Dollars per share)	$ 11.5
Warrants expire, term	5 years
Preference Shares [Member]
Shareholders’ Deficit (Details) [Line Items]
Preference shares, shares outsatanding	1,000,000
Preference shares par value (in Dollars per share)	$ 0.0001
Ordinary Shares [Member]
Shareholders’ Deficit (Details) [Line Items]
PreferredStockSharesOutstanding
Ordinary shares par value (in Dollars per share)		$ 0.0001
Ordinary shares vote, description	Holders of the Company’s ordinary shares are entitled to one vote for each share.
Ordinary shares, shares issued	11,212,117
Ordinary shares, shares outstanding		20,450,000
Ordinary shares subject to possible redemption	6,762,117	16,000,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - Schedule of financial assets that are measured at fair value on a recurring basis	Dec. 31, 2021 USD ($)
Fair Value Measurements (Details) - Schedule of financial assets that are measured at fair value on a recurring basis [Line Items]
Investments held in Trust Account - money market funds	$ 160,022,447
Level 1 [Member]
Fair Value Measurements (Details) - Schedule of financial assets that are measured at fair value on a recurring basis [Line Items]
Investments held in Trust Account - money market funds	160,022,447
Level 2 [Member]
Fair Value Measurements (Details) - Schedule of financial assets that are measured at fair value on a recurring basis [Line Items]
Investments held in Trust Account - money market funds
Level 3 [Member]
Fair Value Measurements (Details) - Schedule of financial assets that are measured at fair value on a recurring basis [Line Items]
Investments held in Trust Account - money market funds

XML 42 R31.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - Subsequent Event [Member]	Jan. 24, 2023 $ / shares shares
Subsequent Events (Details) [Line Items]
Public shares for redemption \| shares	1,597,888
Redemption price \| $ / shares	$ 10.02

XML 43 f10k2022_healthsciences2_htm.xml IDEA: XBRL DOCUMENT 0001814114 2022-01-01 2022-12-31 0001814114 2022-06-30 0001814114 2023-01-23 0001814114 2022-12-31 0001814114 2021-12-31 0001814114 2021-01-01 2021-12-31 0001814114 us-gaap:CommonStockMember 2020-12-31 0001814114 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001814114 us-gaap:RetainedEarningsMember 2020-12-31 0001814114 2020-12-31 0001814114 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001814114 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001814114 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001814114 us-gaap:CommonStockMember 2021-12-31 0001814114 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001814114 us-gaap:RetainedEarningsMember 2021-12-31 0001814114 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001814114 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001814114 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001814114 us-gaap:CommonStockMember 2022-12-31 0001814114 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001814114 us-gaap:RetainedEarningsMember 2022-12-31 0001814114 us-gaap:IPOMember 2020-08-06 0001814114 us-gaap:IPOMember 2020-08-01 2020-08-06 0001814114 us-gaap:PrivatePlacementMember 2020-08-06 0001814114 us-gaap:PrivatePlacementMember 2022-01-01 2022-12-31 0001814114 us-gaap:PrivatePlacementMember 2022-12-31 0001814114 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2022-12-31 0001814114 hsaq:PublicStockholdersMember 2022-12-31 0001814114 hsaq:SponsorMember 2022-01-01 2022-12-31 0001814114 hsaq:SponsorMember 2022-12-31 0001814114 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2022-01-01 2022-12-31 0001814114 hsaq:RTWFundsMember 2022-07-22 2022-07-22 0001814114 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember hsaq:RTWFundsMember 2022-07-22 0001814114 us-gaap:SubsequentEventMember hsaq:TrustAccountMember 2023-01-24 0001814114 us-gaap:OverAllotmentOptionMember 2020-08-06 0001814114 2020-08-01 2020-08-06 0001814114 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2022-01-01 2022-12-31 0001814114 us-gaap:WarrantMember us-gaap:PrivatePlacementMember 2022-12-31 0001814114 hsaq:SponsorMember 2020-06-02 2020-06-11 0001814114 us-gaap:CommonStockMember 2020-08-03 0001814114 hsaq:InsiderSharesMember 2020-08-01 2020-08-06 0001814114 2020-06-02 2020-06-11 0001814114 2020-08-01 2020-08-07 0001814114 2020-08-01 2020-08-03 0001814114 2022-07-22 0001814114 us-gaap:IPOMember 2022-01-01 2022-12-31 0001814114 us-gaap:IPOMember 2022-12-31 0001814114 us-gaap:PreferredStockMember 2022-12-31 0001814114 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001814114 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001814114 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001814114 us-gaap:SubsequentEventMember 2023-01-24 iso4217:USD shares iso4217:USD shares pure 10-K true 2022-12-31 --12-31 2022 false 001-39421 HEALTH SCIENCES ACQUISITIONS CORPORATION 2 E9 40 10th Avenue Floor 7 New York NY 10014 (646) 597-6980 Ordinary Shares, par value $0.0001 per share HSAQ NASDAQ No No Yes Yes Non-accelerated Filer true true false false true 159400000 11212117 WithumSmith+Brown, PC New York 100

175161

1754460

123918

46667

299079

1801127

67776498

160022447

68075577

161823574

376930

1388

1366825

14151

150000

1743755

165539

5600000 5600000

7343755

5765539

0.0001

6762117

16000000

10.01

67676498

160000000

0.0001

1000000

0.0001

100000000

4450000

445

-6945121

-3942410

-6944676

-3941965

68075577

161823574

2960264

274756

120000

-3080264

-394756

345141

16003

-2735123

-378753

16425826

20450000

-0.17

-0.02

4450000

445

-3563657

-3563212

-378753

4450000

445

-3942410

-3941965

267588

-2735123

4450000

445

-6945121

-6944676

-2735123

-378753

345141

16003

77251

-75811

375542

-12422

1352674

-60995

-150000

120000

-1579299

-272362

92591090

-92591090

-1579299

-272362

1754460

2026822

175161

1754460

Note 1-Description of Organization, Business Operations and Going Concern Organization and General Health Sciences Acquisitions Corporation 2 (the “Company”) was incorporated on May 25, 2020 as a Cayman Islands exempted company for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities (“Business Combination”). Although the Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination, the Company intends to pursue prospective targets that are focused on healthcare innovation. The Company has neither engaged in any operations nor generated any operating revenue to date. The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). As of December 31, 2022, the Company had not commenced any operations. All activity for the period from May 25, 2020 (inception) through December 31, 2022 was related to the Company’s formation and its Initial Public Offering (as defined below), and, since the Initial Public Offering, the search for a prospective initial Business Combination. The Company will not generate any operating revenue until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income from its investments held in the Trust Account (as defined below). Sponsor and Financing The Company’s sponsor is HSAC 2 Holdings, LLC (the “Sponsor”). The registration statement for the Company’s initial public offering (the “Initial Public Offering”) was declared effective on August 3, 2020. On August 6, 2020, the Company consummated its Initial Public Offering of 16,000,000 ordinary shares (the “Public Shares”), including the issuance of 2,086,956 Public Shares as a result of the underwriters’ full exercise of their over-allotment option, at an offering price of $10.00 per Public Share, generating gross proceeds of $160.0 million, and incurring offering costs of approximately $9.4 million, inclusive of $5.6 million in deferred underwriting commissions (see Note 6). Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (the “Private Placement”) with the Sponsor of (i) 450,000 ordinary shares (the “Private Placement Shares”), at a price of $10.00 per Private Placement Share (for a total purchase price of $4.5 million), and (ii) 1,500,000 warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant (for a total purchase price of $1.5 million), generating gross proceeds to the Company of $6.0 million (see Note 4). Trust Account Upon the closing of the Initial Public Offering and the Private Placement (including the exercise of the over-allotment option), $160.0 million (or $10.00 per Public Share) of the net proceeds of the Initial Public Offering and the Private Placement was placed in a U.S. based trust account (the “Trust Account”), maintained by Continental Stock Transfer & Trust Company, acting as trustee, and invested in U.S. “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under the Investment Company Act, which invest only in direct U.S. government treasury obligations, until the earlier of (i) the completion of a Business Combination and (ii) the distribution of the Trust Account as described below. On July 25, 2022, the entire Trust Account balance was transferred into cash in connection with the redemptions as described below. Initial Business Combination The Company’s management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering and the Private Placement, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. Furthermore, there is no assurance that the Company will be able to successfully complete a Business Combination. Pursuant to stock exchange listing rules, the Company’s initial Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the net assets held in the Trust Account (excluding the amount of any deferred underwriting discount held in trust and taxes payable on the income earned on the Trust Account) at the time the Company signs a definitive agreement in connection with the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. The Company will provide holders of the Public Shares (“Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to be distributed to Public Shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). As a result, such ordinary shares have been recorded at redemption amount and classified as temporary equity, in accordance with the Financial Accounting Standard Board (“FASB”), Accounting Standard Codification (“ASC”) 480, “Distinguishing Liabilities from Equity.” The amount in the Trust Account is initially anticipated to be $10.00 per Public Share. In such case, the Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the ordinary shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (the “SEC”), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, a shareholder approval of the transactions is required by law, or the Company decides to obtain shareholder approval for business or legal reasons, the Company will offer to redeem ordinary shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Shareholder may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks shareholder approval in connection with a Business Combination, the holders of the Insider Shares (as defined in Note 5) prior to the Initial Public Offering (the “Initial Shareholders”) have agreed to vote their Insider Shares and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination, to the extent permitted by law. In addition, the Initial Shareholders have agreed to waive their redemption rights with respect to their Insider Shares, Private Placement Shares, and Public Shares in connection with the completion of a Business Combination. Notwithstanding the foregoing, the Company’s Amended and Restated Memorandum and Articles of Association provides that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its ordinary shares with respect to more than 20% the ordinary shares sold in the Initial Public Offering, without the prior consent of the Company. The Company’s Sponsor, executive officers, directors and director nominees have agreed not to propose an amendment to the Company’s Amended and Restated Memorandum and Articles of Association that would affect the substance or timing of the Company’s obligation to provide for the redemption of its Public Shares in connection with a Business Combination or to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the Public Shareholders with the opportunity to redeem their ordinary shares in conjunction with any such amendment. If a Business Combination has not been consummated by February 6, 2023 (taking into account the extension as described under “Extension, Redemptions and Private Purchase” section below, the “Combination Period”), or such later time as the Company’s shareholders may approve in accordance with the Amended and Restated Memorandum and Articles of Association, it will trigger the Company’s automatic winding up, liquidation and dissolution. If the Company does not consummate a Business Combination within the Combination Period, upon notice from the Company, the trustee of the Trust Account will distribute the amount in the Trust Account to the Public Shareholders. Concurrently, the Company shall pay, or reserve for payment, from funds not held in the Trust Account, its liabilities and obligations, although the Company cannot assure that there will be sufficient funds for such purpose. If there are insufficient funds held outside the Trust Account for such purpose, the Sponsor has agreed that it will be liable to ensure that the proceeds in the Trust Account are not reduced by the claims of target businesses or claims of vendors or other entities that are owed money by the Company for services rendered or contracted for or products sold to the Company and which have not executed a waiver agreement. However, the Company cannot assure that the liquidator will not determine that he or she requires additional time to evaluate creditors’ claims (particularly if there is uncertainty over the validity or extent of the claims of any creditors). The Company also cannot assure that a creditor or shareholder will not file a petition with the Cayman Islands Court which, if successful, may result in the Company’s liquidation being subject to the supervision of that court. Such events might delay distribution of some or all of the Company’s assets to the Public Shareholders. The Initial Shareholders have agreed to waive their liquidation rights with respect to the Insider Shares and the Private Placement Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Shareholders should acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commissions held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Company’s Public Shares. In the event of such distribution, it is possible that the per ordinary share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00 per ordinary share initially held in the Trust Account. Liquidity and Going Concern As of December 31, 2022, the Company had approximately $175,000 of cash in its operating account and a working capital deficit of approximately $1.8 million. Prior to the completion of the Initial Public Offering, the Company’s liquidity needs had been satisfied through the capital contribution of $28,750 from the Sponsor to purchase the Insider Shares, and a loan of $300,000 pursuant to the Note (as defined in Note 5) issued to the Sponsor, which was repaid in full on August 7, 2020. Subsequent to the consummation of the Initial Public Offering and the Private Placement, the Company’s liquidity needs have been satisfied with the net proceeds from the Private Placement not held in the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Initial Shareholders or their affiliates may, but are not obligated to, provide the Company with Working Capital Loans (see Note 5). As of December 31, 2022 and 2021, there were no Working Capital Loans available or outstanding. In connection with the Company’s assessment of going concern considerations in accordance with FASB Accounting Standards Update (“ASU”) 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the working capital deficit, as well as the mandatory liquidation and subsequent dissolution, raises substantial doubt about the Company’s ability to continue as a going concern. Management intends to complete a business combination prior to the mandatory liquidation date. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after February 6, 2023. The consolidated financial statements do not include any adjustment that might be necessary if the Company’s is unable to continue as a going concern. Proposed Business Combination On July 4, 2022, the Company entered into an agreement and plan of merger agreement (as amended on July 21, 2022, the “Merger Agreement”) with HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), and Orchestra BioMed, Inc., a Delaware corporation (“Orchestra”). Pursuant to the terms of the Merger Agreement, a business combination between the Company and Orchestra (the “Orchestra Business Combination”) will be effected in two steps. First, before the closing of the Orchestra Business Combination, the Company will deregister in the Cayman Islands and domesticate as a Delaware corporation. Second, at the closing of the Orchestra Business Combination, Merger Sub will merge with and into Orchestra, with Orchestra surviving such merger as the surviving entity (the “Merger”). Upon consummation of the Orchestra Business Combination, Orchestra will become a wholly owned subsidiary of the Company. The Company will then change its name to “Orchestra BioMed Holdings, Inc.”. The Company, after giving effect to the Orchestra Business Combination, will be referred to as “New Orchestra”. The Merger Agreement contains customary representations, warranties and covenants of the parties thereto. The consummation of the proposed Merger is subject to certain conditions as further described in the Merger Agreement. Simultaneously with the execution of the Merger Agreement, the Company and Orchestra entered into separate forward purchase agreements (the “Forward Purchase Agreements”) with certain funds managed by RTW Investments, LP (the “RTW Funds”) and Covidien Group S.à.r.l., an affiliate of Medtronic plc (“Medtronic” and the RTW Funds, each a “Purchasing Party”), pursuant to which each of the Purchasing Parties agreed to purchase approximately $10.0 million of the Company’s ordinary shares, for a total of approximately $20.0 million, less the dollar amount of the Company’s ordinary shares holding redemption rights that the Purchasing Party acquires and holds until immediately prior to the domestication. Simultaneously with the execution of the Merger Agreement and the Forward Purchase Agreements, the Company, Orchestra, and the RTW Funds entered into a Backstop Agreement (the “Backstop Agreement”) pursuant to which the RTW Funds, jointly and severally, agreed to purchase such number of the Company’s ordinary shares at a price of $10.00 per share to the extent that the amount of Parent Closing Cash (as defined in the Merger Agreement) as of immediately prior to the closing of the Orchestra Business Combination is less than $60.0 million (inclusive of the $10.0 million commitment by the RTW Funds pursuant to the Forward Purchase Agreement described above). On October 21, 2022, the Backstop Agreement and the Forward Purchase Agreement with the RTW Funds were amended to provide that (1) the per share purchase price under each of the Backstop Agreement and the Forward Purchase Agreement will not exceed the redemption price available to Public Shareholders exercising redemption rights at the shareholder meeting held to approve the Business Combination; (2) any shares purchased pursuant to the Backstop Agreement or the Forward Purchase Agreement, or otherwise acquired by the RTW Funds outside of the existing redemption offer, will not be voted in favor of approving the Business Combination; and (3) the RTW Funds will waive redemption rights with respect to such purchases in the vote to approve the Business Combination. The amendments have been filed with the SEC on a Current Report on Form 8-K on October 21, 2022. The Forward Purchase Agreement with Medtronic was not amended. The closing under the Forward Purchase Agreement with the RTW Funds occurred on July 22, 2022, pursuant to which the RTW Funds purchased 1,000,000 of the Company’s ordinary shares at a price of $10.01 per share from an accredited investor in a privately negotiated transaction (see Note 5). The closing under the Forward Purchase Agreement with Medtronic and the closing under the Backstop Agreement, if any, will occur immediately prior to the domestication. The Company’s Sponsor, and the Purchasing Parties will have registration rights pursuant to the Amended and Restated Registration Rights and Lock-Up Agreement with respect to the Company’s ordinary shares, received in the domestication. In addition, the Sponsor has agreed that 25% or 1,000,000 shares of its New Orchestra common stock received in the domestication will be forfeited to New Orchestra on the first business day following the fifth anniversary of the closing unless, as to 500,000 shares, the VWAP (as defined in the Merger Agreement) of the New Orchestra common stock is greater than or equal to $15.00 per share over any 20 Trading Days (as defined in the Merger Agreement) within any 30-Trading Day period, and as to the remaining 500,000 shares, the VWAP of the New Orchestra common stock is greater than or equal to $20.00 per share over any 20-Trading Days within any 30-Trading Day period. In addition, subject to the closing of the Orchestra Business Combination, the Sponsor has agreed to forfeit 50% of its Private Placement Warrants, comprising 750,000 Private Placement Warrants, for no consideration. Further, the Sponsor and the other Initial Shareholders prior to the Company’s initial public offering have agreed to subject the 4,000,000 shares of New Orchestra common stock to be received in the domestication in exchange for the 4,000,000 Insider Shares and 450,000 shares of New Orchestra common stock to be received in the domestication in exchange for the 450,000 Private Placement Shares, to a lock-up for up to 12 months. See the proxy statement/prospectus included in the Registration Statement on Form S-4/A filed by the Company with the SEC on December 13, 2022 for additional information. Extension, Redemptions and Private Purchase On July 26, 2022, the Company held an extraordinary general meeting of its shareholders, where the shareholders approved a special resolution (the “Extension Proposal”) to amend the Company’s amended and restated memorandum and articles of association to (i) extend from August 6, 2022 (the “Original Termination Date”) to November 6, 2022 (the “Extended Date”), the date by which, if the Company has not consummated a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination involving one or more businesses or entities, the Company must liquidate and dissolve, and (ii) allow the Company, without another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to three times by an additional one month each time after the Extended Date, upon five days’ advance notice prior to the applicable deadlines, until February 6, 2023 or a total of up to six months after the Original Termination Date, unless the closing of the Company’s initial business combination shall have occurred. On October 31, 2022, November 15, 2022, and December 15, 2022, the directors of the Company elected to extend the deadline until December 6, 2022, January 6, 2023, and February 6, 2023, respectively. In connection with the vote to approve the Extension Proposal, the holders of 9,237,883 Public Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.02 per share, for an aggregate redemption amount of approximately $92.6 million. As such, approximately 57.7% of the Public Shares were redeemed and approximately 42.3% of the Public Shares remain outstanding. After the satisfaction of such redemptions, the balance in the Company’s Trust Account was $67.8 million. On July 22, 2022, the RTW Funds purchased 1,000,000 of the Company’s ordinary shares at a price of $10.01 per share from an accredited investor in a privately negotiated transaction, in order to fulfill their obligations under the Forward Purchase Agreements and to ensure that such shares purchased were not redeemed and the amounts that would have been paid by the Company if such shares were redeemed remain in the Company’s trust account at the closing of the Orchestra Business Combination. See the preliminary proxy statement/prospectus included in the Registration Statement on Form S-4 filed by the Company with the SEC on August 8, 2022, and any amendments thereto and the final proxy statement/prospectus that the Company may subsequently file with the SEC, for additional information. Business Combination Meeting On January 24, 2023, the Company held an extraordinary general meeting of shareholders (the “General Meeting”) for the purpose of considering and voting upon, among other things, the Orchestra Business Combination. Each of the proposals presented at the General Meeting, as more fully described in the proxy statement/prospectus filed by the Company with the SEC on December 16, 2022, was approved. The submission of the Orchestra Business Combination to the shareholders entitled holders of Public Shares to redeem their shares for their pro rata portion of the funds held in the Trust Account. In connection with the General Meeting, as of January 24, 2023, we received requests for redemption from holders with respect to 1,597,888 Public Shares.

16000000

2086956

160000000

9400000

5600000 Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (the “Private Placement”) with the Sponsor of (i) 450,000 ordinary shares (the “Private Placement Shares”), at a price of $10.00 per Private Placement Share (for a total purchase price of $4.5 million), and (ii) 1,500,000 warrants (the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant (for a total purchase price of $1.5 million), generating gross proceeds to the Company of $6.0 million (see Note 4). 160000000

0.80

0.50

10 10

5000001

0.20 1

175000

1800000 28750 300000

10000000

20000000

60000000

10000000

1000000

10.01

In addition, the Sponsor has agreed that 25% or 1,000,000 shares of its New Orchestra common stock received in the domestication will be forfeited to New Orchestra on the first business day following the fifth anniversary of the closing unless, as to 500,000 shares, the VWAP (as defined in the Merger Agreement) of the New Orchestra common stock is greater than or equal to $15.00 per share over any 20 Trading Days (as defined in the Merger Agreement) within any 30-Trading Day period, and as to the remaining 500,000 shares, the VWAP of the New Orchestra common stock is greater than or equal to $20.00 per share over any 20-Trading Days within any 30-Trading Day period. In addition, subject to the closing of the Orchestra Business Combination, the Sponsor has agreed to forfeit 50% of its Private Placement Warrants, comprising 750,000 Private Placement Warrants, for no consideration. Further, the Sponsor and the other Initial Shareholders prior to the Company’s initial public offering have agreed to subject the 4,000,000 shares of New Orchestra common stock to be received in the domestication in exchange for the 4,000,000 Insider Shares and 450,000 shares of New Orchestra common stock to be received in the domestication in exchange for the 450,000 Private Placement Shares, to a lock-up for up to 12 months. In connection with the vote to approve the Extension Proposal, the holders of 9,237,883 Public Shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.02 per share, for an aggregate redemption amount of approximately $92.6 million. As such, approximately 57.7% of the Public Shares were redeemed and approximately 42.3% of the Public Shares remain outstanding. After the satisfaction of such redemptions, the balance in the Company’s Trust Account was $67.8 million.

1597888

Note 2-Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Principles of Consolidation The consolidated financial statements of the Company include its wholly owned subsidiary in connection with the planned merger. All inter-company accounts and transactions are eliminated in consolidation. Emerging Growth Company As an emerging growth company, the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s consolidated financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period, difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents as of December 31, 2022 and 2021. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times, may exceed the federal depository insurance coverage of $250,000, and investments held in Trust Account. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Cash and Investments Held in the Trust Account The Company’s portfolio of investments held in the Trust Account has been comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments were classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments were recognized at fair value. Trading securities and investments in money market funds are presented on the consolidated balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in interest income from investments held in Trust Account in the accompanying consolidated statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. On July 25, 2022, the entire Trust Account balance was transferred into cash following redemptions in connection with the vote to approve the Extension Proposal. As of December 31, 2022, only cash is held in the Trust Account. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC Topic 820, “Fair Value Measurements,” equals or approximates the carrying amounts represented in the consolidated balance sheets, primarily due to their short-term nature. Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers consist of: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in">●</td> <td style="text-align: justify">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in">●</td> <td style="text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in">●</td> <td style="text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</td></tr> </table> In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Derivative Assets and Liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Offering Costs Associated with Initial Public Offering The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin Topic 5A - “Expenses of Offering.” Offering costs consist of costs incurred in connection with the formation and preparation for the Initial Public Offering. These costs, together with the underwriting discount, were charged to the carrying value of the Public Shares upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. Ordinary Shares Subject to Possible Redemption The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480, “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Public Shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, as of December 31, 2022 and 2021, 6,762,117 and 16,000,000 ordinary shares subject to possible redemption at the redemption amount, respectively, were presented at redemption value as temporary equity, outside of the shareholders’ deficit section of the Company’s consolidated balance sheets. Under ASC 480-10-S99, the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Effective with the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit. Net Loss Per Ordinary Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net loss per ordinary share is calculated by dividing the net loss by the weighted average number of ordinary shares outstanding for the respective period. The calculation of diluted net loss per ordinary share does not consider the effect of the Private Placement Warrants to purchase 1,500,000 ordinary shares since their exercise is contingent upon future events and their inclusion would be anti-dilutive under the treasury stock method. As a result, diluted net loss per share is the same as basic net loss per share for years ended December 31, 2022 and 2021. Accretion associated with the redeemable ordinary shares is excluded from earnings per share as the redemption value approximates fair value. Income Taxes ASC Topic 740, “Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman Islands federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s consolidated financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have an effect on the Company’s consolidated financial statements.

Basis of Presentation The accompanying consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC.

Principles of Consolidation The consolidated financial statements of the Company include its wholly owned subsidiary in connection with the planned merger. All inter-company accounts and transactions are eliminated in consolidation.

Emerging Growth Company As an emerging growth company, the Company may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Further, section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s consolidated financial statements with another public company, which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period, difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates.

Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents as of December 31, 2022 and 2021.

Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash accounts in a financial institution which, at times, may exceed the federal depository insurance coverage of $250,000, and investments held in Trust Account. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

250000

Cash and Investments Held in the Trust Account The Company’s portfolio of investments held in the Trust Account has been comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments were classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments were recognized at fair value. Trading securities and investments in money market funds are presented on the consolidated balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities are included in interest income from investments held in Trust Account in the accompanying consolidated statements of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. On July 25, 2022, the entire Trust Account balance was transferred into cash following redemptions in connection with the vote to approve the Extension Proposal. As of December 31, 2022, only cash is held in the Trust Account.

Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under the FASB ASC Topic 820, “Fair Value Measurements,” equals or approximates the carrying amounts represented in the consolidated balance sheets, primarily due to their short-term nature.

Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers consist of: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in">●</td> <td style="text-align: justify">Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in">●</td> <td style="text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in">●</td> <td style="text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</td></tr> </table> In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

Derivative Assets and Liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and FASB ASC Topic 815, “Derivatives and Hedging” (“ASC 815”). The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.

Offering Costs Associated with Initial Public Offering The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin Topic 5A - “Expenses of Offering.” Offering costs consist of costs incurred in connection with the formation and preparation for the Initial Public Offering. These costs, together with the underwriting discount, were charged to the carrying value of the Public Shares upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as non-current liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities.

Ordinary Shares Subject to Possible Redemption The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480, “Distinguishing Liabilities from Equity.” Ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s Public Shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, as of December 31, 2022 and 2021, 6,762,117 and 16,000,000 ordinary shares subject to possible redemption at the redemption amount, respectively, were presented at redemption value as temporary equity, outside of the shareholders’ deficit section of the Company’s consolidated balance sheets. Under ASC 480-10-S99, the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of the security to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Effective with the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional paid-in capital (to the extent available) and accumulated deficit.

6762117 16000000

Net Loss Per Ordinary Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net loss per ordinary share is calculated by dividing the net loss by the weighted average number of ordinary shares outstanding for the respective period. The calculation of diluted net loss per ordinary share does not consider the effect of the Private Placement Warrants to purchase 1,500,000 ordinary shares since their exercise is contingent upon future events and their inclusion would be anti-dilutive under the treasury stock method. As a result, diluted net loss per share is the same as basic net loss per share for years ended December 31, 2022 and 2021. Accretion associated with the redeemable ordinary shares is excluded from earnings per share as the redemption value approximates fair value.

1500000

Income Taxes ASC Topic 740, “Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman Islands federal income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s consolidated financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have an effect on the Company’s consolidated financial statements.

Note 3-Initial Public Offering On August 6, 2020, the Company consummated its Initial Public Offering of 16,000,000 Public Shares, including the 2,086,956 Public Shares as a result of the underwriters’ full exercise of their over-allotment option, at an offering price of $10.00 per Public Share, generating gross proceeds of $160.0 million, and incurring offering costs of approximately $9.4 million, inclusive of $5.6 million in deferred underwriting commissions.

16000000

2086956

160000000

9400000

5600000 Note 4-Private Placement Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement with the Sponsor of (i) 450,000 Private Placement Shares at $10.00 per Private Placement Share (for a total purchase price of $4.5 million) and (ii) 1,500,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant (for a total purchase price of $1.5 million), generating gross proceeds to the Company of $6.0 million. Each Private Placement Warrant entitles the holder thereof to purchase one ordinary share at an exercise price of $11.50 per ordinary share. A portion of the proceeds from the Private Placement was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will be non-redeemable and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees.

450000

4500000

1500000

6000000

11.5

Note 5-Related Party Transactions Insider Shares On June 11, 2020, the Company issued 3,593,750 ordinary shares to the Sponsor (the “Insider Shares”) for an aggregate purchase price of $28,750. On August 3, 2020, the Company effected a share dividend of 0.113043478 ordinary shares for each outstanding ordinary share (an aggregate of 406,250 ordinary shares), resulting in an aggregate of 4,000,000 ordinary shares outstanding. All shares and associated amounts have been retroactively restated to reflect the share dividend. The holders of the Insider Shares had agreed to forfeit up to an aggregate of 521,739 Insider Shares, on a pro rata basis, to the extent that the option to purchase additional ordinary shares is not exercised in full by the underwriters. On August 6, 2020, the underwriters fully exercised the over-allotment option; thus, the 521,739 Insider Shares were no longer subject to forfeiture. The Initial Shareholders agreed not to transfer, assign or sell any of their Insider Shares (except to certain permitted transferees) until, with respect to 50% of the Insider Shares, the earlier of six months after the date of the consummation of the initial Business Combination and the date on which the closing price of the Company’s ordinary shares equals or exceeds $12.50 per ordinary share for any 20 trading days within a 30-trading day period following the consummation of the initial Business Combination, and, with respect to the remaining 50% of the Insider Shares, six months after the date of the consummation of the initial Business Combination, or earlier in each case if, subsequent to the initial Business Combination, the Company completes a liquidation, merger, stock exchange or other similar transaction which results in all of the shareholders having the right to exchange their ordinary shares for cash, securities or other property. Related Party Loans On June 11, 2020, the Sponsor agreed to loan the Company up to $300,000 to be used for the payment of costs related to the Initial Public Offering pursuant to a promissory note (the “Note”). The Note was non-interest bearing, unsecured and due on the date the Company consummates the Initial Public Offering or the date on which the Company determines not to conduct the Initial Public Offering. The Company borrowed $300,000 under the Note and repaid the Note in full on August 7, 2020. Subsequent to the repayment, the facility was no longer available to the Company. In addition, in order to finance transaction costs in connection with a Business Combination, the Initial Shareholders or their affiliates may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion (the “Working Capital Loans”). Each loan would be evidenced by a promissory note. The notes would either be paid upon consummation of the initial Business Combination, without interest, or, at the lender’s discretion, up to $500,000 of such loans may be converted upon consummation of the Business Combination into additional private warrants at a price of $1.00 per warrant. If the Company does not complete a Business Combination within the Combination Period, the Working Capital Loans will be repaid only from amounts remaining outside the Trust Account, if any. The warrants would be identical to the Private Placement Warrants. As of December 31, 2022 and 2021, the Company had no outstanding Working Capital Loans. Administrative Services Agreement Commencing on the date of the Company’s prospectus, the Company agreed to pay the Sponsor a total of $10,000 per month for office space and certain office and secretarial services. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. For the years ended December 31, 2022 and 2021, the Company incurred $120,000 in expenses for these services. As of December 31, 2022 and 2021, $0 and $150,000 were due to the Sponsor and are included in accrued expenses - related party on the accompanying consolidated balance sheets, respectively. Purchase Agreements and Backstop Agreement On August 3, 2020, in connection with the consummation of the Initial Public Offering, the Company entered into a purchase agreement (“FPA”) with its Sponsor pursuant to which the Sponsor agreed that it will purchase an aggregate of 2,500,000 ordinary shares of the Company at a price of $10.00 per share, for an aggregate purchase price of $25.0 million prior to, currently with, or following the consummation of a Business Combination, either in open market transactions (to the extent permitted by law) or in a private placement with the Company. This FPA commitment has been satisfied by the RTW Funds through: (a) an investment of $15 million in Orchestra’s Series D Financing, and (b) the Forward Purchase Agreements described below. Simultaneously with the execution of the Merger Agreement, the Company and Orchestra entered into separate Forward Purchase Agreements with the RTW Funds and Medtronic, pursuant to which each of the Purchasing Parties agreed to purchase approximately $10.0 million of the Company’s ordinary shares, for a total of approximately $20.0 million, less the dollar amount of the Company’s ordinary shares holding redemption rights that the Purchasing Party acquires and holds until immediately prior to the domestication. Simultaneously with the execution of the Merger Agreement and the Forward Purchase Agreements, the Company, Orchestra, and the RTW Funds entered into the Backstop Agreement, pursuant to which the RTW Funds, jointly and severally, agreed to purchase such number of the Company’s ordinary shares at a price of $10.00 per share to the extent that the amount of Parent Closing Cash (as defined in the Merger Agreement) as of immediately prior to the closing of the Orchestra Business Combination is less than $60.0 million (inclusive of the $10.0 million commitment by the RTW Funds pursuant to the Forward Purchase Agreement described above). On October 21, 2022, the Backstop Agreement and the Forward Purchase Agreement with the RTW Funds were amended to provide that: (1) the per share purchase price under each of the Backstop Agreement and the Forward Purchase Agreement will not exceed the redemption price available to Public Shareholders exercising redemption rights at the shareholder meeting held to approve the Business Combination; (2) any shares purchased pursuant to the Backstop Agreement or the Forward Purchase Agreement, or otherwise acquired by the RTW Funds outside of the existing redemption offer, will not be voted in favor of approving the Business Combination; and (3) the RTW Funds will waive redemption rights with respect to such purchases in the vote to approve the Business Combination. The amendments have been filed with the SEC on a Current Report on Form 8-K on October 21, 2022. The Forward Purchase Agreement with Medtronic was not amended. On July 22, 2022, the RTW Funds purchased 1,000,000 of the Company’s ordinary shares at a price of $10.01 per share from an accredited investor in a privately negotiated transaction, in order to fulfill their obligations under the Forward Purchase Agreements and to ensure that such shares purchased were not redeemed and the amounts that would have been paid by the Company if such shares were redeemed remain in the Company’s trust account at the closing of the Orchestra Business Combination. The closing under the Forward Purchase Agreement with Medtronic and the closing under the Backstop Agreement, if any, will occur immediately prior to the domestication. The Company’s Sponsor, and the Purchasing Parties will have registration rights pursuant to the Amended and Restated Registration Rights and Lock-Up Agreement with respect to the Company’s ordinary shares, received in the domestication. Company Shareholder Support Agreement and Forfeiture Contemporaneously with the execution of the Merger Agreement, the Company and Orchestra entered into a support agreement (the “Parent Support Agreement”) with the Sponsor and certain of the Company’s other shareholders (each a “Shareholder”) pursuant to which the Shareholders identified therein have agreed (a) to appear at any shareholder meetings called to approve the Merger or any proposal to extend the period of time the Company is afforded under its organizational documents and its prospectus to consummate an initial business combination (an “Extension Proposal”), (b) not to redeem their shares or any other of the Company’s equity securities now or in future acquired or beneficially owned, (c) to vote such shares and equity securities, to the extent permitted by law, (i) in favor of the domestication, the Merger and related transactions, (ii) in favor of any Extension Proposal, (iii) against any change in the Company’s business, management or board contrary to the Merger Agreement and against any other proposal reasonably expected to breach, prevent or impede the Merger, and (d) to waive anti-dilution and similar rights with respect to such shares, whether under the Company’s amended and restated memorandum and articles of association, applicable law, or a contract regarding the Merger and related transactions with the Company. In addition, the Sponsor has agreed that 25% or 1,000,000 shares of its New Orchestra common stock received in the domestication will be forfeited to New Orchestra on the first business day following the fifth anniversary of the closing of the Orchestra Business Combination unless, as to 500,000 shares, the VWAP (as defined in the Merger Agreement) of the New Orchestra common stock is greater than or equal to $15.00 per share over any 20 Trading Days (as defined in the Merger Agreement) within any 30-Trading Day period, and as to the remaining 500,000 shares, the VWAP of the New Orchestra common stock is greater than or equal to $20.00 per share over any 20-Trading Days within any 30-Trading Day period. Further, subject to the closing of the Orchestra Business Combination, the Sponsor has agreed to forfeit 50% of its warrants, comprising 750,000 warrants for no consideration.

3593750

28750

0.113043478

406250

4000000

521739

300000

The notes would either be paid upon consummation of the initial Business Combination, without interest, or, at the lender’s discretion, up to $500,000 of such loans may be converted upon consummation of the Business Combination into additional private warrants at a price of $1.00 per warrant.

10000

120000

0 150000 2500000

25000000

15000000

10000000

20000000

60000000 10000000

1000000

10.01

Note 6-Commitments and Contingencies Registration Rights The holders of the Insider Shares, the Private Placement Shares, the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any ordinary shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to a registration rights agreement. The holders of a majority of these securities are entitled to make up to two demands that the Company registers such securities. The holders of the majority of the Insider Shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these ordinary shares are to be released from escrow. The holders of a majority of the Private Placement Shares, the Private Placement Warrants or warrants that may be issued upon conversion of Working Capital Loans made to the Company can elect to exercise these registration rights at any time after the Company consummates a Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s consummation of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The Company granted the underwriters a 45-day option from the effective date of the registration statement relating to the Initial Public Offering to purchase up to 2,086,956 additional ordinary shares at the Initial Public Offering price less the underwriting discounts and commissions. On August 6, 2020, the underwriters fully exercised the over-allotment option. The underwriters were entitled to an underwriting discount of $0.20 per Public Share, or $3.2 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, the underwriters were entitled to a deferred underwriting commission of $0.35 per Public Share, or $5.6 million in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. Risks and Uncertainties Various social and political circumstances in the United States and around the world (including wars and other forms of conflict, including rising trade tensions between the United States and China, and other uncertainties regarding actual and potential shifts in the United States and foreign, trade, economic and other policies with other countries, terrorist acts, security operations and catastrophic events such as fires, floods, earthquakes, tornadoes, hurricanes and global health epidemics) may contribute to increased market volatility and economic uncertainties or deterioration in the United States and worldwide. Specifically, the rising conflict between Russia and Ukraine, and resulting market volatility could adversely affect the Company’s ability to complete a business combination. In response to the conflict between Russia and Ukraine, the United States and other countries have imposed sanctions or other restrictive actions against Russia. Any of the above factors, including sanctions, export controls, tariffs, trade wars and other governmental actions, could have a material adverse effect on the Company’s ability to complete a business combination and the value of the Company’s securities. Management continues to evaluate the impact of these types of risks on the industry and has concluded that while it is reasonably possible that these types of risks could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

3200000

0.35 5600000 Note 7-Ordinary Shares Subject to Possible Redemption The Company’s Public Shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of future events. The Company is authorized to issue 100,000,000 ordinary shares with a par value of $0.0001 per share. Holders of the Company’s ordinary shares are entitled to one vote for each share. As of December 31, 2022 and 2021, there were 11,212,117 and 20,450,000 ordinary shares outstanding, respectively, 6,762,117 and 16,000,000 of which were subject to possible redemption, respectively, and are classified outside of permanent equity in the consolidated balance sheets. The ordinary shares subject to possible redemption reflected on the consolidated balance sheets is reconciled on the following table: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Gross proceeds received from Initial Public Offering</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">160,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Offering costs allocated to Public Shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,418,420</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td>Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Accretion on ordinary shares to redemption value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,418,420</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in">Ordinary shares subject to possible redemption as of December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">160,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">Redemption of Public Shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(92,591,090</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Increase in redemption value of ordinary shares subject to possible redemption</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">267,588</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Ordinary shares subject to possible redemption as of December 31, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">67,676,498</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

100000000

0.0001

Holders of the Company’s ordinary shares are entitled to one vote for each share.

11212117

20450000

6762117 16000000 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Gross proceeds received from Initial Public Offering</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">160,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Offering costs allocated to Public Shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(9,418,420</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td>Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Accretion on ordinary shares to redemption value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,418,420</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in">Ordinary shares subject to possible redemption as of December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">160,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in">Redemption of Public Shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(92,591,090</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Increase in redemption value of ordinary shares subject to possible redemption</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">267,588</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Ordinary shares subject to possible redemption as of December 31, 2022</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">67,676,498</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 160000000

9418420

160000000

-92591090

267588 67676498

Note 8-Shareholders’ Deficit Preference Shares - The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share. As of December 31, 2022 and 2021, there are no preference shares issued or outstanding. Ordinary Shares - The Company is authorized to issue 100,000,000 ordinary shares, par value $0.0001. Holders of the Company’s ordinary shares are entitled to one vote for each share. As of December 31, 2022 and 2021, there were 11,212,117 and 20,450,000 ordinary shares issued or outstanding, respectively, including 6,762,117 and 16,000,000 ordinary shares subject to possible redemption, respectively, and classified as temporary equity. Private Warrants - Private Placement Warrants may only be exercised for a whole number of ordinary shares. The Private Placement Warrants will become exercisable 30 days after the completion of a Business Combination; provided in each case that the Company has an effective registration statement under the Securities Act covering the ordinary shares issuable upon exercise of the Private Placement Warrants and a current prospectus relating to them is available and such ordinary shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or the Company permit holders to exercise their warrants on a cashless basis under certain circumstances). Each warrant is exercisable to purchase one of ordinary shares at an exercise price of $11.50 per full share and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share capitalization, or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants shares. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless.

1000000

0.0001

Holders of the Company’s ordinary shares are entitled to one vote for each share.

11212117

20450000

6762117 16000000

11.5

P5Y

Note 9-Fair Value Measurements The following table presents information about the Company’s financial assets that are measured at fair value on a recurring basis as of December 31, 2021 by level within the fair value hierarchy: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measured as of December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Investments held in Trust Account - U.S. Treasury Securities</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">160,022,447</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">160,022,447</td><td style="width: 1%; text-align: left"> </td></tr> </table> Transfers to/from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for years ended December 31, 2022 and 2021. Level 1 instruments include investments in money market funds that invest in U.S. Treasury securities with an original maturity of 185 days or less. The Company uses inputs such as actual trade data, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments. As of December 31, 2022, only cash is held in the Trust Account.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair Value Measured as of December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Investments held in Trust Account - U.S. Treasury Securities</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">160,022,447</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">160,022,447</td><td style="width: 1%; text-align: left"> </td></tr> </table>

160022447

Note 10-Subsequent Events On January 24, 2023, the Company held an extraordinary general meeting of shareholders (the “General Meeting”) for the purpose of considering and voting upon, among other things, the Orchestra Business Combination. Each of the proposals presented at the General Meeting, as more fully described in the proxy statement/prospectus filed by the Company with the SEC on December 16, 2022, was approved. The submission of the Orchestra Business Combination to the shareholders entitled holders of Public Shares to redeem their shares for their pro rata portion of the funds held in the Trust Account. In connection with the General Meeting, as of January 24, 2023, we received requests for redemption from holders with respect to 1,597,888 Public Shares, at a redemption price of approximately $10.02 per share, which is expected to be paid following the closing of the Orchestra Business Combination. The Company evaluated subsequent events and transactions that occurred after the consolidated balance sheet date up to the date that the consolidated financial statements were issued. Based upon this review, other than as described above, the Company did not identify any other subsequent events that have occurred that would require adjustments to the disclosures in the consolidated financial statements.

1597888

10.02

00-0000000

16425826

20450000

-0.02

-0.17

false FY 0001814114

EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 53 205 1 false 18 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.prnewswire.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://www.prnewswire.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.prnewswire.com/role/ConsolidatedBalanceSheet_Parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations Sheet http://www.prnewswire.com/role/ConsolidatedIncomeStatement Consolidated Statements of Operations Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Operations (Parentheticals) Sheet http://www.prnewswire.com/role/ConsolidatedIncomeStatement_Parentheticals Consolidated Statements of Operations (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Changes in Shareholders??? Deficit Sheet http://www.prnewswire.com/role/ShareholdersEquityType2or3 Consolidated Statements of Changes in Shareholders??? Deficit Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Cash Flows Sheet http://www.prnewswire.com/role/ConsolidatedCashFlow Consolidated Statements of Cash Flows Statements 7 false false R8.htm 007 - Disclosure - Description of Organization, Business Operations and Going Concern Sheet http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcern Description of Organization, Business Operations and Going Concern Notes 8 false false R9.htm 008 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.prnewswire.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Initial Public Offering Sheet http://www.prnewswire.com/role/InitialPublicOffering Initial Public Offering Notes 10 false false R11.htm 010 - Disclosure - Private Placement Sheet http://www.prnewswire.com/role/PrivatePlacement Private Placement Notes 11 false false R12.htm 011 - Disclosure - Related Party Transactions Sheet http://www.prnewswire.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 012 - Disclosure - Commitments and Contingencies Sheet http://www.prnewswire.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 13 false false R14.htm 013 - Disclosure - Ordinary Shares Subject to Possible Redemption Sheet http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemption Ordinary Shares Subject to Possible Redemption Notes 14 false false R15.htm 014 - Disclosure - Shareholders??? Deficit Sheet http://www.prnewswire.com/role/ShareholdersDeficit Shareholders??? Deficit Notes 15 false false R16.htm 015 - Disclosure - Fair Value Measurements Sheet http://www.prnewswire.com/role/FairValueMeasurements Fair Value Measurements Notes 16 false false R17.htm 016 - Disclosure - Subsequent Events Sheet http://www.prnewswire.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 017 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.prnewswire.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.prnewswire.com/role/SummaryofSignificantAccountingPolicies 18 false false R19.htm 018 - Disclosure - Ordinary Shares Subject to Possible Redemption (Tables) Sheet http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemptionTables Ordinary Shares Subject to Possible Redemption (Tables) Tables http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemption 19 false false R20.htm 019 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.prnewswire.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.prnewswire.com/role/FairValueMeasurements 20 false false R21.htm 020 - Disclosure - Description of Organization, Business Operations and Going Concern (Details) Sheet http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails Description of Organization, Business Operations and Going Concern (Details) Details http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcern 21 false false R22.htm 021 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.prnewswire.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details 22 false false R23.htm 022 - Disclosure - Initial Public Offering (Details) Sheet http://www.prnewswire.com/role/InitialPublicOfferingDetails Initial Public Offering (Details) Details http://www.prnewswire.com/role/InitialPublicOffering 23 false false R24.htm 023 - Disclosure - Private Placement (Details) Sheet http://www.prnewswire.com/role/PrivatePlacementDetails Private Placement (Details) Details http://www.prnewswire.com/role/PrivatePlacement 24 false false R25.htm 024 - Disclosure - Related Party Transactions (Details) Sheet http://www.prnewswire.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.prnewswire.com/role/RelatedPartyTransactions 25 false false R26.htm 025 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.prnewswire.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.prnewswire.com/role/CommitmentsandContingencies 26 false false R27.htm 026 - Disclosure - Ordinary Shares Subject to Possible Redemption (Details) Sheet http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemptionDetails Ordinary Shares Subject to Possible Redemption (Details) Details http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemptionTables 27 false false R28.htm 027 - Disclosure - Ordinary Shares Subject to Possible Redemption (Details) - Schedule of condensed consolidated balance sheets Sheet http://www.prnewswire.com/role/ScheduleofcondensedconsolidatedbalancesheetsTable Ordinary Shares Subject to Possible Redemption (Details) - Schedule of condensed consolidated balance sheets Details http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemptionTables 28 false false R29.htm 028 - Disclosure - Shareholders??? Deficit (Details) Sheet http://www.prnewswire.com/role/ShareholdersDeficitDetails Shareholders??? Deficit (Details) Details http://www.prnewswire.com/role/ShareholdersDeficit 29 false false R30.htm 029 - Disclosure - Fair Value Measurements (Details) - Schedule of financial assets that are measured at fair value on a recurring basis Sheet http://www.prnewswire.com/role/ScheduleoffinancialassetsthataremeasuredatfairvalueonarecurringbasisTable Fair Value Measurements (Details) - Schedule of financial assets that are measured at fair value on a recurring basis Details http://www.prnewswire.com/role/FairValueMeasurementsTables 30 false false R31.htm 030 - Disclosure - Subsequent Events (Details) Sheet http://www.prnewswire.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.prnewswire.com/role/SubsequentEvents 31 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - f10k2022_healthsciences2.htm 5896, 5897, 5898, 5899 f10k2022_healthsciences2.htm f10k2022ex21_healthscien2.htm f10k2022ex31-1_healthscien2.htm f10k2022ex31-2_healthscien2.htm f10k2022ex32_healthscien2.htm f10k2022ex4-4_healthscien2.htm hsaq-20221231.xsd hsaq-20221231_cal.xml hsaq-20221231_def.xml hsaq-20221231_lab.xml hsaq-20221231_pre.xml http://fasb.org/srt/2022 http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 50 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10k2022_healthsciences2.htm": { "axisCustom": 0, "axisStandard": 8, "baseTaxonomies": { "http://fasb.org/srt/2022": 1, "http://fasb.org/us-gaap/2022": 219, "http://xbrl.sec.gov/dei/2022": 38 }, "contextCount": 53, "dts": { "calculationLink": { "local": [ "hsaq-20221231_cal.xml" ] }, "definitionLink": { "local": [ "hsaq-20221231_def.xml" ] }, "inline": { "local": [ "f10k2022_healthsciences2.htm" ] }, "labelLink": { "local": [ "hsaq-20221231_lab.xml" ] }, "presentationLink": { "local": [ "hsaq-20221231_pre.xml" ] }, "schema": { "local": [ "hsaq-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd" ] } }, "elementCount": 295, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 29, "http://www.prnewswire.com/20221231": 2, "http://xbrl.sec.gov/dei/2022": 4, "total": 35 }, "keyCustom": 46, "keyStandard": 159, "memberCustom": 5, "memberStandard": 13, "nsprefix": "hsaq", "nsuri": "http://www.prnewswire.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.prnewswire.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hsaq:InitialPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Initial Public Offering", "menuCat": "Notes", "order": "10", "role": "http://www.prnewswire.com/role/InitialPublicOffering", "shortName": "Initial Public Offering", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hsaq:InitialPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hsaq:PrivatePlacementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Private Placement", "menuCat": "Notes", "order": "11", "role": "http://www.prnewswire.com/role/PrivatePlacement", "shortName": "Private Placement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hsaq:PrivatePlacementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "12", "role": "http://www.prnewswire.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "13", "role": "http://www.prnewswire.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hsaq:OrdinarySharesSubjectToPossibleRedemptionDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Ordinary Shares Subject to Possible Redemption", "menuCat": "Notes", "order": "14", "role": "http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemption", "shortName": "Ordinary Shares Subject to Possible Redemption", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hsaq:OrdinarySharesSubjectToPossibleRedemptionDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Shareholders\u2019 Deficit", "menuCat": "Notes", "order": "15", "role": "http://www.prnewswire.com/role/ShareholdersDeficit", "shortName": "Shareholders\u2019 Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "16", "role": "http://www.prnewswire.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "17", "role": "http://www.prnewswire.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Accounting Policies, by Policy (Policies)", "menuCat": "Policies", "order": "18", "role": "http://www.prnewswire.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Ordinary Shares Subject to Possible Redemption (Tables)", "menuCat": "Tables", "order": "19", "role": "http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemptionTables", "shortName": "Ordinary Shares Subject to Possible Redemption (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.prnewswire.com/role/ConsolidatedBalanceSheet", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "20", "role": "http://www.prnewswire.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c3", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Description of Organization, Business Operations and Going Concern (Details)", "menuCat": "Details", "order": "21", "role": "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails", "shortName": "Description of Organization, Business Operations and Going Concern (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c3", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Summary of Significant Accounting Policies (Details)", "menuCat": "Details", "order": "22", "role": "http://www.prnewswire.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c36", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Initial Public Offering (Details)", "menuCat": "Details", "order": "23", "role": "http://www.prnewswire.com/role/InitialPublicOfferingDetails", "shortName": "Initial Public Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c36", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c3", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentOwnedBalancePrincipalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Private Placement (Details)", "menuCat": "Details", "order": "24", "role": "http://www.prnewswire.com/role/PrivatePlacementDetails", "shortName": "Private Placement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c3", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentOwnedBalancePrincipalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionDescriptionOfTransaction", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Related Party Transactions (Details)", "menuCat": "Details", "order": "25", "role": "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionDescriptionOfTransaction", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hsaq:UnderwritingAgreementDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "26", "role": "http://www.prnewswire.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hsaq:UnderwritingAgreementDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Ordinary Shares Subject to Possible Redemption (Details)", "menuCat": "Details", "order": "27", "role": "http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemptionDetails", "shortName": "Ordinary Shares Subject to Possible Redemption (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c5", "decimals": "0", "first": true, "lang": null, "name": "hsaq:GrossProceedsReceivedFromInitialPublicOfferings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Ordinary Shares Subject to Possible Redemption (Details) - Schedule of condensed consolidated balance sheets", "menuCat": "Details", "order": "28", "role": "http://www.prnewswire.com/role/ScheduleofcondensedconsolidatedbalancesheetsTable", "shortName": "Ordinary Shares Subject to Possible Redemption (Details) - Schedule of condensed consolidated balance sheets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c5", "decimals": "0", "first": true, "lang": null, "name": "hsaq:GrossProceedsReceivedFromInitialPublicOfferings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Shareholders\u2019 Deficit (Details)", "menuCat": "Details", "order": "29", "role": "http://www.prnewswire.com/role/ShareholdersDeficitDetails", "shortName": "Shareholders\u2019 Deficit (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c3", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://www.prnewswire.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c3", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrust", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Fair Value Measurements (Details) - Schedule of financial assets that are measured at fair value on a recurring basis", "menuCat": "Details", "order": "30", "role": "http://www.prnewswire.com/role/ScheduleoffinancialassetsthataremeasuredatfairvalueonarecurringbasisTable", "shortName": "Fair Value Measurements (Details) - Schedule of financial assets that are measured at fair value on a recurring basis", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrust", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c52", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Subsequent Events (Details)", "menuCat": "Details", "order": "31", "role": "http://www.prnewswire.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c52", "decimals": "2", "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://www.prnewswire.com/role/ConsolidatedIncomeStatement", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Operations (Parentheticals)", "menuCat": "Statements", "order": "5", "role": "http://www.prnewswire.com/role/ConsolidatedIncomeStatement_Parentheticals", "shortName": "Consolidated Statements of Operations (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Changes in Shareholders\u2019 Deficit", "menuCat": "Statements", "order": "6", "role": "http://www.prnewswire.com/role/ShareholdersEquityType2or3", "shortName": "Consolidated Statements of Changes in Shareholders\u2019 Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c6", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://www.prnewswire.com/role/ConsolidatedCashFlow", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:UnrealizedGainLossOnInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Description of Organization, Business Operations and Going Concern", "menuCat": "Notes", "order": "8", "role": "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcern", "shortName": "Description of Organization, Business Operations and Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://www.prnewswire.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_healthsciences2.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 18, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r273", "r274", "r275" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r273", "r274", "r275" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r273", "r274", "r275" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r273", "r274", "r275" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r273", "r274", "r275" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.prnewswire.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "hsaq_AccruedExpensesRelatedPartyOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accrued Expenses Related Party Outstanding", "terseLabel": "Accrued expenses related party outstanding" } } }, "localname": "AccruedExpensesRelatedPartyOutstanding", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "hsaq_AggregatePurchasePrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Aggregate Purchase Price", "terseLabel": "Aggregate to purchase price" } } }, "localname": "AggregatePurchasePrice", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "hsaq_AggregatePurchaseToOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Aggregate Purchase To Ordinary Shares", "terseLabel": "Aggregate purchase to ordinary shares (in Shares)" } } }, "localname": "AggregatePurchaseToOrdinaryShares", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "hsaq_BorrowedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Borrowed amount.", "label": "Borrowed Amount", "terseLabel": "Borrowed amount" } } }, "localname": "BorrowedAmount", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "hsaq_BusinessCombinationAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination amount,", "label": "Business Combination Amount", "terseLabel": "Business combination amount" } } }, "localname": "BusinessCombinationAmount", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "hsaq_CashWithdrawnFromTrustAccountToRedeemPublicShares": { "auth_ref": [], "calculation": { "http://www.prnewswire.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash withdrawn from Trust Account to redeem public shares.\r \n.", "label": "Cash Withdrawn From Trust Account To Redeem Public Shares", "terseLabel": "Cash withdrawn from Trust Account to redeem Public Shares" } } }, "localname": "CashWithdrawnFromTrustAccountToRedeemPublicShares", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "hsaq_CommitmentsandContingenciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Line Items]" } } }, "localname": "CommitmentsandContingenciesDetailsLineItems", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "hsaq_CommitmentsandContingenciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "localname": "CommitmentsandContingenciesDetailsTable", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "hsaq_DeferedUnderwritingCommissions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Defered Underwriting Commissions", "terseLabel": "Deferred underwriting commissions" } } }, "localname": "DeferedUnderwritingCommissions", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/InitialPublicOfferingDetails" ], "xbrltype": "monetaryItemType" }, "hsaq_DeferredUnderwritingCommission": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred underwriting commission.", "label": "Deferred Underwriting Commission", "terseLabel": "Deferred underwriting commission" } } }, "localname": "DeferredUnderwritingCommission", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "hsaq_DeferredUnderwritingCommissions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred underwriting commission.", "label": "Deferred Underwriting Commissions", "terseLabel": "Deferred underwriting commission" } } }, "localname": "DeferredUnderwritingCommissions", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "hsaq_DeferredUnderwritingCommissionsInConnectionWithTheInitialPublicOffering": { "auth_ref": [], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deferred Underwriting Commissions In Connection With The Initial Public Offering", "terseLabel": "Deferred underwriting commissions" } } }, "localname": "DeferredUnderwritingCommissionsInConnectionWithTheInitialPublicOffering", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "hsaq_DescriptionOfPrivatePlacementWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of private placement warrant.", "label": "Description Of Private Placement Warrant", "terseLabel": "Description of private placement warrant" } } }, "localname": "DescriptionOfPrivatePlacementWarrant", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "stringItemType" }, "hsaq_DescriptionofOrganizationBusinessOperationsandGoingConcernDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of Organization, Business Operations and Going Concern (Details) [Line Items]" } } }, "localname": "DescriptionofOrganizationBusinessOperationsandGoingConcernDetailsLineItems", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "stringItemType" }, "hsaq_DescriptionofOrganizationBusinessOperationsandGoingConcernDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of Organization, Business Operations and Going Concern (Details) [Table]" } } }, "localname": "DescriptionofOrganizationBusinessOperationsandGoingConcernDetailsTable", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "stringItemType" }, "hsaq_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.prnewswire.com/20221231", "xbrltype": "stringItemType" }, "hsaq_ExtensionRedemptionsAndPrivatePurchaseDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension, redemptions and private purchase description.", "label": "Extension Redemptions And Private Purchase Description", "terseLabel": "Extension, redemptions and private purchase description." } } }, "localname": "ExtensionRedemptionsAndPrivatePurchaseDescription", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "stringItemType" }, "hsaq_FairValueMeasurementsDetailsScheduleoffinancialassetsthataremeasuredatfairvalueonarecurringbasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) - Schedule of financial assets that are measured at fair value on a recurring basis [Line Items]" } } }, "localname": "FairValueMeasurementsDetailsScheduleoffinancialassetsthataremeasuredatfairvalueonarecurringbasisLineItems", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/ScheduleoffinancialassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "hsaq_FairValueMeasurementsDetailsScheduleoffinancialassetsthataremeasuredatfairvalueonarecurringbasisTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) - Schedule of financial assets that are measured at fair value on a recurring basis [Table]" } } }, "localname": "FairValueMeasurementsDetailsScheduleoffinancialassetsthataremeasuredatfairvalueonarecurringbasisTable", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/ScheduleoffinancialassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "hsaq_GrossProceedsReceivedFromInitialPublicOfferings": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Gross Proceeds Received From Initial Public Offerings", "terseLabel": "Gross proceeds received from Initial Public Offering" } } }, "localname": "GrossProceedsReceivedFromInitialPublicOfferings", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/ScheduleofcondensedconsolidatedbalancesheetsTable" ], "xbrltype": "monetaryItemType" }, "hsaq_IncreaseInRedemptionValueOfOrdinarySharesSubjectToPossibleRedemption": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase in redemption value of ordinary shares subject to possible redemption.", "label": "Increase In Redemption Value Of Ordinary Shares Subject To Possible Redemption", "terseLabel": "Increase in redemption value of ordinary shares subject to possible redemption" } } }, "localname": "IncreaseInRedemptionValueOfOrdinarySharesSubjectToPossibleRedemption", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/ScheduleofcondensedconsolidatedbalancesheetsTable" ], "xbrltype": "monetaryItemType" }, "hsaq_InitialPublicOfferingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Initial Public Offering [Abstract]" } } }, "localname": "InitialPublicOfferingAbstract", "nsuri": "http://www.prnewswire.com/20221231", "xbrltype": "stringItemType" }, "hsaq_InitialPublicOfferingDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Initial Public Offering (Details) [Line Items]" } } }, "localname": "InitialPublicOfferingDetailsLineItems", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/InitialPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "hsaq_InitialPublicOfferingDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Initial Public Offering (Details) [Table]" } } }, "localname": "InitialPublicOfferingDetailsTable", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/InitialPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "hsaq_InitialPublicOfferingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Initial Public Offering Text Block", "terseLabel": "Initial Public Offering" } } }, "localname": "InitialPublicOfferingTextBlock", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/InitialPublicOffering" ], "xbrltype": "textBlockItemType" }, "hsaq_InsiderSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Insider Shares Member", "terseLabel": "Insider Shares [Member]" } } }, "localname": "InsiderSharesMember", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "hsaq_InvestmentsHeldInTheTrustAccountPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments Held In The Trust Account Policy Text Block", "terseLabel": "Cash and Investments Held in the Trust Account" } } }, "localname": "InvestmentsHeldInTheTrustAccountPolicyTextBlock", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "hsaq_IssuanceOfPublicSharesUnderOverallotment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of public shares under over-allotment.", "label": "Issuance Of Public Shares Under Overallotment", "terseLabel": "Issuance of public shares under over-allotment (in Shares)" } } }, "localname": "IssuanceOfPublicSharesUnderOverallotment", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "sharesItemType" }, "hsaq_LessAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Less Abstract", "terseLabel": "Less:" } } }, "localname": "LessAbstract", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/ScheduleofcondensedconsolidatedbalancesheetsTable" ], "xbrltype": "stringItemType" }, "hsaq_LoanAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loan amount.", "label": "Loan Amount", "terseLabel": "Loan amount" } } }, "localname": "LoanAmount", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "hsaq_MinimumOfClosingBusinessCombinationAmount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum of closing business combination amount.", "label": "Minimum Of Closing Business Combination Amount", "terseLabel": "Minimum of closing business combination amount" } } }, "localname": "MinimumOfClosingBusinessCombinationAmount", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "hsaq_OfferingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire policy disclosure of offering cost.", "label": "Offering Costs Policy Text Block", "terseLabel": "Offering Costs Associated with Initial Public Offering" } } }, "localname": "OfferingCostsPolicyTextBlock", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "hsaq_OrdinaryShareSubjectToPossibleRedemption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of redemptions are when a company requires shareholders to sell a portion of their shares back to the company. For a company to redeem shares, it must have stipulated upfront that those shares are redeemable, or callable.", "label": "Ordinary Share Subject To Possible Redemption", "terseLabel": "Ordinary shares subject to possible redemption" } } }, "localname": "OrdinaryShareSubjectToPossibleRedemption", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/ScheduleofcondensedconsolidatedbalancesheetsTable" ], "xbrltype": "monetaryItemType" }, "hsaq_OrdinaryShareValuePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ordinary share price percentage.", "label": "Ordinary Share Value Percentage", "terseLabel": "Aggregate shares, percentage" } } }, "localname": "OrdinaryShareValuePercentage", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "percentItemType" }, "hsaq_OrdinarySharesSubjectToPossibleRedemption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ordinary shares subject to possible redemption.", "label": "Ordinary Shares Subject To Possible Redemption", "terseLabel": "Ordinary shares subject to possible redemption" } } }, "localname": "OrdinarySharesSubjectToPossibleRedemption", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/ShareholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "hsaq_OrdinarySharesSubjectToPossibleRedemptionDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ordinary Shares Subject To Possible Redemption Disclosure Abstract" } } }, "localname": "OrdinarySharesSubjectToPossibleRedemptionDisclosureAbstract", "nsuri": "http://www.prnewswire.com/20221231", "xbrltype": "stringItemType" }, "hsaq_OrdinarySharesSubjectToPossibleRedemptionDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ordinary Shares Subject To Possible Redemption Disclosure Text Block", "terseLabel": "Ordinary Shares Subject to Possible Redemption" } } }, "localname": "OrdinarySharesSubjectToPossibleRedemptionDisclosureTextBlock", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemption" ], "xbrltype": "textBlockItemType" }, "hsaq_OrdinarySharesSubjecttoPossibleRedemptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ordinary Shares Subject to Possible Redemption [Abstract]" } } }, "localname": "OrdinarySharesSubjecttoPossibleRedemptionLineItems", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemption" ], "xbrltype": "stringItemType" }, "hsaq_OrdinarySharesSubjecttoPossibleRedemptionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ordinary Shares Subject to Possible Redemption [Table]" } } }, "localname": "OrdinarySharesSubjecttoPossibleRedemptionTable", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemption" ], "xbrltype": "stringItemType" }, "hsaq_OrdinarySharesSubjecttoPossibleRedemptionTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ordinary Shares Subject to Possible Redemption Table [Abstract]" } } }, "localname": "OrdinarySharesSubjecttoPossibleRedemptionTablesLineItems", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemptionTables" ], "xbrltype": "stringItemType" }, "hsaq_OrdinarySharesSubjecttoPossibleRedemptionTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ordinary Shares Subject to Possible Redemption (Tables) [Table]" } } }, "localname": "OrdinarySharesSubjecttoPossibleRedemptionTablesTable", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemptionTables" ], "xbrltype": "stringItemType" }, "hsaq_OrdinarySharesTotalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of ordinary shares total amount.", "label": "Ordinary Shares Total Amount", "terseLabel": "Ordinary shares total amount" } } }, "localname": "OrdinarySharesTotalAmount", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "hsaq_PercentageHeldInTrustAccount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage held in trust account.", "label": "Percentage Held In Trust Account", "terseLabel": "Assets held in the trust account, percentage" } } }, "localname": "PercentageHeldInTrustAccount", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "percentItemType" }, "hsaq_PlusAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Plus Abstract", "terseLabel": "Plus:" } } }, "localname": "PlusAbstract", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/ScheduleofcondensedconsolidatedbalancesheetsTable" ], "xbrltype": "stringItemType" }, "hsaq_PricePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Price Per Unit", "terseLabel": "Price per unit (in Dollars per share)" } } }, "localname": "PricePerUnit", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "perShareItemType" }, "hsaq_PrivatePlacementDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placement (Details) [Line Items]" } } }, "localname": "PrivatePlacementDetailsLineItems", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/PrivatePlacementDetails" ], "xbrltype": "stringItemType" }, "hsaq_PrivatePlacementDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placement (Details) [Table]" } } }, "localname": "PrivatePlacementDetailsTable", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/PrivatePlacementDetails" ], "xbrltype": "stringItemType" }, "hsaq_PrivatePlacementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placement Disclosure Abstract" } } }, "localname": "PrivatePlacementDisclosureAbstract", "nsuri": "http://www.prnewswire.com/20221231", "xbrltype": "stringItemType" }, "hsaq_PrivatePlacementDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placement Disclosure Text Block", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementDisclosureTextBlock", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/PrivatePlacement" ], "xbrltype": "textBlockItemType" }, "hsaq_PrivatePlacementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placement [Abstract]" } } }, "localname": "PrivatePlacementLineItems", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/PrivatePlacement" ], "xbrltype": "stringItemType" }, "hsaq_PrivatePlacementPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Private Placement Per Share", "terseLabel": "Price per share" } } }, "localname": "PrivatePlacementPerShare", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/PrivatePlacementDetails" ], "xbrltype": "perShareItemType" }, "hsaq_PrivatePlacementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placement [Table]" } } }, "localname": "PrivatePlacementTable", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/PrivatePlacement" ], "xbrltype": "stringItemType" }, "hsaq_ProceedFromIssuanceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceed From Issuance Of Common Stock", "terseLabel": "Capital contribution" } } }, "localname": "ProceedFromIssuanceOfCommonStock", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "hsaq_ProceedFromIssuancesInitialPublicOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceed From Issuances Initial Public Offering", "terseLabel": "Gross proceeds" } } }, "localname": "ProceedFromIssuancesInitialPublicOffering", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "hsaq_ProceedsFromIssuanceOfPrivatePlacements": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds From Issuance Of Private Placements", "terseLabel": "Private placement amount" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacements", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "hsaq_ProposedBusinessCombinationDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Proposed business combination.", "label": "Proposed Business Combination Description", "terseLabel": "Proposed business combination" } } }, "localname": "ProposedBusinessCombinationDescription", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "stringItemType" }, "hsaq_PublicPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Public Per Share", "terseLabel": "Public per share (in Dollars per share)" } } }, "localname": "PublicPerShare", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "perShareItemType" }, "hsaq_PublicStockholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Public Stockholders Member", "terseLabel": "Public Shareholders [Member]" } } }, "localname": "PublicStockholdersMember", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "domainItemType" }, "hsaq_PurchaseAgreementAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase agreement amount.", "label": "Purchase Agreement Amount", "terseLabel": "Purchase agreement amount" } } }, "localname": "PurchaseAgreementAmount", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "hsaq_RTWFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RTWFunds Member", "terseLabel": "RTW Funds [Member]" } } }, "localname": "RTWFundsMember", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "domainItemType" }, "hsaq_RedeemSharesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeem Shares Percentage", "terseLabel": "Redeem shares, percentage" } } }, "localname": "RedeemSharesPercentage", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "percentItemType" }, "hsaq_RedemptionOfPublicShare": { "auth_ref": [], "calculation": { "http://www.prnewswire.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of redemption of public shares.", "label": "Redemption Of Public Share", "negatedLabel": "Redemption of Public Shares" } } }, "localname": "RedemptionOfPublicShare", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "hsaq_RelatedPartyTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartyTransactionsDetailsLineItems", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "hsaq_RelatedPartyTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "localname": "RelatedPartyTransactionsDetailsTable", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "hsaq_ScheduleOfCondensedConsolidatedBalanceSheetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Condensed Consolidated Balance Sheets Abstract" } } }, "localname": "ScheduleOfCondensedConsolidatedBalanceSheetsAbstract", "nsuri": "http://www.prnewswire.com/20221231", "xbrltype": "stringItemType" }, "hsaq_ScheduleOfFinancialAssetsThatAreMeasuredAtFairValueOnARecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Financial Assets That Are Measured At Fair Value On ARecurring Basis Abstract" } } }, "localname": "ScheduleOfFinancialAssetsThatAreMeasuredAtFairValueOnARecurringBasisAbstract", "nsuri": "http://www.prnewswire.com/20221231", "xbrltype": "stringItemType" }, "hsaq_ShareOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share outstanding.", "label": "Share Outstanding", "terseLabel": "Shares outstanding (in Shares)" } } }, "localname": "ShareOutstanding", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "hsaq_ShareholderSupportAgreementAndForfeitureDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shareholder support agreement and forfeiture.", "label": "Shareholder Support Agreement And Forfeiture Description", "terseLabel": "Shareholder support agreement and forfeiture, description" } } }, "localname": "ShareholderSupportAgreementAndForfeitureDescription", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "hsaq_ShareholdersDeficitDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 Deficit (Details) [Line Items]" } } }, "localname": "ShareholdersDeficitDetailsLineItems", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/ShareholdersDeficitDetails" ], "xbrltype": "stringItemType" }, "hsaq_ShareholdersDeficitDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 Deficit (Details) [Table]" } } }, "localname": "ShareholdersDeficitDetailsTable", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/ShareholdersDeficitDetails" ], "xbrltype": "stringItemType" }, "hsaq_SharesSubjectToPossibleRedemption": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Subject To Possible Redemption", "terseLabel": "Shares subject to possible redemption" } } }, "localname": "SharesSubjectToPossibleRedemption", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemptionDetails", "http://www.prnewswire.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "hsaq_SponsorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sponsor Member", "terseLabel": "Sponsor [Member]" } } }, "localname": "SponsorMember", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails", "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "hsaq_SubjectToForfeitureShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subject To Forfeiture Shares", "terseLabel": "Subject to forfeiture, shares (in Shares)" } } }, "localname": "SubjectToForfeitureShares", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "hsaq_SubsequentEventsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "localname": "SubsequentEventsDetailsLineItems", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "hsaq_SubsequentEventsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "localname": "SubsequentEventsDetailsTable", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "hsaq_TrustAccountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trust Account Member", "terseLabel": "Trust Account [Member]" } } }, "localname": "TrustAccountMember", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "domainItemType" }, "hsaq_UnderwritingAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriting agreement description.", "label": "Underwriting Agreement Description", "terseLabel": "Underwriting agreement, description" } } }, "localname": "UnderwritingAgreementDescription", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "hsaq_UnderwritingDiscountFeeDeferred": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriting discount fee deferred.", "label": "Underwriting Discount Fee Deferred", "terseLabel": "Deferred underwriting commission per public share" } } }, "localname": "UnderwritingDiscountFeeDeferred", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "perShareItemType" }, "hsaq_UnderwritingDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriting discount rate.", "label": "Underwriting Discount Rate", "terseLabel": "Underwriting discount per share" } } }, "localname": "UnderwritingDiscountRate", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "perShareItemType" }, "hsaq_WarrantsToPurchaseOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants to purchase ordinary shares.", "label": "Warrants To Purchase Ordinary Shares", "terseLabel": "Warrants to purchase ordinary shares" } } }, "localname": "WarrantsToPurchaseOrdinaryShares", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "hsaq_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of working capital deficit.", "label": "Working Capital Deficit", "terseLabel": "Working capital deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://www.prnewswire.com/20221231", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails", "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails", "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": { "auth_ref": [ "r287", "r305" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.", "label": "Condensed Financial Statements [Table Text Block]", "terseLabel": "Schedule of condensed consolidated balance sheets" } } }, "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemptionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "The price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.", "label": "Accelerated Share Repurchases, Initial Price Paid Per Share", "terseLabel": "Price per share (in Dollars per share)" } } }, "localname": "AcceleratedShareRepurchasesInitialPricePaidPerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r11", "r269" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrent": { "auth_ref": [ "r11", "r68", "r69", "r286" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Related Parties, Current", "terseLabel": "Accrued expenses - related party" } } }, "localname": "AccountsPayableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r6", "r269" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r186", "r187", "r188", "r288", "r289", "r290", "r299" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile to net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AdministrativeFeesExpense": { "auth_ref": [ "r68" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for administrative services provided to the limited liability company (LLC) or limited partnership (LP) by the managing member or general partner, affiliate of managing member or general partner, or affiliate of LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.", "label": "Administrative Fees Expense", "terseLabel": "Administrative fee - related party" } } }, "localname": "AdministrativeFeesExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r71", "r77", "r91", "r108", "r141", "r143", "r145", "r147", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r198", "r200", "r209", "r269", "r295", "r296", "r303" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r88", "r97", "r108", "r147", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r198", "r200", "r209", "r269", "r295", "r296", "r303" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldInTrust": { "auth_ref": [ "r283" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.", "label": "Assets Held-in-trust", "terseLabel": "Investments held in Trust Account - money market funds" } } }, "localname": "AssetsHeldInTrust", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ScheduleoffinancialassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldInTrustNoncurrent": { "auth_ref": [ "r283" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.", "label": "Assets Held-in-trust, Noncurrent", "terseLabel": "Cash and investments held in Trust Account" } } }, "localname": "AssetsHeldInTrustNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r197", "r267", "r268" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r56", "r57", "r197", "r267", "r268" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Outstanding voting security percentage" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Share price share (in Dollars per share)" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r30", "r90", "r256" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r31", "r70" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r24", "r30", "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash - end of the year", "periodStartLabel": "Cash - beginning of the year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r24", "r67" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "terseLabel": "Federal depository insurance coverage (in Dollars)" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r93", "r94", "r95", "r108", "r125", "r126", "r128", "r130", "r133", "r134", "r147", "r153", "r155", "r156", "r157", "r160", "r161", "r163", "r164", "r166", "r170", "r176", "r209", "r255", "r280", "r284", "r291" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrant exercisable (in Dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ShareholdersDeficitDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Ordinary shares, shares outstanding (in Shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r15", "r74", "r80" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r46", "r151", "r152", "r254", "r294" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r288", "r289", "r299" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "netLabel": "Ordinary share [Member]", "terseLabel": "Ordinary Shares", "verboseLabel": "Ordinary Shares [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails", "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails", "http://www.prnewswire.com/role/ShareholdersDeficitDetails", "http://www.prnewswire.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common Stock, No Par Value", "terseLabel": "Ordinary shares par value (in Dollars per share)" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ShareholdersDeficitDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Ordinary shares, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemptionDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Ordinary shares, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemptionDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Non-redeemable, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r5", "r50" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Non-redeemable, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r5", "r269" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Ordinary shares, $0.0001 par value; 100,000,000 shares authorized; 4,450,000 non-redeemable shares issued and outstanding as of December 31, 2022 and 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock, Voting Rights", "terseLabel": "Voting rights", "verboseLabel": "Ordinary shares vote, description" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemptionDetails", "http://www.prnewswire.com/role/ShareholdersDeficitDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r76", "r137" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r58", "r258" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtConversionDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Description", "terseLabel": "Warrants conversion, description" } } }, "localname": "DebtConversionDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredOfferingCosts": { "auth_ref": [ "r293" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.", "label": "Deferred Offering Costs", "terseLabel": "Offering cost" } } }, "localname": "DeferredOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r60", "r61", "r62", "r63", "r64", "r109" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Assets and Liabilities" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsPayableAmountPerShare": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.", "label": "Dividends Payable, Amount Per Share", "terseLabel": "Dividend per share value (in Dollars per share)" } } }, "localname": "DividendsPayableAmountPerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r104", "r115", "r116", "r117", "r118", "r119", "r123", "r125", "r128", "r129", "r130", "r131", "r204", "r205", "r246", "r247", "r259" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic and diluted net loss per ordinary share (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r104", "r115", "r116", "r117", "r118", "r119", "r125", "r128", "r129", "r130", "r131", "r204", "r205", "r246", "r247", "r259" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Basic and diluted net loss per ordinary share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r38", "r39" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Ordinary Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r50", "r86", "r101", "r102", "r103", "r110", "r111", "r112", "r114", "r120", "r122", "r132", "r148", "r178", "r186", "r187", "r188", "r195", "r196", "r203", "r210", "r211", "r212", "r213", "r214", "r215", "r220", "r248", "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails", "http://www.prnewswire.com/role/PrivatePlacementDetails", "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails", "http://www.prnewswire.com/role/ShareholdersDeficitDetails", "http://www.prnewswire.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Excess Stock, Shares Issued", "terseLabel": "Ordinary shares, shares issued" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ShareholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ExcessStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of excess stock held by shareholders.", "label": "Excess Stock, Shares Outstanding", "terseLabel": "Ordinary shares outstanding", "verboseLabel": "Ordinary shares, shares outstanding" } } }, "localname": "ExcessStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/OrdinarySharesSubjecttoPossibleRedemptionDetails", "http://www.prnewswire.com/role/ShareholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r162", "r179", "r180", "r181", "r182", "r183", "r184", "r207", "r230", "r231", "r232", "r262", "r263", "r264", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ScheduleoffinancialassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r162", "r179", "r184", "r207", "r230", "r264", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ScheduleoffinancialassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r162", "r179", "r184", "r207", "r231", "r262", "r263", "r264", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ScheduleoffinancialassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r162", "r179", "r180", "r181", "r182", "r183", "r184", "r207", "r232", "r262", "r263", "r264", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ScheduleoffinancialassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r162", "r179", "r180", "r181", "r182", "r183", "r184", "r230", "r231", "r232", "r262", "r263", "r264", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ScheduleoffinancialassetsthataremeasuredatfairvalueonarecurringbasisTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r65", "r66" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FederalFundsPurchased": { "auth_ref": [ "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of short term borrowing where a bank borrows, at the federal funds rate, from another bank.", "label": "Federal Funds Purchased", "terseLabel": "Funds purchased" } } }, "localname": "FederalFundsPurchased", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r18" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "Initial Public Offering [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/CommitmentsandContingenciesDetails", "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails", "http://www.prnewswire.com/role/InitialPublicOfferingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r100", "r189", "r190", "r191", "r192", "r193", "r194" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r27" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r27" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r27" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "terseLabel": "Accrued expenses - related party" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r27" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseInCarryingAmountOfRedeemablePreferredStock": { "auth_ref": [ "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustment to retained earnings for the increase in carrying amount of redeemable preferred stock that is classified as temporary equity.", "label": "Increase in Carrying Amount of Redeemable Preferred Stock", "negatedLabel": "Increase in redemption value of ordinary shares subject to possible redemption" } } }, "localname": "IncreaseInCarryingAmountOfRedeemablePreferredStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r20", "r140" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income from investments held in Trust Account" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInvestmentExpense": { "auth_ref": [ "r21", "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses related to the generation of investment income.", "label": "Investment Income, Investment Expense", "terseLabel": "Investment amount" } } }, "localname": "InvestmentIncomeInvestmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentOwnedBalancePrincipalAmount": { "auth_ref": [ "r84", "r253" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For investments which are quantified by principal amount, the principle balance held at close of period.", "label": "Investment Owned, Balance, Principal Amount", "terseLabel": "Generating gross proceeds" } } }, "localname": "InvestmentOwnedBalancePrincipalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/PrivatePlacementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r12", "r108", "r147", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r199", "r200", "r201", "r209", "r260", "r295", "r303", "r304" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r10", "r72", "r79", "r269", "r285", "r292", "r301" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities, Ordinary Shares Subject to Possible Redemption and Shareholders\u2019 Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, Ordinary Shares Subject to Possible Redemption and Shareholders\u2019 Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r14", "r89", "r108", "r147", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r199", "r200", "r201", "r209", "r269", "r295", "r303", "r304" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-Term Purchase Commitment, Amount", "terseLabel": "Purchase amount" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r105" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r105" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r24", "r26", "r29" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r17", "r29", "r75", "r81", "r87", "r98", "r99", "r103", "r108", "r113", "r115", "r116", "r117", "r118", "r121", "r122", "r127", "r141", "r142", "r144", "r146", "r147", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r205", "r209", "r261", "r295" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.prnewswire.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedCashFlow", "http://www.prnewswire.com/role/ConsolidatedIncomeStatement", "http://www.prnewswire.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r141", "r142", "r144", "r146", "r261" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r59" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Description of Organization, Business Operations and Going Concern" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r36", "r37", "r43", "r59" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Emerging Growth Company" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_OriginationOfLoanToPurchaseCommonStock": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow for origination of loan for purchasing common stock.", "label": "Origination of Loan to Purchase Common Stock", "terseLabel": "Purchasing Parties agreed" } } }, "localname": "OriginationOfLoanToPurchaseCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenses": { "auth_ref": [ "r19", "r83" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense classified as other.", "label": "Other Expenses", "terseLabel": "Incurred expenses" } } }, "localname": "OtherExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/InitialPublicOfferingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.", "label": "Payment of Financing and Stock Issuance Costs", "terseLabel": "Offering costs" } } }, "localname": "PaymentOfFinancingAndStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/InitialPublicOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForUnderwritingExpense": { "auth_ref": [ "r25" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.", "label": "Payments for Underwriting Expense", "terseLabel": "Underwriting commission" } } }, "localname": "PaymentsForUnderwritingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfLoanCosts": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan origination associated cost which is usually collected through escrow.", "label": "Payments of Loan Costs", "terseLabel": "Payments of loan costs" } } }, "localname": "PaymentsOfLoanCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfOrdinaryDividends": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.", "label": "Payments of Ordinary Dividends", "terseLabel": "Ordinary shares purchased" } } }, "localname": "PaymentsOfOrdinaryDividends", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Offering costs allocated to Public Shares" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ScheduleofcondensedconsolidatedbalancesheetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preference Shares [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ShareholdersDeficitDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockNoParValue": { "auth_ref": [ "r4", "r297" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, No Par Value", "terseLabel": "Preference shares par value (in Dollars per share)" } } }, "localname": "PreferredStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ShareholdersDeficitDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r4", "r163" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preference shares, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preference shares, shares authorized", "verboseLabel": "Preference shares, shares outsatanding" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.prnewswire.com/role/ShareholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r4", "r163" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preference shares, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preference shares, shares outstanding", "verboseLabel": "PreferredStockSharesOutstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.prnewswire.com/role/ShareholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r4", "r269" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preference shares, $0.0001 par value\u037e 1,000,000 shares authorized\u037e none issued or outstanding as of December 31, 2022 and 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r96", "r149", "r150", "r257" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails", "http://www.prnewswire.com/role/PrivatePlacementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "terseLabel": "Funds amount" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r185", "r223", "r224" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": { "auth_ref": [ "r85", "r92", "r217", "r218", "r219", "r222" ], "lang": { "en-us": { "role": { "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.", "label": "Related Party Transaction, Description of Transaction", "terseLabel": "Related party, description" } } }, "localname": "RelatedPartyTransactionDescriptionOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.", "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party", "terseLabel": "Administrative expenses" } } }, "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r185", "r223", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r302" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r221", "r222", "r224", "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r281", "r282" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r7", "r52", "r78", "r251", "r252", "r269" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r86", "r110", "r111", "r112", "r114", "r120", "r122", "r148", "r186", "r187", "r188", "r195", "r196", "r203", "r248", "r250" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Gross proceeds" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/InitialPublicOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/CommitmentsandContingenciesDetails", "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails", "http://www.prnewswire.com/role/InitialPublicOfferingDetails", "http://www.prnewswire.com/role/PrivatePlacementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Price per share (in Dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r206", "r207" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets that are measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "terseLabel": "Business Acquisitions [Member]" } } }, "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Number of shares purchased for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award", "terseLabel": "Public shares purchased (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Price per share (in Dollars per share)", "verboseLabel": "Redemption price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/InitialPublicOfferingDetails", "http://www.prnewswire.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Issuance of initial public offering units (in Shares)", "verboseLabel": "Shares issued (in Shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails", "http://www.prnewswire.com/role/InitialPublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Shares per share (in Dollars per share)", "verboseLabel": "Ordinary shares price per share (in Dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails", "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognition of changes in redemption value of mandatorily redeemable shares. Provides the period over which changes in redemption value are accreted, usually from the issuance date (or from the date that it becomes probable that the security will become redeemable, if later) to the earliest redemption date of the security.", "label": "Shares Subject to Mandatory Redemption, Changes in Redemption Value, Policy [Policy Text Block]", "terseLabel": "Ordinary Shares Subject to Possible Redemption" } } }, "localname": "SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "The number of shares that would be issued, determined under the conditions specified in the contract, if the settlement were to occur at the reporting date.", "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Number of Shares", "terseLabel": "Public shares for redemption (in Shares)", "verboseLabel": "Public shares for redemption" } } }, "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails", "http://www.prnewswire.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r36", "r106" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r93", "r94", "r95", "r108", "r125", "r126", "r128", "r130", "r133", "r134", "r147", "r153", "r155", "r156", "r157", "r160", "r161", "r163", "r164", "r166", "r170", "r176", "r209", "r255", "r280", "r284", "r291" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r16", "r50", "r86", "r101", "r102", "r103", "r110", "r111", "r112", "r114", "r120", "r122", "r132", "r148", "r178", "r186", "r187", "r188", "r195", "r196", "r203", "r210", "r211", "r212", "r213", "r214", "r215", "r220", "r248", "r249", "r250" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails", "http://www.prnewswire.com/role/PrivatePlacementDetails", "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails", "http://www.prnewswire.com/role/ShareholdersDeficitDetails", "http://www.prnewswire.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r110", "r111", "r112", "r132", "r233" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r4", "r5", "r50", "r52" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Purchase of warrants" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/PrivatePlacementDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Ordinary shares, shares issued (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Purchase of ordinary shares" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ShareholdersDeficitDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r4", "r5", "r50", "r52" ], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited", "terseLabel": "Sponsor forfeit shares (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Aggregate price" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r5", "r8", "r9", "r44", "r269", "r285", "r292", "r301" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total shareholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet", "http://www.prnewswire.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 Deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r54", "r107", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r178", "r202" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders\u2019 Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ShareholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r216", "r228" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails", "http://www.prnewswire.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r216", "r228" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails", "http://www.prnewswire.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r216", "r228" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r227", "r229" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/CommitmentsandContingenciesDetails", "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails", "http://www.prnewswire.com/role/InitialPublicOfferingDetails", "http://www.prnewswire.com/role/PrivatePlacementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalDeferredPurchasePrice": { "auth_ref": [ "r32", "r33", "r34" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.", "label": "Supplemental Deferred Purchase Price", "terseLabel": "Total purchase price" } } }, "localname": "SupplementalDeferredPurchasePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/PrivatePlacementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TangibleAssetImpairmentCharges": { "auth_ref": [ "r0", "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.", "label": "Tangible Asset Impairment Charges", "terseLabel": "Net tangible assets" } } }, "localname": "TangibleAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/DescriptionofOrganizationBusinessOperationsandGoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of accretion of temporary equity to its redemption value during the period.", "label": "Temporary Equity, Accretion to Redemption Value", "terseLabel": "Accretion on ordinary shares to redemption value" } } }, "localname": "TemporaryEquityAccretionToRedemptionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ScheduleofcondensedconsolidatedbalancesheetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.", "label": "Temporary Equity, Accretion to Redemption Value, Adjustment", "terseLabel": "Redemption of Public Shares" } } }, "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ScheduleofcondensedconsolidatedbalancesheetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r153", "r155", "r156", "r157", "r160", "r161" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "terseLabel": "Ordinary shares subject to possible redemption, $0.0001 par value; 6,762,117 and 16,000,000 shares issued and outstanding at approximately $10.01 and $10.00 per share redemption value as of December 31, 2022 and 2021, respectively" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r2", "r48" ], "lang": { "en-us": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Ordinary shares subject to possible redemption, par value (in Dollars per share)" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquityRedemptionPricePerShare": { "auth_ref": [ "r2", "r48" ], "lang": { "en-us": { "role": { "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Redemption Price Per Share", "terseLabel": "Ordinary shares subject to possible redemption, per share redemption value (in Dollars per share)" } } }, "localname": "TemporaryEquityRedemptionPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Ordinary shares subject to possible redemption, shares issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "terseLabel": "Ordinary shares subject to possible redemption, shares outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r28" ], "calculation": { "http://www.prnewswire.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedLabel": "Interest income from investments held in Trust Account" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r40", "r41", "r42", "r135", "r136", "r138", "r139" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantExercisePriceIncrease": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.", "label": "Warrant, Exercise Price, Increase", "terseLabel": "Exercise price per share" } } }, "localname": "WarrantExercisePriceIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/PrivatePlacementDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/PrivatePlacementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants expire, term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ShareholdersDeficitDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r124", "r130" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares outstanding of ordinary shares, basic and diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r123", "r130" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares outstanding of ordinary shares, basic and diluted (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.prnewswire.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4,6)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918703-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919370-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128295416&loc=SL77919784-209982", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r271": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r272": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r273": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r274": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r275": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r276": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r277": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r278": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r279": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(b))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.A)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r294": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r305": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(a)", "Publisher": "SEC", "Section": "12", "Subsection": "04", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r36": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r37": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 3.C)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177168-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.7)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123395306&loc=d3e36975-112693", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 51 0001213900-23-005085-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-005085-xbrl.zip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�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end